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Gastrointestinal side-effects pose a major problem for those taking non-
steroidal anti-inflammatory drugs (NSAIDs). The mechanism by which
NSAIDs adversely affect the gastrointestinal tract is still unclear. The aims of
this study were to test the hypothesis suggesting that NSAID enteropathy is a
multistage process. Firstly, the effect of NSAIDs on mitochondria was
examined, as this is the proposed initial site of damage. Secondly, the
"transitional stage" of the pathogenesis (increase in intestinal permeability)
was studied, by measuring the transepithelial electrical resistance (TER) of
intestinal cells in isolation from any effects of NSAIDs on vascular blood
flow.
A range of acidic NSAIDs were found to uncouple oxidative phosphorylation
in isolated mitochondria. There was no uncoupling with the non-acidic
NSAID nabumetone and also on modification of the acidic side chain (NO-
flurbiprofen). The NSAIDs also inhibited mitochondrial electron transport,
however, this was not specific to the NSAIDs as the analgesic paracetamol
also inhibited. Use of the artificial electron acceptor ferricyanide indicated that
electron transport initiated at complex I of the respiratory chain was more
susceptible to inhibition by the NSAIDs than that from complex II. However,
EPR studies of submitochondrial particles incubated with NSAIDs showed no
one complex in particular seemed to be targeted by these drugs. Nevertheless,
the EPR work did reveal that the NSAIDs evoked free radical and NO signals,
both potentially damaging agents to the gastrointestinal tract.
The TER is inversely proportional to paracellular permeability. Thus, in the
present studies, it was found that acidic NSAIDs decreased the TER of the
intestinal cell line T84 concomitant with an increase in permeability to the
marker 51CrEDTA.
The results strongly indicate that numerous events may interact during
NSAID toxicity to the gastrointestinal tract.
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Inflammation is a physiological response to injury or irritation of living
tissue. It involves many processes including enzyme activation, mediator
release, extravasation of fluid, cell migration, tissue breakdown and repair. If,
for some reason, this normally rapidly reversible physiological process breaks
down and persists, then a pathological one ensues, such as in the case of
rheumatic diseases. Anti-inflammatory drugs, as the name suggests, have
been developed to inhibit such inflammatory processes by, in the main,
inhibiting the generation of pathologically produced prostaglandins. These
drugs include the corticosteroids (steroidal) and the non-steroidal
antiinflammatory drugs (NSAIDs).
1.1 History of NSAIDs
For thousands of years plants containing salicylates have been used as
treatments for various ailments (Gross and Greenberg, 1948). Almost three
and a half thousand years ago the application of an extract of the dried leaves
of Myrtle to the abdomen and back was suggested by the Ebers papyrus, in
order to alleviate rheumatic pains from the womb. A thousand years later
Hippocrates discovered that eye diseases could be treated using the juices of
the Poplar tree and that both fever and the pain during childbirth could be
reduced by chewing Willow leaves.
Such accounts of the medicinal value of Willow leaves, roots, and bark, the
Poplar tree, the wintergreen plant, and other sources of salicylates, continued
to be documented throughout the Middle Ages and in all parts of the world,
with no real idea of the pharmacology of the substance or substances being
utilised. The first so-called 'clinical trial' of Willow bark was undertaken by
the Reverend Edward Stone in 1763 (Stone, 1763). By administering dried,
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ground Willow bark, Stone successfully treated patients suffering from fever
and inflammatory disorders.
The work of Stone and others provided the impetus for the isolation and
purification of the active principle in Willow bark in order to further study it
and put it to clinical use. However, it wasn't until 1829 that the active
ingredient in willow bark, a glycoside called salicin, was isolated by Leroux in
the pure form exhibiting potent antipyretic activity. Salicin could be
hydrolyzed to glucose and salicylic alcohol, and the latter then converted in
vivo or by chemical manipulation, to salicylic acid. In 1874, salicin was found
to lower body temperature and reduce pain and swelling; these being the
antipyretic, antiinflammatory and analgesic properties for which salicylates
were to be used for a century to come (Maclagan, 1876). In the same year
(1874), the practical synthesis of salicylic acid had been elucidated by Kolbe and
Lautemann (Friend, 1974). Salicylic acid then soon had its first use in the
treatment of rheumatoid fever (Stricker, 1876).
Shortly after establishing the therapeutic effectiveness of salicin and salicylic
acid in rheumatic fever, sodium salicylate became the preferred compound
because of its greater water solubility, lower toxicity and the fact that it was
relatively easy to manufacture. Sodium salicylate was effective in the
treatment of chronic rheumatoid arthritis, fever and gout. However, the
sharp bitter taste of sodium salicylate plus its frequent side effects of gastric
irritation, meant that the compound could not be prescribed for a long period
of time.
In 1897, Hoffman acetylated the hydroxyl group on the benzene ring of
salicylic acid to produce acetylsalicylic acid (figure 1.1). His colleague Dreser,














Figure 1.1 Structures of NSAIDs
Figure 1.2 Ion trapping of weak acids in an acidic environment
NSAIDs being weak acids remain unionised (HA) in the acidic environment
of the stomach (left). Therefore, the concentration of HA is greater here than
inside the gastric mucosal cell (right). But in order to maintain an equilibrium
across the cell membrane HA passes into the cell, facilitated by the high
lipophilicity of the drugs. Then the higher intracellular pH means that the
NSAIDs become ionised (H + A-) and trapped within the cell. Modified from
Brooks and Day (1991).
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that the new compound was readily converted to salicylic acid upon
absorption into the body plus had a more pleasant taste and was better
tolerated by the gastric mucosa (Dreser, 1899). He thus introduced
acetylsalicylic acid onto the market under the name of 'aspirin' (a for acetyl,
spir for the genus Spirae, and -in as a popular suffix for drugs of the times). By
the early 1900's the main therapeutic actions of aspirin were known;
antipyretic, antiinflammatory and analgesic.
However, the search for a better tolerated and more effective
antiinflammatory agent continued when, in the late 1940's, corticosteroids
were found to relieve the symptoms of rheumatoid arthritis (Hench et a!.,
1949). This set in motion intensive research during the 1950's, producing
many synthetic corticosteroid analogues with increasing potency. However,
even at therapeutic doses, side-effects resulted, due to the administration of
grossly unphysiological quantities of the hormone preparation. The side-
effects included a clinical picture similar to that of Cushing's syndrome,
osteoporosis, diabetes mellitus, reduced resistance to infections and
hypertension.
This therefore stimulated research into anti-inflammatory drugs of the non-
steroidal type in the late 1950's, with a view to dissociating the serious side-
effects of corticosteroids from their antiinflammatory activities. The first non-
steroidal anti-inflammatory drug, phenylbutazone, was brought onto the
market in 1953 but again increasing reports of adverse effects soon followed
(Smyth, 1982).
Indole derivatives of the potent anti-inflammatory mediator serotonin were
prepared, to see if they would in some way affect serotonin metabolism (Shen
et a!., 1963). This study culminated with the discovery of indomethacin in
19
1961, which was able to mimic the antiinflammatory activity of corticosteroids
without their serious systemic side effects (figure 1.1). Indomethacin was
shown to have both antiinflammatory and analgesic effects in rheumatoid
and acute gouty arthritis, and was also highly effective in the treatment of
ankylosing spondylitis and moderate osteoarthritis (Hart and Boardman,
1963).
The discovery and clinical usage of indomethacin prompted further research
into nonsteroidal compounds. Independent studies at the Boots Laboratories
(England) resulted in the development of a propionic acid derivative
ibuprofen, another widely used NSAID, which was brought onto the market
in 1969 (Boardman et al., 1970). Later its derivative flurbiprofen was
successfully developed. Minor chemical modifications to the propionic acid
structure gave rise to large range of NSAIDs more potent than indomethacin
(Shen, 1972) and with apparently less gastrointestinal side-effects (Shen, 1984),
such as fenbufen and naproxen (figure 1.1). However, it has since been shown
that this increase in tolerability requires further clarification.
Despite the emergence of numerous NSAIDs, their mode of action was not
known until 1971, when it was reported that aspirin and indomethacin could
inhibit prostaglandin formation at therapeutic concentrations (Smith and
Willis, 1971; and Vane, 1971). As prostaglandins were shown to modulate
important cellular and vascular changes in inflammation, the inhibition of
their biosynthesis would therefore suppress inflammation, pain and fever.
These findings prompted the development of yet more compounds, such as
the fenamates and diflunisal. Analogues of fenamates include diclofenac,
another potent NSAID (Ku et a!., 1975). Diflunisal, on the other hand, is a
new analogue of salicylic acid, approximately four times more potent than
aspirin as an analgesic-antiinflammatory agent, with a longer duration of
20
action, plus is less irritating to the stomach than most NSAIDs (Stone et a!.,
1977).
However, the gastrointestinal and CNS side effects (dizziness, headache) seen
with NSAIDs meant that there was still room for improvement. Almost a
decade after the advent of indomethacin, sulindac, an analogue of
indomethacin was established as a new type of prodrug (Shen et al., 1972).
Sulindac is a relatively inert compound, but in the body it is converted to a
biologically active metabolite, which is comparable to indomethacin at
inhibiting prostaglandin biosynthesis (Duggan et al., 1977). The prodrug
concept was tested in short-term endoscopy trials and found to be well
tolerated (Lanza, 1989). Table 1.1 compares the incidence of damage caused by
conventional NSAIDs with that of proNSAIDs. However, short-term
tolerability is not predictive of long-term safety, thus sulindac and subsequent
pro-NSAIDs have been found to be toxic in the long-term. A nonacidic
prodrug which has emerged is nabumetone which is oxidized in vivo to an
active metabolite, and has been shown to be relatively safe (Boyle et a!., 1982).
Table 1.2 summarizes the evolution of NSAIDs.
1.2 Uses of NSAIDs
NSAIDs are one of the most frequently used drugs both in the U.K. and the
rest of the world. For example, over 100 million prescriptions were written
worldwide in 1989, equivalent to 5% of the population in most developed
countries. More than 20°c of patients admitted to hospital in the United
Kingdom and Australia are taking NSAIDs. At any one time there are over 50
NSAIDs marketed or on trial throughout the world, though most countries
have between 7 and 17 available for use.
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Table 1.1	 Incidence of gastric ulcer in normal subjects taking NSAIDs and
pro-NSAIDs
Drug	 Dose (mg/day) % Ulcer Incidence 	 pKa
Aspirin	 3900	 9.8	 3.5
Ibuprofen	 1600	 9.1	 5.2
Naproxen	 750	 8.8	 4.2
Indomethacin	 150	 2.9	 4.6
Piroxicam	 20	 4.0	 5.3
Sulindact	400	 2.6	 4.5
Fenbufen	 1000	 0.0	 4.3
t = Prodrugs. The most commonly used doses are shown. Adapted from
Lanza (1989).
Table 1.2	 The emergence of antiinflammatory compounds
Major Research	 Decade












Modified from Shen (1984).
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There follows a brief description of the disorders that NSAIDs are most
frequently prescribed for.
1.2.1 Musculoskeletal Disorders
The main clinical application of NSAIDs relies on their analgesic and
antiinflammatory properties to treat the signs and symptoms musculoskeletal
disorders, with more than 20 million prescriptions written each year in the
U.K. (Wright, 1988). Over one third of elderly bed-ridden or house-bound
patients suffer from severe rheumatic disorders requiring NSAIDs. Fifty
percent of NSAID use is for osteoarthritis (OA), explaining the rise in NSAID
use in the elderly, and about 20% of NSAIDs are taken for back pain. The
widespread popularity of these drugs means that some are now available over
the counter without prescription. However, NSAIDs provide only
symptomatic relief from the pain and inflammation associated with the
disease and do not prevent the progress of pathological injury to the tissues in
the long term. Table 1.3 summarizes the main musculoskeletal disorders
treated by NSAJDs.
Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disorder
affecting approximately 1% of the world's population, but whose aetiology is
not known (Hochberg, 1981). It is more common in women and can occur at
any age, although the incidence appears to increase with age. Table 1.4 shows
the clinical features of rheumatoid arthritis.
The treatment of RA generally begins with the symptomatic treatment of the
inflammation with NSAIDs in addition to rest and corticosteroid injections.
NSAIDs reduce, but do not completely eliminate, the signs and symptoms of
23
Table 1.3	 Main musculoskeletal disorders treated by NSAIDs
Type of Disorder	 Examples





Vasculitis & connective tissue diseases Systemic lupus erythematosus
Polymyalgia rheumatica
Temporal arteritis
Soft tissue rheumatism	 Rotar cuff shoulder lesions
Frozen shoulder






Table 1.4	 Clinical features of rheumatoid arthritis
Clinical Features
1. Morning stiffness in and around joints
2. At least 3 joint areas have simultaneous swelling or fluid in the soft tissue
3. Swollen wrist
4. Subcutaneous nodules over bony prominences
5. Abnormal amounts of "rheumatoid factor" in the serum
6. Involvement of joint areas on both sides of the body at the same time
7. Erosions or decalcification of bone
A patient with at least 4 of the 7 features is classified as having rheumatoid
arthritis (revised ARA criteria, 1988).
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inflammation so there is no obvious long-term protective benefit with these
drugs. In addition to their antiinflammatory effect, NSAIDs decrease pain,
fever and platelet adhesiveness (Borigini and Paulus, 1995).
Gout
Gout is a syndrome caused by an abnormality in uric acid metabolism
resulting in the deposition of sodium urate crystals in (i) the joints, causing
acute gouty arthritis, (ii) the soft tissue, causing tophi (hardened masses) and
tenosynovitis (inflammation of tendons) or (iii) the urinary tract, causing
urate stones. The biochemical abnormality is hyperuricaemia resulting from
an overproduction or decreased excretion of uric acid. Although coichicine is
often used to treat acute attacks of gout, the potent NSAIDs provide an
excellent alternative by bringing about short-term pain relief. Except in the
elderly, indomethacin, aspirin and diflunisal, appear very effective in the
acute phase because of their analgesic and uricosuric properties, bringing
substantial relief within 24-48 hours. Diflunisal has been suggested as the
preferred drug as lower doses are required plus it causes less gastrointestinal
irritation, though this claim needs to be substantiated (Axon and Huskisson,
1992).
Osteoarthritis
Osteoarthritis (OA) is the commonest type of arthritis, found in 20% of the
population as a whole and in more than 75% of people over the age of 70
(WGPO, 1966). Osteoarthritis is the slow degeneration of cartilage
characterized by the gradual development of joint pain, stiffness, and
limitation of motion. Osteoarthritis is particularly problematic in the large
weight-bearing joints i.e. knee and hip; the commonest cause of disability in
the elderly (Doherty, 1992). NSAIDs are extensive y used in OA since at low
doses they are effective analgesics and at higher doses have antiinflammatory
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activity, beneficial for the treatment of the inflammatory synovitis that often
results from the local degenerative damage (Gramas and Lane, 1995).
Polymyalgia Rheumatica
Patients with polymyalgia rheumatica have widespread joint and muscle
stiffness, and, although quite disabling, complete recovery occurs in most
patients within 1 to 2 years (Gardner, 1995). Salicylates were the first drugs
used to treat polymyalgia rheumatica, giving partial to complete relief of the
musculoskeletal symptoms (Barber, 1957). Other NSAIDs have been used
with similar effects, allowing lower doses of corticosteroids to be used and
thus avoiding the osteoporotic side-effects.
Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is the commonest connective tissue
disorder, characterized by the presence of antinuclear antibodies (ANA) in the
serum. The disease affects numerous organs and systems in the body (joints,
skin, lungs, heart, kidneys, nervous system, eyes, gastrointestinal system), but
arthralgia and rashes are the clinical features most often seen, with cerebral
and renal disease being the most serious associations. NSAJDs are effective for
the frequent arthralgic symptoms and the fever, but not for the accompanying
malaise and lethargy. Aspirin and other NSAIDs have been shown to be
highly effective in alleviating the fever, inflammation and serositis
(inflammation of serous membrane) of SLE (Hughes, 1979).
1.2.2 Non-Rheumatological Uses
Dysmenorrhoea
NSAIDs are also efficacious in controlling the painful symptoms of
dysmenorrhoea (Furniss, 1982). Women suffering from dysmenorrhoea
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normally have painful abdominal cramps together with various other
symptoms including fever, headache, nausea, vomiting, diarrhoea, breast
tenderness, nervousness and mood swings. The pathogenesis of
dysmenorrhoea appears to be related to increased production and release of
endometrial prostaglandins during menstruation, which results in increased
and abnormal uterine activity (Dawood, 1981). Thus, by suppressing
prostaglandin production, NSAIDs can control the action of prostaglandins
on the endometrium and uterus, thereby reducing menstrual flow, cramping,
headache, oedema, bloating, breast tenderness and mood changes. NSAIDs, in
particular indomethacin, naproxen sodium and the fenamic acids, are the
treatment of choice for dysmenorrhoea (Evens, 1984); aspirin, on the other
hand, has been found to be relatively ineffective (Marx, 1979). Table 1.5 gives a
summary of the clinical efficacy of NSAIDs in dysmenorrhoea.
Patent Ductus Arteriosus
NSAIDs have also been found to be useful in the treatment of patent ductus
arteriosus (PDA) (Evens, 1984). A PDA is an anatomical structure in the foetus
in utero, that enables communication between the main pulmonary artery
and the aorta, allowing blood to be shunted away from the pulmonary
vasculature. If the PDA fails to close at birth, cardiovascular abnormalities
result, such as heart murmur and tachycardia. Prostaglandins play a role in
maintaining the patency of a ductus arteriosus during foetal life and NSAIDs,
in particular indomethacin, are considered appropriate drug therapy, along
with fluid restriction, and/or diuretic therapy, and/or ventilatory support, to
close a PDA.
General Analgesia
Although NSAIDs were originally introduced onto the market to treat the
pain and inflammation associated with chronic inflammatory conditions,
27












Modified from Dawood (1988).
Table 1.6	 NSAIDs used as analgesics
Indicated as general purpose analgesic 	 Indicated for painful shoulder
(bursitis/tendinitis)











now many of these drugs are used as general analgesics. When employed as
analgesics, however, these drugs are only effective against pain of low-to-
moderate intensity (Insel, 1996). Though their maximal effects are much
lower than narcotics, NSAIDs have the added advantage of not being
associated with unwanted effects on the central nervous system (CNS) such as
respiratory depression, physical dependence or tolerance, thus are particularly
beneficial when used in the treatment of recurrent or chronic painful
conditions (McCaffery, 1985). Table 1.6 lists the NSAIDs commonly used as
analgesics.
hidomethacin has been shown to prevent or relieve the pain of migraine, and
naproxen, mefenamic acid and fenoprofen, as well as indomethacin, appear to
be very effective in the treatment of menstrual-related migraines. Research
has shown that NSAIDs such as ibuprofen and aspirin can alleviate pain
following postpartum episiotomy, dental extractions, herniorrhaphy and
orthopaedic surgery (Dionne and Cooper, 1978; and Slavic-Svircev, 1984).
Although highly controversial, NSAIDs have been found to very effective in
reducing cancer pain especially in bone metastasis and may actually inhibit
the progress of bone tumours (Ventafridda, 1980).
Antipyretic Use
NSAIDs can bring down a raised body temperature except when elevated by
such factors as exercise or increased ambient temperature (Insel, 1996).
Indomethacin has been shown to give remarkable clinical improvements by
quickly and completely diminishing the fever associated with Hodgkin's
disease and other lymphoid malignancies, where other antipyretic agents
have failed (Berbetto et a!., 1993).
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Cardiovascular Diseases
Low doses of aspirin have a potent and prolonged duration of action on
platelets, and therefore the drug is used in the treatment or prophylaxis of
diseases associated with platelet hyperaggregability, such coronary artery
disease and deep-vein thrombosis (Patrono, 1994). The antithrombotic action
of aspirin is utilised to prevent the clinical complications of atherosclerosis
(Schror, 1997).
Pregnancy
Aspirin is administered to pregnant women who have a high risk of
developing hypertension in order to lower the blood pressure and prevent
preeclampsia (Imperiale and Petrulis, 1991). Indomethacin and aspirin can be
used as to suppress uterine contractions in women with preterm labour
(Mosler, 1975).
1.3 Chemical Classification of NSAIDs
NSAIDs come from a variety of chemical classes (table 1.7). NSAIDs are
primarily organic acids, with the exception of nabumetone.
1.4 Pharmacokinetics of NSAIDs
Pharmacokinetics describes the disposition of a drug and its metabolites in the
body with relation to time. It has been suggested that the pharmacokinetics of
NSAIDs contributes not only to their therapeutic effects but also to the type
and incidence of their side-effects (Brune and Lanz, 1985). The main processes




Chemical classification of nonsteroidal antiinflammatory drugs
Chemical Family	 NSAIDs
Carboxylic acid - acetylated	 Aspirin
- nonacetylated	 Diflunisal, magnesium salicylate,
salicylamide, salsalate,
sodium salicylate






Fenamic acid	 Flufenamic acid, mefenamic acid
Enolic acid	 Piroxicam, tenoxicam,
phenylbutazone, oxyphenbutazone
Nonacidic	 Nabumetone
From Brooks and Day (1991).
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absorption, protein binding, its distribution within the body, metabolism and
excretion.
1.4.1 Absorption
All NSAIDs are rapidly and almost completely absorbed intact following oral
administration, with the exception of aspirin (and also diclofenac, tolfenamic
acid and perhaps fenbufen), which undergoes presystemic hydrolysis to form
salicylic acid before being absorbed (Verbeeck et al., 1983). Absorption takes
place in the stomach and upper small intestine by passive diffusion and is
affected by the pH of the aqueous layer near the mucous membrane (Brogden,
1986). The majority of NSAIDs are weak acids, with ionisation constants
(pKa's) ranging from 2.5 to 4.7, thus become unionised in the acidic
environment of the stomach. Under these conditions, NSAIDs are lipid
soluble and freely partition across the lipid bilayer membrane of gastric lining
cells. On the one hand, the ease with which NSAIDs are absorbed within the
stomach may lead to a rapid build-up of effective plasma concentrations,
causing early analgesic effect (Brune and Lanz, 1985). On the other hand
however, as the intracellular pH is higher, the drug becomes ionised and
subsequently "ion-trapped" within the mucosal cells (figure 1.2). Such high
local drug concentrations, together with prostaglandin synthesis inhibition,
could contribute to the gastrointestinal side-effects seen with NSAIDs (Halter,
1988).
Although absorption of the NSAID may be delayed by taking antacids
(Verbreeck et al., 1979) or food prior to the drug, the amount of drug
32
eventually absorbed is the same. However, under these circumstances in the
small intestine, the fraction of the NSAID dose absorbed is larger (Mortensen
and Rennebohm, 1989). Nevertheless, slow absorption is not a problem when
these drugs are used to treat chronic rheumatic diseases, though rapid
absorption may be desirable when NSAIDs are being employed as analgesics
or antipyretics. Enteric coated tablets of e.g. aspirin and diclofenac, are often
used to improve gastrointestinal tolerability. This has the effect of delaying
release and absorption of the drug until within the small intestine, with the
aim to reduce gastric damage by bypassing the "topical" effect of the drug at
this site (Day et al., 1988), though this does not reduce long-term toxicity.
1.4.2 Distribution
Following its administration and absorption, a drug is then distributed
throughout the body. NSAIDs bind substantially to serum albumin (90-99%).
Therefore, in most cases, less than 1% of the total plasma concentration is in
the unbound form of the drug and available to distribute in extravascular
tissues (Verbeeck et a!., 1983). This would explain why the apparent volumes
of distribution of NSAIDs are very low, usually less than 0.2L/kg.
The weak acidity of NSAIDs means that they are completely ionised at plasma
pH and, as already mentioned, only unionised molecules are lipid soluble and
able to diffuse through biological membranes (Brune and Lanz, 1985).
Therefore this property of the NSAIDs, together with the fact that they are
protein bound, means that leakage out of the plasma space is slow in most
parts of the body except in inflamed tissues, liver, bone marrow and spleen.
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1.4.3 Half-Life
The half-life (ti /2) of elimination of a drug is the time take for a given
concentration of drug to fall by half. The interval between doses is normally
set at approximately the half-life in order to limit plasma fluctuations of the
drug. Furthermore, it generally takes 3-5 half-lives for the drug to reach
steady-state concentrations.
NSAIDs can be divided into two categories on the basis of their half-lives,
those with half-lives less than 6h and those with half-lives greater than 12h.
This distinction has been made in order to serve as a rough guide to the
dosage regimens of these drugs. It was also used from a promotional
standpoint, rather than a factual one, to suggest better tolerability.
NSAIDs With Long Half-Lives
NSAIDs with long half-lives of elimination are usually given one to two
times a day, thus the plasma concentration and the pharmacological effect
remain relatively constant throughout the day. As the half-life of elimination
is equal to the half-life of accumulation, drugs with long half-lives
accumulate in the body slowly, albeit to a considerable degree, and for a long
time after the start of dosing. During long-term treatment, NSAIDs with long
half-lives are generally administered as conventional tablets containing the
acid forms of the drug, as modifying the rate of absorption has little effect on
the day-to-day plasma concentration of the drug. Table 1.8 shows a list of
NSAIDs with long half-lives.
NSAIDs With Short Half-Lives
NSAIDs with short half-lives are usually administered every 6-8h, which is
considerably longer than their half-lives and so plasma concentrations
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* Active metabolite. Taken from Day et al. (1988).
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fluctuate significantly during a dosage interval. Despite the swinging plasma
concentrations, analgesic and anti-inflammatory activity is well maintained
with these NSAIDs (Graham et al, 1984). In contrast to NSAIDs with long
half-lives, the plasma concentration of those with short half-lives is very
much affected by the rate of absorption. Slowing the rate of absorption
markedly decreases the peak plasma concentrations of these drugs. Sustained
release preparations of several NSAIDs with short half-lives have been
produced in order to maintain active plasma levels for a prolonged period of
time, although there appears to be no improvement in therapeutic response
(Yeh, 1985). Table 1.8 lists NSAIDs with short half-lives.
1.4.4 Synovial Kinetics
In inflammatory joint diseases, the main site of action of NSAIDs is most
likely to be in the synovial compartment. Since passage of the NSAIDs across
the synovial membrane occurs by simple diffusion, it is determined by
protein binding of the drug plus other physicochemical properties such as
pKa, lipophilicity, molecular size and distance between the plasma and the
synovial compartment (i.e. the amount of oedema and inflammation in the
tissues) (Furst, 1994). In rheumatoid arthritis, the synovial blood flow is
diminished plus there is an accumulation of metabolic waste products
(Verbreeck, 1988). There is also a reduction in serum albumin levels which
means higher imbound drug concentrations, and it is only the unbound drug
which is pharmacologically effective. In addition, there is a decrease in pH of
the synovial fluid, thus NSAIDs become "ion-trapped" within the synovial
cells. Therefore, the selective concentration of NSAIDs in the cells of the
synovium may be responsible for some of the characteristic therapeutic and
adverse effects of NSAIDs.
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1.4.5 Clearance
Clearance describes all the processes leading to the removal of a drug. At a
fixed dose of drug, a lower than average clearance leads to a higher than
average level in all tissues including plasma. Generally, total body clearance
of NSAIDs is relatively low (Verbeeck et a!., 1983).
Hepatic Clearance
NSAIDs are mainly cleared by hepatic metabolism and the metabolites are
generally inactive. In man most of the NSAIDs are metabolised by
cytochrome P450-mediated oxidation and/or glucuronide conjugation (table
1.9). Hepatic microsomal oxidation is affected by several factors including
advancing age, hepatocellular disease (e.g. cirrhosis), enzyme inducers or
inhibitors, and genetic constitution of the patient (Vesell, 1982). Glucuronide
conjugation, on the other hand, appears to be less susceptible to such
interfering factors (Verbreeck, 1988).
Hepatic clearance of NSAIDs is independent of liver blood flow but
dependent on protein binding. If an NSAID is displaced from its binding site,
there is an increase in clearance and a decrease in the total plasma
concentrations of the drug. Metabolism of the NSAIDs vary markedly
between patients, resulting in huge variations in the steady-state
concentrations of the drugs.
Metabolic activation
Most NSAIDs are metabolised to an inactive metabolite which is then
excreted in the urine. Alternatively, there are also compounds which are
inactive themselves but have active metabolites. The best known example is
aspirin, which although itself can inhibit prostanoid synthesis, owes its
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Table 1.9
	 Hepatic metabolic pathways of NSAIDs
NSAID	 Primary Metabolic	 Active Metabolites
Pathway(s)
Aspirin	 Hydrolysis	 Salicylic acid


















Fenbufen	 Oxidation	 y-OH-4-bipheny1 butyric

















A = amino acid conjugation; G = glucuronidation; S = suiphation. Adapted
from Verbreeck (1988).
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pharmacological properties to its metabolite salicylate, which is an active anti-
inflammatory agent. Salicylate, however, is eliminated more slowly than
aspirin, and the accumulation of salicylate puts a limit on how much aspirin
can be administered.
Until metabolised, the NSAIDs nabumetone, fenbufen and sulindac, have
little intrinsic activity with respect to cyclooxygenase inhibition. Such drugs
are known as 'prodrugs'. The drug sulindac is oxidised to the sulphone then
reversibly reduced in the large intestine by microflora to the suiphide (figure
1.3a); the latter metabolite is responsible for the anti-inflammatory activity of
parent compound (Strong et a!., 1985). The metabolism of sulindac is
reversible and in the kidney the suiphide is converted back to the inactive
sulindac, a possible explanation for the reduced effect of sulindac on
glomerular filtration when compared to other NSAIDs (Sedor et al., 1984).
Fenbufen is converted by n-oxidation to the active metabolites biphenylacetic
acid and -hydroxybiphenylbutanoic acid (figure 1.3b), which are responsible
for its antiinflammatory and analgesic activity (Child et a!., 1977), but it is only
biphenylacetic acid which inhibits prostaglandin synthesis (Sloboda et a!.,
1980). The conversion of nabumetone to its active metabolite 6-methoxy-2-
naphthylacetic acid (6-MNA), occurs in the liver by oxidative cleavage of the
side chain to the acetic acid derivative (figure 1.3c). Final elimination in the
urine follows glucuronide or suiphide conjugation of the metabolites (Friedel
et a!., 1993).
Liver disease
Little is known about the pharmacokinetics of NSAIDs in liver disease.
However, it has been shown that the plasma levels of sulindac sulphide
increase four-fold in alcoholic liver disease (Juhl et a!., 1983) and clearance of
















































In most cases, renal excretion of intact NSAID accounts for only a small
proportion (<10%) of the administered NSAID. Moreover, being mainly weak
acids, the renal clearance of NSAIDs increases with increasing urinary pH.
However, overall the renal clearance of NSAIDs is much lower than their
hepatic clearance even when the urinary pH is high. Thus, changes in urinary
pH do not significantly affect the total body clearance of NSAIDs. The main
exception is salicylate which, when urinary pH exceeds 6.5, has increased renal
clearance and decreased plasma concentration (Levy and Leonards, 1971), a
feature that is utilised for the treatment of aspirin overdose.
Renal failure
Although ordinarily only small amounts of the given doses of the NSAIDs
are excreted unchanged, in renal failure the clearance of several NSAIDs
including indomethacin, diflunis a!, ketoprofen, fenoprofen, naproxen is
decreased. This is due to the retention of the acyl glucuronide metabolites of
the NSAIDs in subjects with renal failure which are then hydrolysed back to
the parent compound in vivo (Meffin, 1985). Thus in patients with renal
failure, it would be preferable to use NSAIDs which are not metabolised
directly to glucuronides.
Biliary Clearance
The metabolites of most NSAIDs are also excreted to a significant extent via
the bile, for example indomethacin (Kwan et a!., 1975), sulindac (Dujovne et
al., 1983), tolfenamic acid (Pentikainen et a!., 1984), carprofen and piroxicam
(Verbreeck, 1988). Biliary excretion of glucuronide conjugates may be followed
by their hydrolysis in the gut reexposing the intestine to the parent compound
with subsequent reabsorption. This enterohepatic cycle could be important in
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prolonging the duration of action of the drug, as well as contributing to their
gastrointestinal toxicity. 6-MNA is not excreted in the bile, perhaps another
reason why its precursor nabumetone appears to cause less gastrointestinal
injury.
1.5 Mechanism of Action of NSAIDs
The beneficial effects of NSAIDs are primarily due to their ability to inhibit
prostaglandin synthesis (Vane, 1971). In order to understand the mechanism
by which NSAIDs act, it is important to have a clear picture of prostaglandin
biosynthesis.
1.5.1 Prostaglandin Biosynthesis
Prostaglandins were first isolated over 60 years ago from ram seminal vesicles
(von Euler, 1937); their name 'prostaglandin' was a reference to the source of
origin the prostate gland. It is now known that the enzymes used to
synthesize prostaglandins are ubiquitous and present in virtually all
mammalian tissues, with the exception of red blood cells (Smith, 1987).
The precursor of prostaglandins is a C-20 fatty acid 5,8,11,14-eicosatetraenoic
acid, more commonly known as arachidonic acid (figure 1.4). Arachidonic
acid is converted to prostaglandins and thromboxanes by the enzyme
cyclooxygenase and to leukotrienes by lipoxygenase. Prostaglandins,
leukotrienes and thromboxanes are a group of oxygenated lipids collectively
known as 'eicosanoids'. Eicosanoids are local hormones being short-lived
and, as they are not stored within cells, must be synthesized de novo from


























Figure 1.4 The arachidonic acid cascade
This diagram illustrates prostaglandin biosynthesis (see main text).
1 = phospholipases; 2 = COX-1 or COX-2; 3 = PGH synthase; 4 = TXA synthase;
5 = PGD synthase; 6 = PGF synthase; and 7 = PGE isomerase.
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stimulation of the cell. The eicosanoids act near or at their sites of synthesis,
with the nature of these effects varying from one type of cell to another.
Arachidonic acid is not present in cells in the free form but is esterified in
lipids and phospholipids and so needs to be released by a hydrolase enzyme..
As arachidonic acid is most commonly esterified to cellular phospholipids, it
is the enzyme phopholipase A2 which is normally responsible for its
cleavage. Thus, prostaglandin biosynthesis is thought to be regulated by the
level of arachidonic acid mobilization and hence substrate availability.
Although prostaglandins are all 20-carbon carboxylic acids containing a five
carbon ring, there are differences in the number of double bonds and whether
the cyclopentane portion is a diol or a keto alcohol (Fessenden and Fessenden,
1986). For example, in conventional terminology, PG means prostaglandin, E
means the keto alcohol, and F means the diol. The subscript number denotes
the number of carbon-carbon double bonds present outside the ring and the
subscript a refers to the configuration of the hydroxyl group at C-9 (cis to the
carboxyl side chain).
As shown in figure 1.4, the initial step of prostaglandin synthesis is the
removal of hydrogen at C-13 of arachidonic acid and peroxidation at C-il,
followed by the addition of oxygen at C-15 and ring closure between C-8 and C-
12 to form the unstable cyclic endoperoxides PGG2 and PGH2. This reaction is
catalyzed by cyclooxygenase. Alternatively, removal of the C-13 hydrogen
from arachidonic acid can also facilitate peroxidation at C-15 in which case 15-
HETE (15-hydroxyeicosatetraenoic acid) results via its corresponding
hydroperoxy acid. In addition, if there is no cyclisation of arachidonic acid
then i1-HETE is produced.
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The cyclic endoperoxides are converted to various products depending upon
the tissue in which they are manufactured. The eicosanoid thromboxane A2
(TXA2), is synthesized in a number of tissues including platelets (Needleman
et al., 1976) and polymorphonuclear leukocytes (Higgs et al., 1976a), and has
potent platelet aggregating activity. Prostacyclin (PGI2) is the major
cyclooxygenase product of blood vessel walls and can prevent platelet
aggregation, relax smooth muscle and is also a potent vasodilator (Moncada
and Vane, 1977). TXA2 and prostacyclin then break down to relatively stable
and inert products, thromboxane B2 and 6-oxo-PGF1a respectively.
The other stable prostaglandins identified so far PGD2, PGF2a and PGE2 are
relatively minor products of fatty acid oxidation. However, prostaglandin E2
(PGE2) is the main eicosanoid detected in inflammatory lesions, causing the
vasodilatation and erythema (redness) characteristic of acute inflammation
(Higgs and Salmon, 1979). PGE2 is also responsible for the fever associated
with bacterial and viral infections (Saxena et al., 1979). Furthermore, although
PGE2 itself does not directly cause pain, it acts along with other mediators,
sensitizing pain receptors on afferent nerve endings to the actions of
bradykinin and histamine (Moncada et a!., 1979).
1.5.2 The Cyclooxygenase Enzyme
The enzyme cyclooxygenase (COX) catalyses the first step in the biosynthesis of
prostaglandins, converting arachidonic acid to PGH2, which is then rapidly
converted to one of several prostanoids. This enzyme is bifunctional: the
initial cyclooxygenase reaction, the target for NSAIDs, converts arachidonic
acid to PGG2, while the subsequent peroxidase reaction converts PGG2 to
PGH2.
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Two isoforms of cyclooxygenase have now been identified, the constitutive
(COX-1) and the inducible (COX-2) forms, encoded by different genes (Merlie
et al., 1988; and Xie et a!., 1991). Differences in the NH2-terminus or COOH-
terminus of COX-1 and COX-2 appears to affect their subcellular localisation;
COX-1 is found predominantly in the endoplasmic reticulum (ER) of
prostanoid-forming cells, whereas COX-2 is in the nuclear membrane (Morita
et a!., 1995). If the two isoenzymes occur in different subcellular
compartments then it is possible that their respective metabolites would also
be distributed in separate locations. For example, the arachidonic acid
metabolites generated via COX-2 may preferentially distribute to the nuclear
compartment of the cell and therefore be available to modulate transcription
of target genes (DuBois et al., 1996).
Cyclooxygenase-1 (COX-1)
COX-1 is a constituent enzyme of most tissues, regulating normal cell activity
by synthesizing physiological amounts of prostaglandins. The prostaglandins
so produced have a protective role in the organism by facilitating repair
(Dewitt, 1991). In the main the concentration of COX-1 remains relatively
stable, except when stimulated by hormones or growth factors, in which case
2- to 4-fold increases may occur.
COX-1 is a haemo- and glycoprotein with a molecular weight of 7lkDa
(Miyamoto et a!., 1976). The structure is that of a monotopic dimer, that is, the
binding surface of the protein integrates into only one leaflet of the lipid
bilayer of the ER (figure 1.5). The dimer is ellipsoidal in shape. The tertiary
structure comprises three independent folding domains: an epidermal growth
factor-like domain linked to the main body of the enzyme by a disulphide
bridge, a second folding unit enabling insertion of the enzyme into the lipid
bilayer and leading to the main body of the enzyme which forms the third
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Figure 1.5 The structure of cyclooxygenase-1
This is a Molescript diagram of the COX-1 dimer derived from the 3.1A
refined structure. Haem groups are shown in red, Tyr 385 in green and
flurbiprofen in yellow. Orange corresponds to a bound detergent molecule in
the cyclooxygenase channel. Helices A, B, C and D of the membrane binding
domain, and the site of trypsin cleavage (Arg 277), are also illustrated. Taken
from Garavito (1996).
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folding unit, a large, globular, catalytic domain. The catalytic domain is polar
and therefore should be external to the membrane, with the bulk of the
protein facing the lumen (Picot et a!., 1994).
It is within the catalytic domain that the cyclooxygenase and peroxidase active
sites reside, adjacent but spatially distinct (Smith and Marnett, 1994). The
cyclooxygenase active site consists of a long hydrophobic channel (8x25A),
extending from the outer surface of the membrane-binding domain to the
centre of the protein. With the substrate arachidonic acid being hydrophobic,
once released from membrane phospholipids, it will presumably remain
associated with the bilayer, and so could feasibly gain direct access to the
hydrophobic channel from the interior of the bilayer.
The residue tyrosine (Tyr) 385 is found at the apex of this channel, with serine
(Ser) 530 lying just below it (Picot et al., 1994). The active centre of
cyclooxygenase is in the upper portion of the channel near Tyr 385. The only
two polar residues within this otherwise hydrophobic channel are arginine
(Arg) 120 and glutamine (Glu) 524; situated near to each other they probably
interact by forming a salt bridge (figure 1.6).
Cyclooxygenase-2 (COX-2)
The gene encoding for a second cyclooxygenase enzyme, termed COX-2, was
discovered serendipitously in 1991 (Xie et al., 1991). Catalytically COX-2 is
indistinguishable from COX-1 with respect to its function, substrate
preference, enzyme kinetics, biochemistry and mechanism of prostaglandin
biosynthesis (Loll and Garavito, 1994). The amino acid sequence of the cDNA
of COX-2 has approximately 60% homology to that of COX-1 (OBanion et
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al.,1992) and both enzymes have a molecular weight of 7OkDa. The active site
of COX-2 is larger than that of COX-1, and can accept a wider range of
substrates. With the exception of the kidneys and the central nervous system,
little or no COX-2 can be found in resting cells. However, COX-2 expression is
increased markedly when fibroblasts, vascular smooth muscle or endothelial
cells are exposed to growth factors, phorbol esters, cytokines, endotoxins or
bacteria etc. The levels of COX-2 also increases in conditions of chronic
inflammation, resulting in vastly elevated prostaglandin synthesis in many
cells and tissues. Thus, COX-2 is induced in settings of inflammation by
cytokines and inflammatory mediators.
1.5.3 Inhibition of Cyclooxygenase by NSAIDs
NSAIDs have been shown to inhibit the cyclooxygenase enzyme, thus
preventing the synthesis of prostaglandins (Vane, 1971). NSAIDs bind at the
top of the channel of COX, near to the putative catalytic residue Tyr 385
(Shimokawa et al., 1990). The carboxylate group of the drug probably ligands to
the guanidinium group of the Arg 120 residue in the channel (Picot et a!.,
1994). NSAIDs such as flurbiprofen and indomethacin prevent substrate
access by filling the entire channel from Tyr 385 downwards, a length of
approximately 12-14A. Aspirin, on the other hand, acetylates the residue Ser
530 in the channel. Although the acetyl group of aspirin would not fully
occupy the channel, it does take up enough space to prevent the substrate
gaining access to the upper portion of the channel and hence the active site.
(figure 1.7).
This model would also explain the binding of the substrate arachidonic acid to
the COX active site. The existence of Arg 120 in the channel would provide
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a suitable ligand for the carboxylate group of arachidonic acid to attach to
whereas its C-13 would lie in a bent conformation in the vicinity of Tyr 385.
Mode of Inhibition
Enzyme inhibition can be either reversible or irreversible. An irreversible
inhibitor dissociates very slowly from its target enzyme because it becomes
tightly bound to the enzyme, either covalently or noncovalently. In reversible
inhibition, on the other hand, there is rapid dissociation of the enzyme-
substrate complex. Reversible inhibition can be further subdivided into
competitive and noncompetitive. A competitive inhibitor normally
resembles the substrate, and competes with the substrate for the active site of
the enzyme. A noncompetitive inhibitor has a separate binding site to the
active site; it acts by decreasing enzyme turnover rather than substrate
binding.
In general, NSAIDs such as ibuprofen, inhibit cyclooxygenase by reversibly
competing with its substrate arachidonic acid for the active site of the enzyme
(Vane et a!., 1990). In the case of aspirin, however, the drug irreversibly
inhibits cyclooxygenase by acetylation of Ser 530 on COX-1 or the Ser 516 on
COX-2, thereby excluding access for arachidonic acid to Tyr 385 by steric
hindrance (Roth et al., 1975). Other NSAIDs such as indomethacin,
flurbiprofen or meclofenamate cause an irreversible, time-dependent
inhibition of cyclooxygenase (Loll and Garavito, 1994). That is, inhibition
increases with time, probably by a non-covalent structural alteration of the
enzyme-ligand complex creating a tighter complex.
It is possible that there are a number of subsites on COX for drug binding,
some kinetically indistinguishable, since although the NSAIDs are a
chemically diverse group of drugs, even compounds within the same
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chemical family have some members which are reversible, competitive
inhibitors whereas others are irreversible, time-dependent inhibitors of
cyclooxygenase (Picot et a!., 1994). In addition, NSAIDs bear no close
resemblance in structure to their substrate arachidonic acid (Smith and
Marnett, 1994).
Whether cyclooxygenase is inhibited reversibly or irreversibly, the peroxidase
is generally unaffected by NSAIDs (Kulmacz, 1989). That is, in the absence of
cyclooxygenase activity peroxidase activity is still possible, though
impairment of peroxidase activity of the enzyme would be accompanied by an
impairment of cyclooxygenase activity.
Membrane Interaction
In order for the NSAID to reach its site of action, it needs to move from
within the plasma compartment of the circulatory system, through tissue
membrane structures, and eventually across the plasma membrane of the
target cell, which usually contains relatively high amounts of cholesterol
(Herbette et a!., 1996). The drug must then cross many intracellular barriers
before being incorporated into the ER membrane network (COX-1), which has
low levels of cholesterol, or further within the nuclear envelope (COX-2).
NSAIDs must therefore have ampiphilic properties in order to be able to
traverse several membrane barriers. Once within the membrane bilayer
compartment, good membrane partitioning ability will allow the NSAID
molecule to reach the intrabilayer active site of COX. Therefore, NSAIDs also
need to be highly lipophilic in order to reside in the target membranes at
sufficient concentrations to inhibit COX. Indeed, NSAIDs are generally planar,
anionic molecules that partition into lipid environments, such as lipid
bilayers of plasma membranes, and the more acidic the pH, such as at
inflammatory sites, the greater the lipophilicity (Lombardino et a!., 1975).
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COX-1 versus COX-2
The active site topographies of COX-1 and COX-2 have been shown to be
subtly different in that during aspirin acetylation, there is almost a complete
block of COX-1 activity, but in the slightly larger channel of COX-2 the acetyl-
serine side-chain can rotate, thus allowing limited access of arachidonic acid
to the active site. Therefore, even when acetylated by aspirin, COX-2 has been
shown to oxygenate arachidonic acid, producing 15-HPETE, though not PGG2,
which is then converted to 15-HETE by the COX peroxidase (Lecomte et al.,
1994).
Evidence suggests that COX-1 has a 'housekeeping' function, generating
prostaglandins necessary for normal cellular processes, whereas COX-2 is
responsible for producing prostaglandins involved in inflammation and
growth regulation. Therefore, the unwanted side-effects of NSAIDs such as
gastrointestinal lesions, is thought to be due the inhibition of COX-1, while
their main antiinflammatory effects are due to inhibition of COX-2 (figure 1.8;
and Herschman, 1994). Studies are currently being undertaken to identify
NSAIDs which reduce inflammation but spare the associated side effects
(Yang, 1996). However, it is obvious that further work needs to carried out to
understand the precise role of COX in gastric pathophysiology since mouse
deficient in the COX-1 gene gave an apparent paradoxic decrease in their
susceptibility to NSAID-induced gastric damage (Langenbach et a!., 1995).
1.5.4 The Role of Prostaglandins
Inflammation
Inflammation can be thought of as essentially a protective response to
noxious stimuli such as physical injury (mechanical trauma, irradiation, cold
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NORMAL GI TRACT	 INFLAMMATORY SITE










Figure 1.8 Proposed role of COX-1 and COX-2 in normal and inflamed
tissues
Under normal physiological conditions, the gastrointestinal (GI) tract
synthesizes cytoprotective prostaglandins (PGs) via cyclooxygenase-1 (COX-1).
Inhibition of COX-1 by NSAIDs results in gastric lesions. During
inflammation cytokines stimulate COX-2 which produces large amounts of
pro-inflammatory prostaglandins, pain and oedema. COX-2 selective NSAIDs
are anti-inflammatory without GI side-effects seen with traditional NSAIDs.
Adapted from Masferrer et a!. (1996).
Arachidonic Acid
l9 7" 12-LOt
15-HPETE	 12-HPETE	 5-HPETE	 5-HETE
15-HETE	 12-HETE	 LTA4/\
LTB4
	LTC4 - LTD,	 LTE
Figure 1.9 Lipoxygenase biosynthesis
In addition to cyclooxygenase, arachidonic acid can also be metabolised by
lipoxygenase to form leukotrienes. See main text for abbreviations.
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or heat), chemical injury (acids, alkalis, phenols or other inflammatory
irritants) and injury due to a living organism (viruses, bacteria, fungi,
parasites). The characteristic signs of inflammation are erythema, oedema
(swelling), tenderness (hyperalgesia) and pain.
The defense mechanisms involved in the inflammatory response include
firstly the recognition of the foreign material, followed by the generation of
mediators (such as leukotrienes, platelet-activating factor and prostaglandins)
and cytokines (such as tumour necrosis factor, interleukin-1 and interleukin-
8) from immunocytes (mast cells, macrophages, neutrophils etc),
accumulation of phagocytes and finally activation of phagocytes at the site of
inflammation (Wallace and Tigley, 1995). For example, when an organism is
re-exposed to an antigen to which it has been previously sensitised, mast cells
are activated, releasing the mediators histamine and leukotrienes. In the case
of leukotriene B4, this would be responsible for recruiting neutrophils from
the vasculature into the tissues, an important defensive response. Moreover,
both mast cells and macrophages can act as cytotoxic cells, using nitric oxide
and/or tumour necrosis factor to kill other cells.
Under normal conditions macrophages, neutrophils, fibroblasts and
endothelial cells show very little cyclooxygenase activity and thus no
prostaglandin production. During inflammation, however, several
phospholipases are activated in the inflamed tissue and infiltrating cells,
liberating large amounts of free arachidonic acid. Likewise, cyclooxygenase
activity is stimulated. It is prostaglandin E2 and prostacyclin which are the
predominant cyclooxygenase products found in acute inflammatory exudates
and have potent pro-inflammatory actions (Whittle, 1992). These
prostaglandins play a role in modulating, or down-regulating, the activity of
many immunocytes, including macrophages and mast cells, and hence the
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inflammatory response. For example, PGE2 has been shown to be a potent
suppresser of TNF release from macrophages (Kunkel et a!., 1986a) and also to
modulate the expression of the TNF gene in macrophages (Kunkel et aL,
1988). Prostaglandins can also regulate the release of other cytokines, such as
interleukin-1, from macrophages (Kunkel et a!., 1986b). Release of the
mediators TNF, PAF and histamine from mast cells can be inhibited by E-type
prostaglandins (Hogaboam et al., 1993).
During inflammation, neutrophils are recruited to the site(s) of injury by the
chemical mediators (chemotaxins) released from immunocytes.
Prostaglandins can suppress the release of LTB4 (Ham et a!., 1983) and IL-8
(Wertheim et a!., 1993) from neutrophils, and the adherence of neutrophils to
the vascular endothelium (Granger and Kubes, 1994).
In the gastrointestinal tract eicosanoids together with other substances such as
cytokines, reactive oxygen metabolites, platelet activating factor and the
bacterial chemotactic peptide fMLP modulate host responses (Powell, 1991). In
inflammatory bowel disease the levels of eicosanoids PGE2, LTB4, and
perhaps LTC4, 12-HETE, 15-HETE and TXA2 are increased in inflamed tissues
compared with normal mucosa, and return to normal during remission
(Ebehart and DuBois, 1995).
Involvement of COX-2 in inflammation
It is the activity of COX-2, as opposed to COX-1, which increases in response to
an inflammatory stimulus. The expression of the COX-2 gene is responsible
for a transient production of proinflammatory prostaglandins.
Many studies have implicated COX-2 in inflammation. One of the first and
more important observations that supported the existence of an inducible
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cyclooxygenase enzyme was found when its expression was increased
following incubation with the pro-inflammatory cytokine IL-13 (OBanion et
a!., 1992) and TNFa (O'Banion et al., 1994). Pharmacological intervention
with the antiinflammatory glucocorticoid dexamethasone could block the
expression of this inducible cyclooxygenase without effect on basal
cyclooxygenase activity, whereas the NSAID indomethacin inhibited both
basal and stimulated cyclooxygenase activity (Masferrer et a!., 1994). In
response to inflammatory stimuli, COX-2 expression is readily induced in
vitro and in vivo in cells such as macrophages, monocytes (Fu et al., 1990),
synovial cells (Crofford et a!., 1994), and endothelial cells (Habib et a!., 1993).
Furthermore, in animal models of inflammation, cyclooxygenase activity and
expression have been shown to be markedly increased. For example, Vane
and associates (1994) demonstrated a significant increase in COX-2 mRNA and
protein in a murine air pouch model of granulomatus inflammation, while
the COX-1 protein levels remained unchanged. In a model of acute
inflammation, such as carrageenan injection into the footpad, a marked
accumulation of COX-2 mRNA was reported plus a selective inhibitor of
COX-2 (SC-58125) inhibited oedema at the inflammatory site and was also
shown to be analgesic. Again COX-1 expression was unaltered during the
inflammatory process (Seibert et a!., 1994). Similarly in adjuvant-induced
arthritis an induction of COX-2 mRNA and protein correlated with the rise in
prostaglandin levels in the inflamed joint and the incidence of oedema. By
selectively inhibiting COX-2 and the production of these prostaglandins, the
oedema was attenuated in these chronically inflamed animals (Crofford et a!.,
1994).
Vascular events in inflammation
Acute inflammation is characterized by vasodilatation, increased vascular
permeability, accumulation of leukocytes and pain. Certain prostaglandins are
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potent vasodilators. Prostaglandin E2 (PGE2) and prostacyclin (PGI2) produce a
long-lasting (up to 10 hours) erythema, seen in acute inflammation (Solomon
et al., 1968). During inflammation, the prostaglandins are generated locally
and cause vasodilatation by acting directly on vascular smooth muscle by
relaxing vascular tone (Williams, 1985). The prolonged vascular effects of
stable prostaglandins and their ability to counteract the vasoconstriction
caused by agents such as noradrenaline and angiotensin, are properties not
shared by the other inflammatory mediators (Higgs et al., 1980).
Prostaglandins themselves do not increase vascular permeability, but PGEi,
PGE2 and PGI1 are very potent at enhancing the oedema induced by other
inflammatory mediators such as bradykinin and histamine (Moncada et a!.,
1973). This is possibly due to the arteriolar dilatation caused by prostaglandins,
increasing hydrostatic pressure within venules (Johnston et a!., 1976).
Pain and Hvperalgesia
The pain that accompanies inflammation and tissue injury is caused by local
stimulation of pain fibres and enhanced pain sensitivity (hyperalgesia) due to
the increased excitability of the central neurones in the spinal cord (Konttinen
et a!., 1994). Bradykinin and cytokines such as IL-i, TNF and IL-8 are thought
to be involved in eliciting the peripheral pain of inflammation.
Prostaglandins (PGE2 and PGI2) can sensitize afferent pain receptors to
normally painless mechanical or chemical stimulation, by lowering the
threshold of polymodal noiciceptors (peripheral sensory nerves) of C fibres.
However, although NSAIDs are particularly effective in the relief of the pain
of inflammation, this again may not be only by reducing prostaglandin
production, but the drugs may also have an antinociceptive effect at
peripheral or central neurones (Gebhart and McCormack, 1994).
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Fever
Fever results from various disease states including inflammation,
malignancy, graft rejection, tissue damage (Dascombe, 1985). During fever
there is an increased production of cytokines IL-i and IL-6, interferons a and
, and TNFa. The cytokines cause an increase in the synthesis of PGE2, via
increases in cyclic AMP, and PGE2 then stimulates the hypothalamus to
elevate body temperature by promoting an increase in heat production and a
decrease in heat loss. NSAIDs bring down a raised body temperature by
inhibiting PGE2.
Dysmenorrhoea
The pathogenesis of dysmenorrhoea is thought to be due to increased
production and release of endometrial prostaglandins during menstruation,
which results in increased and abnormal uterine activity (Dawood, 1981).
During the ovulatory cycle, the corpus luteum undergoes regression and the
resulting decrease in progesterone levels gives rise to lysosomal labilization,
thereby releasing the lysosomal enzyme phospholipase A2. Phospholipase A2
hydrolyses cell membrane phospholipids in the endometrium producing
arachidonic acid. The availability of arachidonic acid together with the
cellular trauma that occurs in the endometrium during the onset of
menstruation, drives the arachidonic acid cascade towards prostaglandin
production. In dysmenorrhoea, the increased levels of prostaglandins PGF2a
and PGE2 in the menstrual fluid, stimulates the myometrium causing
increased and abnormal myometrial contractions. As a result, uterine blood
flow decreases and uterine ischaemia develops.
Thus, prostaglandins are responsible for the labour-like pain and contractions
as well as the diarrhoea, nausea and vomiting seen in dysmenorrhoea. The
production and release of prostaglandins occurs mainly during the first 48
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hours of menstrual flow, explaining why in dysmenorrhoea the intense pain
is normally felt in the first or second day of menstruation. NSAIDs relieve
dysmenorrhoea by suppressing prostaglandin production in menstrual fluid.
The failure of aspirin to relieve the symptoms of dysmenorrhoea may be due
to its rapid hydrolysis, consequently insufficient drug reaches the cells of the
uterus to inhibit cyclooxygenase (Mustard, 1982).
Patent Ductus Arteriosus
Prostaglandins are important in maintaining the patency of the ductus
arteriosus (Coceani and 011ey, 1973). During parturition, the blood oxygen
increases and prostaglandin production drops, one of the factors in the closure
of the ductus arteriosus. Administration of NSAIDs at doses that inhibit
prostaglandin formation can also cause closure of the patent ductus, although
the drugs may sometimes cause premature closure when given late in
pregnancy (Sharpe et al., 1974).
Labour
The use of NSAIDs such as indomethacin to prevent preterm labour is based
on their ability to suppress the formation of prostaglandins. During labour the
prostaglandins Ei, E2, Fla and F2a appear in large quantities in amniotic fluid
and maternal blood, the most abundant being the F prostaglandins (Karim
and Devlin, 1967). These prostaglandins probably originate from the uterine
endometrium which, during labour, synthesizes them at a higher than
normal rate. The prostaglandins initiate labour by causing uterine contraction
with the uterus being more sensitive to prostaglandins in late pregnancy.
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Cardiovascular Diseases
Thromboxane A2 causes platelet aggregation forming a white thrombus,
which obstructs coronary or cerebral arteries, eventually leading to a heart
attack or stroke (Collier, 1984). The ability of aspirin to protect against coronary
infarction and stroke is by way of its virtue of preventing blood platelets
generating thromboxane A2 from arachidonic acid without preventing
production of PGI2 from endothelial cells.
Pregnancy
Excess production of TXA2 and PGI2 has been implicated in the genesis of
preeclampsia and pregnancy-induced hypertension (Lubbe, 1987). Aspirin has
been shown to prevent both these conditions by inhibiting prostaglandin
synthesis.
1.5.5 Prostaglandin-Independent Mechanism of Action of NSAIDs
Although generally it is accepted that the mechanism of action NSAIDs is due
to their ability to inhibit cyclooxygenase, this may not account for all the
effects of NSAIDs. For example, sodium salicylate is equipotent with aspirin
in its antirheumatic effects, but does not inhibit cyclooxygenase (Ferreira,
1977). Although relatively low doses of NSAIDs are required to inhibit
prostaglandin biosynthesis, higher doses are required for an antiinflammatory
effect (Higgs et iii., 1976b), suggesting that the antiinflammatory activity
exhibited by NSAIDs at higher concentrations is independent of their ability
to inhibit cyclooxygenase (Abramson et a!., 1985).
Inhibition of Lipoxygenase
In addition to the cyclooxygenase pathway, arachidonic acid can also be
metabolised by lipoxygenase (LO) to form leukotrienes which have an
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important role in inflammatory processes (figure 1.9; and Bray, 1986). NSAIDs
can inhibit lipoxygenase, thereby stimulating the reincorporation of
arachidonic acid into triglycerides and decreasing the production of
leukotrienes from leukocytes and synovial cells (Ku et al., 1985). All NSAIDs
appear to inhibit 15- and 12-lipoxygenase (Siegel et al., 1980).
The end product of the lipoxygenase pathway in human platelets is 12L-
hydroxy-5,8,10,14-eicosatetraenoic acid (HETE), with the unstable intermediate
being 12L-hydroperoxy-5,8,10,14-eicosatetraenoic acid (HPETE). Aspirin and
indomethacin have been shown to inhibit the conversion of HPETE to HETE
in human platelets via a putative HPETE peroxidase activity (Siegel et al.,
1979). Thus, the pharmacological actions of aspirin, indomethacin and other
NSAIDs may be related to their property of causing an accumulation of
HPETE at the expense of enzymatic HETE production. For example, HPETE
analogues, by inhibiting prostacyclin synthetase inhibit the formation of
prostacyclin which causes hyperalgesia; this is a possible explanation for the
analgesic effects of NSAIDs (Moncada et al., 1976). The antiinflammatory
activity of the drugs, on the other hand, may partly be due to the fact that
HETE is chemotactic, therefore inhibition of its production by NSAIDs will
prevent the recruitment of phagocytic cells (Vinegar et a!., 1973).
Inhibition of Neutrophil Function
At high (antirheumatic) concentrations, NSAIDs inhibit neutrophil
activation (Kaplan et a!., 1984). Abramson et a!. (1985) showed that aspirin,
ibuprofen, piroxicam and indomethacin all inhibited neutrophil aggregation,
lysosomal enzyme release, and superoxide generation, albeit to varying
extents. They suggested this effect was not due to inhibition of prostaglandin
synthesis since addition of exogenous prostaglandin to NSAID-treated
neutrophils did not restore the cell responses. Moreover, sodium salicylate,
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which does not inhibit cyclooxygenase, was as effective an inhibitor of
neutrophil aggregation as was aspirin. Therefore, it was postulated that
inhibition of neutrophil activation by NSAIDs occurred independently to that
of prostaglandin synthesis, probably by inhibiting calcium translocations, the
early signals in the activation of neutrophils.
In addition, NSAIDs have been shown to inhibit discrete neutrophil
responses such as aggregation, superoxide generation, and lysosomal enzyme
release induced by the chemotactic peptides fMLP, concanavalin-A, and
phorbol myristate acetate, which participate in the inflammation and tissue
destruction associated with rheumatoid arthritis (Abramson et al., 1983; and
Forrest and Brooks, 1988). It has been suggested that these effects are
independent of the prostaglandin inhibition caused by the NSAJDs.
Interference With Leukocyte Migration
There is a variation in the effect of NSAIIJs on the migration of inflammatory
cells. For example, ibuprofen and benoxaprofen inhibit monocyte chemotaxis
in vivo whereas indomethacin, naproxen and salicylate do not. Similarly,
several NSAIDs have been shown to significantly inhibit polymorphonuclear
leukocyte chemotaxis, but indomethacin has not (Dawson, 1980). If this was a
prostaglandin-mediated response then all NSAIDs should inhibit migration
as they all inhibit cyclooxygenase (Goodwin, 1984). Several studies have
substantiated the lack of correlation between the dose-response curve for this
effect and inhibition of prostaglandin production by NSAIDs (Ford-
Hutchinson et a!., 1979; and Adams et al., 1977).
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1.6	 Side-effects of NSAIDs
NSAIDs appear to induce toxic reactions in almost all of the major organ
systems in man, albeit to varying severity and frequency (Rainsford, 1984).
The scale of the problem is immense, for example, over the past 15 years or so,
one quarter of all adverse drug reactions reported to the Committee on Safety
of Medicines in the United Kingdom, have been due to NSAIDs (Mann, 1987).
This equates to approximately 30,000 major complications a year. For arthritic
patients, in particular, who have to take NSAIDs in large quantities and for a
long period of time, the frequent occurrence of side-effects often warrants
interruption or discontinuation of the use of these drugs (Rainsford, 1989a).
Even more worrying is the relatively high incidence of deaths associated with
the use of NSAIDs (expressed as annual deaths per million prescriptions):
oxyphenbutazone (14.3), aspirin (11.5), phenylbutazone (7.1), and
indomethacin (4.4) (Girdwood, 1974).
Generally, the adverse effects are dose-related, though some are idiosyncratic,
and largely (but not solely) attributable to inhibition of prostaglandin
synthesis (Rainsford, 1988). Some of the most common unwanted effects of
NSAIDs are summarised in table 1.10.
The most frequently seen adverse effects of NSAIDs, especially patients taking
the drugs long-term and in the elderly, is gastrointestinal (CI) upset. The
proposed mechanism of CI damage will be discussed in detail in the next
section.
Another major target for NSAID toxicity is the kidney. PGE2 and PGI2 are
vasodilatory. In the kidneys, these prostaglandins are produced in response to
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Personality changes (irritability, hyperactivity, nervousness, drowsiness
and depression)
Adapted from Thompson and Dunne (1995), and Mortensen and Rennebohm
(1989).
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the vasoconstrictor hormones noradrenaline, angiotensin II and vasopressin,
in order to antagonise the renal vasoconstriction and renal ischaemia caused
by the hormones, by a negative feedback ioop. The prostaglandins thereby act
by maintaining renal blood flow and glomerular filtration rate (GFR) which,
in healthy individuals, is not very important as there is a considerable reserve
capacity for GFR. A decrease in prostaglandin production by NSAIDs in
conditions where there is already reduced GFR e.g. shock, congestive heart
failure, hepatic cirrhosis with ascites, chronic renal disease, and in
hypovoleamic individuals, will cause significant changes in renal function
(i.e. further reduction in GFR), which may then lead to acute renal failure
(Clive and Stoff, 1984). By inhibiting the production of renal prostaglandins,
NSAIDs decrease renal perfusion in these patients, thus acute renal failure
may result. NSAIDs also promote salt and water retention by inhibiting
prostaglandin-induced chloride reabsorption and the action of antidiuretic
hormone. Therefore, in patients treated with NSAIDs, oedema may occur and
the drugs may also reduce the effectiveness of antihypertensive regimens
(Oates et al., 1988).
NSAIDs have also been shown to cause hypersensitivity, due to intolerance,
in 20-25% of middle-aged patients with asthma, nasal polyps or chronic
urticaria, with symptoms resembling those of anaphylaxis (Ng, 1992). The
underlying mechanism for this hypersensitivity reaction to NSAIDs is
unknown, although one theory is that by inhibiting cyclooxygenase,
arachidonic acid metabolism is diverted toward the formation of leukotrienes
by the lipoxygenase pathway. This hypothesis is based on the fact that
leukotrienes C4 and D4 may precipitate bronchial spasm and that inhibition
of 5-lipoxygenase by the drug zileuton, may prevent the signs and symptoms
of aspirin intolerance (Israel et al., 1993). Alternatively, NSAID-induced
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hypersensitivity may be caused by a perturbation of cellular immune
reactions (O'Brien and Bagby, 1985).
Haematological disturbances are also often seen with NSAIDs, in particular
an increase in bleeding time (Insel, 1996). This is due to their ability to prevent
the formation by platelets of thromboxane A2 (TXA2), a potent platelet
aggregator. Aspirin is a particularly effective inhibitor of platelet function due
to its irreversible inhibition of cyclooxygenase; new platelet needs to be
produced in order to restore enzyme activity. This effect of aspirin is exploited
in the prophylaxis treatment of cardiovascular diseases.
1.6.1 Mechanism of Gastrointestinal Damage
The most common side-effects of NSAIDs is seen in the gastrointestinal tract,
and these range from mild dyspepsia, heartburn, constipation and diarrhoea
(symptomatic reactions) to the potentially life-threatening effects of ulceration
and haemorrhage (Rainsford, 1987). Ironically, it was the discovery that
aspirin induced GI damage which was responsible for the proliferation of
NSAIDs, in an effort to find newer compounds with good anti-inflammatory
and analgesic properties but with reduced GI toxicity (Borda, 1992). Both in
animal models (Cucala et al.,1987) and healthy human volunteers (Lanza,
1984), there is a strong correlation between the antiinflammatory potency of
NSAIDs and their gastric ulcerogenicity. The effects of NSAIDs on the GI tract
are both local and systemic.
Local Effects of NSAIDs
According to data from rats, the local effect of the NSAIDs on the gastric
mucosa occurs within 15 to 60 minutes of oral administration and involves
extensive shedding of superficial mucous cells in the glandular mucosa,
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followed by the development of endoscopically visible erosions in the upper
glandular mucosal region and subsequent haemorrhage in the eroded areas
(Rainsford, 1989b). (Maximal development of lesions may take longer with
those NSAIDs which have a slower absorption into the gastric mucosa
(Rainsford et a!., 1984)). The local effect occurs by the phenomenon of "ion-
trapping" (see figure 1.2). At the low pH in the stomach, the NSAID (a weak
acid) is almost totally unionised and, being also highly lipophilic, freely
partitions into the cells of the gastric epithelium (Schoen and Vender, 1989).
Once within the cells, which have a neutral pH, the drug reionises and
becomes trapped at high concentrations. Direct cellular injury is presumably
caused by the toxicity of high intracellular levels of the NSAID. These toxic
effects lead to the cell membrane permeability becoming altered, enabling back
diffusion of acid thereby damaging the deeper layers of the gastric mucosa.
This phenomenon may explain why aspirin is much more gastrotoxic than
other NSAIDs. That is, aspirin has a higher solubility in the acidic pH
conditions of the stomach than most other NSAIDs, and so more readily
enters the cells of the stomach wall (Beck et a!., 1990). Highly buffered aspirin,
enteric-coated aspirin or naproxen have been formulated to somewhat lessen
their topical irritation.
Systemic Effects of NSAIDs - Prostaglandin Inhibition
The fact that not just orally but parenterally administered NSAIDs also cause
gastric damage, suggests that factors other than the local effects of cell
exfoliation and back diffusion of acid from the stomach lumen into the
mucosa of the stomach wall, also apply. The systemic effect of NSAIDs is
thought to be via the inhibition of cyclooxygenase both COX-1 and COX-2,
leading to both beneficial (anti-inflammatory and antipyretic) and toxic
(gastrointestinal injury) effects. Nevertheless, it is the inhibition of the
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synthesis of gastroprotective prostaglandins, now hypothesized to be COX-1
mediated, which plays a role in NSAID-induced gastrointestinal damage.
Mucus and bicarbonate secretion
Prostaglandins are important in mucosal defense by stimulating mucus
(McQueen et a!., 1983) and bicarbonate (Kauffman et a!., 1980) secretion.
Mucus slows down the diffusion of luminal gastric acid and secretion of
bicarbonate neutralizes it. The mucus, a mixture of mucin, other proteins and
lipids, is secreted by gastric and duodenal epithelial cells forming a polymeric
gel into which bicarbonate is secreted by these cells, thereby providing a
protective pH gradient that maintains a neutral pH at the epithelial cell
surface (Quigley and Turnberg, 1987). Mucin is a viscous glycoprotein whose
physicochemical properties provide a relatively acid-resistant barrier. Gastric
acid is secreted in a pulsatile manner through the mucus gel forming
temporary channels within the gel, and these rapidly close to prevent luminal
acid back-diffusion. This mechanism maintains a neutral pH at the mucosa
despite the low luminal pH.
In addition, gastric mucus also acts as a physical barrier by lubricating the
mucosal surface to allow free passage of solid particles whilst at the same time
protecting the surface from mechanical damage by such material (Whittle,
1984). It has also been suggested that the mucus layer may even thicken in
response to injury, enabling re-epithelialization of the mucosa (Morris et a!.,
1984).
In the gastric mucosa, a mucoid cap, consisting of mucus, lipids, fibrin and
cellular debris, forms over an area of superficial damage, providing an
alkaline microenvironment required for mucosal restitution (Wallace and
Whittle, 1986). The pH gradient across this cap is produced by bicarbonate
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secretion and plasma flux. Together with mucus and bicarbonate secretion,
the repair of superficial injury is also enhanced by prostaglandins, which
maintain endothelial integrity by stimulating cell proliferation and migration
along the basement membrane (Tarnawski et a!., 1985).
Enhance mucosal blood flow
E and I prostaglandins enhance mucosal blood flow, which is beneficial in
maintaining the cellular and functional integrity of the gastric tissue (Main
and Whittle, 1973). The blood supplies essential nutrients, oxygen, and
gastrointestinal hormones to support the upper structure, function and
turnover of the gastric mucosa. The blood also prevents intramucosal
accumulation of hydrogen ions, metabolic waste, and other potential toxins
and sustains bicarbonate secretion, thereby protecting the mucosa by
maintaining a neutral pH in the regional mucosa. In fact, irritants stimulate
prostaglandin-induced vasodilatation but when this is prevented erosions
develop (Whittle, 1977).
Other mechanisms
At extremely low concentrations, prostaglandins can inhibit pro-
inflammatory mediator release, such as histamine, by acting directly on
mucosal mast cells (Hogaboam et al., 1993). As a result, there is a reduction in
the acidity, volume and pepsin content of gastric secretions and also the
defensive hyperaemic responses to luminal irritants. Prostaglandins of the E
and I type inhibit the production of reactive oxygen species production and
enzyme release by neutrophils, found to be important in gastric damage
(Kainoh et al., 1990). Prostaglandins also appear to increase the production of
phospholipid molecules at the surface of the gastric epithelium, which may
repel fluid and provide some degree of protection (Lichtenberger et a!., 1985).
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Finally, prostaglandins can stabilize lysosomal membranes (Ferguson et a!.,
1973).
Consequence of PG inhibiton by NSAIDs
By inhibiting of the synthesis of these prostaglandins, NSAIDs interfere with
gastric mucosal defense. Indeed, pretreatment with NSAIDs certainly
predisposes the mucosa to injury by topical irritants (Whittle, 1983). Many
lines of evidence show that NSAIDs are responsible for forming a mucus gel
poorly suited as a barrier to acid diffusion. Aspirin and other NSAIDs can
reduce mucus secretion (Garner and Allen, 1987), its viscosity (Sarosiek et al.,
1986) and the biosynthesis of mucus glycoproteins (Rainsford, 1978). Aspirin
and indomethacin have also been reported to suppress basal bicarbonate
secretion from gastric and duodenal mucosa, which can be reversed on
administration of exogenous PGE2 (Selling et al., 1987). Inhibition of mucus
and bicarbonate secretion by aspirin causes a substantial reduction in the
hydrophobicity of the mucosal surface (Goddard et a!., 1990). As it is believed
that it is the water-repellent properties of the luminal surface which protects
the mucosa from attack by the luminal acid, such changes by aspirin and other
NSAIDs could, therefore, augment back-diffusion of acid and contribute to the
local irritant effects of these drugs (Whittle, 1992). Additionally, NSAIDs may
impair mucosal defense by decreasing the feedback inhibition of gastric acid
secretion dependent on prostaglandins, and thereby increasing acid secretion
(Taylor et al., 1994). NSAIDs also prevent epithelial repair by dissipating the
pH gradient across the mucoid cap, thereby reducing its effectiveness (Wallace
and McKnight, 1990).
Mucosal injury is associated with focal areas of decreased blood flow, and
experimentally a reduction in mucosal blood flow has been shown as an early
event in NSAID-induced mucosal injury (Kitahora and Guth, 1987). NSAIDs
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induce microvascular ischaemia, partly by causing neutrophil adherence to
the vascular endothelium of the gastric microcirculation, and this can be
blocked by exogenous prostaglandins (Wallace et a!., 1990).
Prostaglandin-Independent Mechanism of NSAID-induced
Gastrointestinal Injury
Lack of correlation between PG inhibition and gastrointestinal damage
It is uncertain that the gastrointestinal injury caused by NSAIDs is due solely
to inhibition of prostaglandin synthesis as several recent studies have shown
no correlation between reduction in mucosal prostaglandin biosynthesis by
NSAIDs and degree of mucosal injury. For example, aspirin given
parenterally (100 mg/kg) or orally (25 mg/kg) to rats did not produce acute
mucosal lesions despite inhibiting prostaglandin generation by up to 95%
(Ligumsky et al., 1983). Only by increasing the dose of aspirin 4-fold and
administering it orally, did the drug produce mucosal injury. It was suggested
that inhibition of cyclooxygenase activity may be a prerequisite for lesion
formation, but alone is not the cause of aspirin-induced damage. The
mechanism of injury may involve topical irritation by high dose of aspirin at
the cellular level. Evidence of a direct mucosal irritant effect of aspirin can be
seen by light or electron microscopy of human gastric mucosa, which shows
signs of ultrastructural damage within 5-10 minutes of oral ingestion of the
drug, too short a time course for prostaglandirt inhibition (Baskin et al., 1976).
Furthermore, omeprazole can abolish aspirin-induced gastric mucosal
lesions, presumably because omeprazole raises the intragastric pH to 5.6-6.9
(Scheiman et al., 1994). Therefore, aspirin which has a pKa of 3.5 is totally
ionised (less than 1% unionised) and unable to diffuse passively into the
gastric cells and evoke damage by "ion-trapping".
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In another study, aspirin was reported to cause structural changes to the
basement membrane of capillary and postcapillary venules in the rat stomach
before damaging the surface epithelium (Rowe et al., 1987). It was postulated
that the vascular injury brought about by aspirin is possibly a result of it being
hydrolysed in vivo to salicylic acid and secondary to the inhibition of
prostacyclin in the vessel wall or thromboxane in the platelets. Salicylic acid
causes direct toxic effects on the epithelial and endothelial cells producing
haemorrhage into the tissue or vascular thrombosis by disruption of the
endothelial cells, and these effects cannot be prevented by the administration
of exogenous prostaglandins. As already mentioned aspirin, as with other
NSAIDs, are thought to damage the gastric mucosa by two mechanisms,
inhibition of prostaglandin synthesis and direct irritant action. It is possible,
therefore, that the topical irritation caused by aspirin is partly due to salicylic
acid formed on hydrolysis.
A lack of correlation was also found with oral ingestion of indomethacin (50
mg for 4 days) by healthy human subjects, which caused a significant
reduction in PGE2 and PGF2a in the fundic and antral regions of the stomach
without any apparent mucosal injury (Redfern et a!., 1987). Again, higher
doses of the drug (a single 100mg dose) did produce mucosal lesions, but did
not further reduce the mucosal concentrations of the prostaglandins. Similar
observations were reported by Ligumsky and coworkers (1990), who showed
that rectal administration of only indomethacin (10, 20 and 30 mg/kg) and
diclofenac (10, 20 and 50 mg/kg) induced significant gastric damage in rats
whereas ibuprofen did so only at its highest dose (100 mg/kg). Sulindac (10, 20
and 30 mg/kg) and aspirin (50, 100 and 200 mg/kg) failed to cause any lesions
at all, despite the drugs inhibiting PGE2 to the same extent.
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Levine et a!. (1988) showed that the NSAID carprofen produced less damage to
the upper gastrointestinal tract despite having comparable antiinflammatory,
analgesic and antipyretic effects to indomethacin in man, and being as
effective at inhibiting prostaglandin synthesis.
NSAID-induced small intestinal damage
Most NSAIDs are known to damage the stomach mucosa. However, an
increasing number of reports suggest that these drugs also cause lesions of the
small intestine. In fact up to 70% of patients receiving NSAIDs for 6 months
or more have evidence of small-intestinal inflammation as a consequence of
increased mucosal permeability (Bjarnason et a!., 1987a). Blood loss is
commonly seen, possibly leading to iron deficiency anaemia, as is protein loss,
which may cause hypoalbuminaemia in some patients. The drugs also cause
ileal dysfunction, reflected as a malabsorption of bile acids. More rarely,
strictures of the small bowel occur (Bjarnason et al., 1988). The inflammation
and the biochemical abnormalities can persist for up to 16 months after
discontinuation of the NSAIDs (Bjarnason and Macpherson, 1989).
High local concentrations of the NSAID are required to induce small-
intestinal lesions. It appears that the damage is partially related to
enterohepatic circulation of the NSAID since drugs not undergoing this
process have been shown not to develop lesions (Reuter et a!., 1997).
Enterohepatic circulation is created when the drug is conjugated in the liver,
eliminated via the bile, then the acyiglucuronide conjugates hydrolysed in the
small intestine by the action of enteric bacterial 3-glucuronidases. The parent
compounds are then reabsorbed lower in the alimentary canal where these
free acids will irritate the mucosal surface. By undergoing enterohepatic
circulation there is long-term exposure of the small intestinal mucosa to the
noxious effect of the NSAID (Duggan et a!., 1975; and Brune et a!., 1985).
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However, this may also result in prolonged prostaglandin inhibition and
damage (Brune et al., 1988).
In addition, the near neutral pH of the intestine together with increased
intestinal permeability, favours entry of bacterial or foreign enteric antigens
into the mucosa, initiating an immunoinflammatory reaction. It is unlikely,
however, that bacteria directly cause intestinal ulceration but instead prolong
or aggravate the drug-induced damage (Benoni et al., 1985). Indeed, NSAID-
induced intestinal ulceration can be significantly reduced by antibiotic
treatment. In contrast, bacterial flora are probably not involved in the
pathogenesis of gastric injury by NSAIDs since the relatively sterile acidic
environment of the stomach minimises contact between bacterial antigens
and the gastric mucosa (Rainsford, 1988).
It is worth noting that electron microscopy shows bacterial invasion at the
sites of the intestinal mucosa damaged by NSAIDs and the development of
the mucosal lesions coincides with a decrease in prostaglandin production
(Rainsford, 1986). Therefore, the reduction in prostaglandin levels is probably
a manifestation, but not the main causal factor, in the development of
NSAID-induced intestinal damage.
A prostaglandin-independent mechanism of NSAID-induced intestinal
injury is further substantiated by the finding that a single dose of
indomethacin caused a significant reduction in prostaglandin generation
within 3h, but it was only after 48h, a time when cyclooxygenase inhibition
was declining, that macroscopic intestinal lesions were apparent (Whittle,
1981). These lesions then develop further, despite the return of
cyclooxygenase activity to normal.
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Redirection of arachidonic acid metabolism
By inhibiting cyclooxygenase, NSAIDs could enhance conversion of
arachidonic acid through the 5-lipoxygenase pathway resulting in elevated
production of vasoconstrictor peptidoleukotrienes ie. LTC4 and LTD 4, plus
the generation of an oxyradical during the conversion of 5-HPETE's to HETE's
in this pathway (Siegel et al., 1979). Similar diversion to the 12-lipoxygenase
pathway by NSAIDs is unlikely as the drugs inhibit peroxidation of 12-HPETE.
The leukotrienes and oxygen radicals could be responsible for mucosal cell
injury by producing vasoconstriction, stasis, and increased vascular
permeability, thereby disturbing gastric mucosal microcirculation. These
microvascular disturbances could then lead to hypoxemia, erosions, and
deepening of ulcerative lesions (Szabo et al., 1985). The role of leukotrienes in
NSAID-induced GI damage is substantiated by the fact that both leukotriene
antagonists and inhibitors of 5-lipoxygenase (MK 447, benoxaprofen and BW
755) reduce the gastric and intestinal ulcers caused by indomethacin
(Rainsford, 1987). Also, there are less ulcers if both cyclooxygenase and
lipoxygenase are inhibited than just cyclooxygenase alone (Rainsford, 1988).
Reactive oxygen species
Reactive oxygen species have one or more unpaired electrons in the outer
orbital shell, rendering them chemically reactive. These may damage proteins
resulting in enzyme inhibition, cause lipid peroxidation leading to
irreversible cellular damage, and react with DNA to cause strand scission and
other abnormalities (Lauristen et al., 1989).
These radicals are thought to initiate the tissue destruction in acute and
chronic inflammation (Lunec et a!., 1981). Ordinarily the host possesses
numerous antioxidant enzymes and free radical scavengers in order to protect
the tissue against the deleterious effects of reactive oxygen species. However,
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in conditions such as rheumatoid arthritis, the inhibitory capacity of these
molecules can be overcome in the synovial fluid and degradation of tissue
can ensue (Harris et a!., 1975).
The gastrointestinal tract is supplied with abundant enzymes necessary for the
production of reactive oxygen species. In addition, the attraction of
neutrophils to areas of mucosal damage, contributes substantially to the
generation of reactive oxygen species via the activation of their NADPH-
oxidase (Lauristen et a!., 1989) and possibly xanthine oxidase (Rajagopalan,
1980). The involvement of cytotoxic reactive oxygen radicals, namely the
superoxide anion 02 ,the hydrogen peroxide H202 and the hydroxyl radical
OH., which probably originate from the peroxidative cleavage of 5-HPETE,
has been shown to be involved in the pathogenesis of NSAID enteropathy
(Del Soldato et a!., 1985; and Fisher et a!., 1991). This is based on the findings
that pretreatment with cysteamine or other free radical scavengers such as
catalase, superoxide dismutase, thiourea, and aminopyrine, significantly
reduced ethanol- or indomethacin-induced gastric and intestinal mucosal
damage in rats.
Adaptive cyto protection
The ability of the gastric mucosa to increase its resistance to injury when
challenged by NSAIDs and other potentially harmful agents such as ethanol,
acid, alkali, bile acids, is known as "adaptive cytoprotection" (Robert et a!.,
1983). It has been proposed that this process involves endogenous
prostaglandin synthesis since prostaglandins enhance mucosal defense by
enhancing bicarbonate and mucus output, and maintaining mucosal blood
flow, plus exogenous prostaglandin therapy effectively mitigates NSAID
associated gastric lesions (Konturek et a!., 1982). However, mild irritants have
not always been shown to stimulate endogenous prostaglandin synthesis,
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even though adaptive cytoprotection has occurred. Some agents, at
cytoprotective concentrations, have even been shown to depress
prostaglandin release (Rees et al., 1984). Indeed, inhibition of PGE2 by
indomethacin did not prevent the cytoprotective changes induced by 20%
ethanol against gastric mucosal injury caused by 100% ethanol (Hawkey et a!.,
1988). Finally, a true 'cyto'-protective effect involving cell membrane
stabilisation could not be demonstrated on administration of prostaglandin
analogues (Guth et a!., 1983). Thus, when assessed microscopically, a
mechanism other than stimulation of prostaglandin synthesis appears to be
involved in adaptive cytoprotection (Hawkey et a!., 1988). There is evidence to
suggest that injury to the gastric mucosa is followed by a formation of a
gelatinous surface layer, which protects against subsequent injury by the same
stimulus (Lacey, 1985).
Neutrophil involvement
The cytokine interleukin-1 has been shown to reduce NSAID injury
presumably by affecting neutrophil function (Wallace et al., 1992). The
somatostatin analogue, octreotide, also reduces NSAID injury in rats and
humans possibly by blocking neutrophil-endothelial interaction (Scheiman et
al., 1997).
Nitric oxide involvement
Nitric oxide also appears to maintain epithelial integrity by enhancing
mucosal blood flow. Inhibition of nitric oxide synthesis in animal models
exacerbates NSAID injury, and nitric oxide donors reduce NSAID toxicity
(Wallace et a!., 1994a).
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1.7	 Hypothesis
In the light of all the evidence that NSAID-induced gastrointestinal injury
can be caused by mechanisms other than inhibition of prostaglandin
synthesis, it has been proposed that the damage is a result of a multistage
process of which prostaglandin inhibition plays a part (figure 1.10). Basically, it
is suggested that the initial 'topical' biochemical action of NSAIDs (stage 1)
would be transformed via a transitional stage of increased intestinal
permeability, to generalised macroscopic damage. There follows a brief
outline of the hypothesis which will be covered in more detail in subsequent
chapters.
On absorption, the NSAID affects the mitochondria causing uncoupling of
oxidative phosphorylation (or inhibition of electron transport). As a result,
there will be a reduction in adenosine triphosphate (AlP) synthesis together
with leakage of calcium (Ca2+) out of the mitochondria. The consequences of
this will be: (a) an increase in cytosolic Ca 2 with subsequent Ca2 toxicity, (b)
generation of reactive oxygen species, (c) a disturbance in Na+/K+ and
therefore cellular osmotic balance, (d) an increase in adenosine diphosphate
(ADP) and adenosine monophosphate (AMP) levels and (d) a loss of control
of intracellular tight junctions resulting in an increased intestinal
permeability.. The events in this first stage of the damage should be caused by
all NSAIDs and occur at any site of absorption, be it the stomach, duodenum,







































































































The increase in intestinal permeability plays an important role in the
transitional stage of NSAID damage. The inhibition of cyclooxygenase
prolongs rather than initiates the permeability changes by preventing the
production of reparative prostaglandins. The increased intestinal permeability
permits mucosal exposure to luminal toxins, which results in non-specific
tissue inflammation. In a somewhat vicious cycle, this inflammation may act
synergistically with the biochemical damage, to further maintain an increase
in intestinal permeability.
The second and final stage in the hypothesized mechanism of NSAID-
induced CI damage is the macroscopic damage caused by the drugs. The
impaired gastric mucosal barrier will enable back-diffusion of acid, pepsin and
bile, whereas disruption of the small intestinal barrier exposes the mucosa to
bile, digestive enzymes, bacteria and their degradation products.
1.8 Aims of the Thesis
1.8.1 Biochemical Stage
The primary goal of this thesis is to investigate the mitochondrial changes
caused by NSAIDs which may preclude to the gastrointestinal damage seen
with these drugs. By using the oxygen electrode it will be possible to monitor
effects of the compounds on mitochondrial respiration. If the NSAIDs
uncouple mitochondrial oxidative phosphorylation then a stimulation of
respiration will occur. If the drugs inhibit mitochondrial electron transport
then oxygen uptake will decline. By using the artificial electron acceptor
ferricyanide, the inhibition, if any, can be localised to particular complex(es) of
the electron transport chain. Then using electron paramagnetic resonance
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(EPR), changes to individual components of the electron transport chain
complexes, in the presence of the NSAIDs, can be viewed. Finally, a measure
of mitochondrial ATP production in the presence of the NSAIDs, will further
validate whether mitochondrial function has been compromised by these
drugs.
1.8.2 Transitional Stage
The transition between the biochemical changes and the macroscopic damage
caused by NSAIDs is characterised by increased intestinal permeability. This
can be studied in detail by using intestinal cell lines (namely Caco-2 and T84)
and measuring effect of the drugs on their transepithelial electrical resistance
(TER). A decrease in the TER will reflect an increase in permeability. The TER








Experimental evidence suggests that the mitochondrion is the main site of
early NSAID-induced gastrointestinal damage. Before macroscopic damage is
evident, electron microscopy (EM) reveals extensive ballooning,
vacuolisation and cristae disruption of the rat gastric (Robins, 1980; and
Rainsford, 1975) and intestinal (Somasundaram et a!., 1992) mitochondria
within only 1 hour of NSAID administration (figure 2.1). At 1 and 6 hours,
after NSAID administration there are significant increases in specific
mitochondrial marker enzymes, these being succinate dehydrogenase, citrate
synthase and cytochrome c oxidase. Gross gastrointestinal damage caused by
NSAIDs only becomes apparent in rats after 10 or more hours of drug
administration.
In order to assess the effect(s) of NSAIDs on mitochondria, it is necessary first
to understand the normal structure and function of this organelle.
2.1	 Structure of Mitochondria
Mitochondria are subcellular organelles, often located near a source of fuel on
which they depend, such as cytoplasmic fat droplets, or near structures such as
muscle fibres that require ATP, the major product of their biochemical
activity (Lehninger, 1975). Mitochondria take up about 20 percent of the
cytoplasmic volume in liver cells and over 50 percent in heart muscle cells.
Mitochondria are generally ellipsoidal, approximately 0.5j.tm in diameter and
1pm in length. They have two membranes, a smooth outer membrane and an
inner membrane folded into cristae which project into the interior matrix (see
figure 2.1). Embedded in the phospholipid bilayer of the inner mitochondrial
membrane (1MM) are numerous biologically active proteins,
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(the 1MM is 75% protein by mass). These proteins include electron transfer
proteins, enzymes involved in ATP synthesis, certain dehydrogenases, and
various metabolite transport proteins such as those for AlP, ADP, pyruvate
and Ca2 . The remaining 25% of the 1MM comprises of lipids, predominantly
phosphatidyicholine (-40%), (-35%), and cardiolipin (-15%). The extent to
which the cristae are folded relates to the respiratory activity of the cell, since
this increases the surface area of the 1MM. Therefore, muscle mitochondria
contain a larger number of more densely packed cristae than, say, liver
mitochondria. Table 2.1 summarises the enzymes located in the different
compartments of rat liver mitochondria.
Inside the inner compartment of the mitochondria is a gel-like protein-rich
matrix of <50% water, whose volume and state of organisation changes with
alterations in respiratory activity (Voet and Voet, 1995). As well as containing
soluble oxidative enzymes (see table 2.1), the matrix also contains DNA, RNA
and ribosomes, responsible for generating some mitochondrial proteins. The
human mitochondrial DNA is a double helical circle and 60% of its protein-
coding capacity is used to specify seven subunits of NADH-coenzyme Q
reductase (Complex I) in the 1MM (see section 2.2.1). The DNA also encodes a
cytochrome reductase subunit, three cytochrome oxidase subunits, and two
ATP synthase subunits (Stryer, 1988).
The outer membrane of the mitochondria contains a protein known as porin
which forms nonspecific aqueous pores that enable free diffusion of
molecules up to lOkDa (Voet and Voet, 1995). The 1MM, on the other hand, is
impermeable to most ions, metabolites, and low molecular weight
compounds and is only freely permeable to 02, CO2. and H20. Thus,
compartmentalisation of metabolic functions occurs between the cytosol and
the mitochondrial matrix.
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Fatty acyl-CoA oxidation enzymes
Adapted from Lehninger (1975).
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2.2 Function of Mitochondria
The mitochondrion is known as the "powerhouse" of the cell since it is this
organelle which transduces most of the energy derived from respiratory
oxidation.
2.2.1 The Respiratory (Electron Transport) Chain
The free energy from the oxidation of fats, amino acids and carbohydrates is
made available within the mitochondria as reducing equivalents (H or
electrons), mainly carried on NADH. The respiratory chain transports these
reducing equivalents to their final reaction with molecular oxygen to form
water. Electrons flow through the chain from the more electronegative
components to the more electropositive oxygen (figure 2.2). The
mitochondria also contains the enzyme systems responsible for producing the
reducing equivalents in the first place, i.e. the enzymes of n-oxidation and of
the citric acid cycle (Mayes, 1993).
Inhibitors exist which can block electron transport at specific sites in the chain,
thereby reducing mitochondrial oxygen consumption. These inhibitors have
been used as tools for studying the structure and function of the respiratory
chain and will be looked at more closely in chapter 3.
2.2.2 ATF Generation
The passage of electrons through the protein complexes with progressively
greater electron affinity (increasing standard reduction potentials), generates a
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Figure 2.2 The electron transport chain
Electrons are passed from one electron carrier to the next down the electron
transport chain, which spans the inner mitochondrial membrane (1MM). This
eventually results in the reduction of molecular oxygen to form water. The
transport of electrons down the chain (thick lines) causes protons (H+) to be
pumped out of the mitochondrial matrix (dashed lines). The passage of H
back into the matrix, through F 1 F0 .ATPase (Complex V) 1 enables ATP to be
synthesised.
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large amount of free energy which is captured to synthesise ATP from ADP
and P1• The process by which mitochondria couples respiration to the
generation of ATP is termed "oxidative phosphorylation".
The mechanism by which the energy released from respiration is harnessed to
drive AlP synthesis can be explained by the "Chemiosmotic Coupling" model
(Mitchell, 1976). The model proposes that the energy from electron transport
enables protons to be actively pumped out of the mitochondrial matrix by the
respiratory complexes, into the intermembrane space (see figure 2.2). Since the
1MM is impermeable to protons, an electrochemical gradient for protons is
generated, with a lower pH outside the 1MM than inside. In other words, the
free energy is used to maintain this proton gradient. When protons do flow
back into the matrix down their gradient, it is via the F 1 F0 complex or
complex V (figure 2.3). The H passes back into the matrix down a specific
proton channel in the F0 portion of this complex which spans the 1MM. The
free energy released, as the proton gradient is dissipated, is used to
phosphorylate ADP to AlP, and is catalysed by the F1 component of the
complex.
Stoichiometric relationships between the oxidation reactions during electron
transport and proton pumping have not been established with certainty
(Wrigglesworth, 1997). It is often reported between two and four protons are
pumped out of the mitochondria per pair of electrons passing through each
respiratory complex. Between 2 and 3 protons are required to synthesise ATP
by the F0F1ATPase. Other protons are required for various transport systems,
such as for the transport of inorganic phosphate into the mitochondria. PlO
ratios for oxidation by complexes I, II and III therefore vary according to
conditions, but experimental values are usually taken to be 2.6, 1.6 and 1.2
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respectively for complete oxidation of an electron pair entering into each
complex respectively.
2.2.3 Uncoupling of Oxidative Phosphorylation
Electron transport (the oxidation of NADH and FADH2) and phosphorylation
(AlP synthesis) are normally tightly coupled. In the resting state when ATP
synthesis is minimal, the electrochemical gradient across the 1MM continues
to build up until it prevents further pumping of protons and inhibits electron
transport. A class of compounds have been shown to uncouple these
processes and include 2,4-dinitrophenol (DNP) and the 300 times more potent
trifluorocarbonylcyanide phenyihydrazone (FCCP). These uncouplers, when
added to mitochondria, remove the link between substrate oxidation and ATP
synthesis.
Uncouplers are all moderately weak acids with pKa's in the range 5-7, and
therefore will normally be dissociated at intracellular pH. However, when the
uncoupler molecule approaches the 1MM from the outside, the phenolic
hydroxyl group of DNP or the N of FCCP, become protonated due to the lower
pH in this region. This protonation makes the molecule more hydrophobic so
that it can diffuse into the membrane and pass through down its
concentration gradient. Once inside the mitochondrial matrix, the higher pH
means that the phenolic hydroxyl group deprotonates (figure 2.4). Thus, the
uncoupler acts as a protonophore, transporting H back into the matrix whilst
bypassing the F0 proton channel. Hence, ATP synthesis is prevented by
dissipation of the electrochemical gradient. Electron transport can then
proceed at a much faster rate due to the lack of inhibition by the









































































Another interesting feature of most of the classic uncouplers is that in
excessive concentrations (higher than that required to uncouple oxidative
phosphorylation), these compounds will inhibit mitochondrial respiration
(Kraayenhof and van Dam, 1969), a characteristic not directly related to their
uncoupling properties (Wedding et al., 1967). Consequently, these compounds
have also been termed "inhibitory uncouplers" (Moreland, 1994). It has been
suggested that the uncoupler competes with respiratory substrates (e.g.
succinate or glutamate and malate) for penetration into the mitochondrial
matrix, and a decrease in the intramitochondrial concentration of these
substrates results in an inhibition of mitochondrial respiration (van Dam,
1967; and Quagliariello and Palmieri, 1968). In addition, the diminution in
substrate uptake is reversible since it can be overcome by higher substrate
concentration (Quagliariello and Palmieri, 1968). This competitive
mechanism could explain why a relatively high concentration of uncoupler is
required to inhibit respiration. Indeed, at lower uncoupler concentrations,
when respiration was still being stimulated, there was no effect of these
compounds on substrate uptake (Harris et al., 1967).
An alternative mechanism for uncoupler-induced inhibition of respiration is
thought to be mediated by a 3lkDa hydrophobic polypeptide, the "uncoupler
binding protein" (Hanstein et a!., 1979). Binding to this protein of higher
uncoupler concentrations than those required for complete uncoupling, has
been shown to induce inhibition of respiration (Katre and Wilson, 1978). This
protein is thought to reside on the inside of the inner mitochondrial
membrane, probably a component of the membrane sector of ATPase i.e. F0
(Hanstein et a!., 1979). However, a later study showed that it was a
conformational change of the cytochrome bci complex which elicited
inhibition of mitochondrial respiration by uncouplers (Tokutake et a!., 1991).
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2.3 Effect of NSAIDs on Oxidative Phosphorylation
2.3.1 The Salicylates
As early as 1956 it was reported that salicylates uncouple oxidative
phosphorylation in mitochondrial systems (Brody, 1956). Since then, many
more studies have also demonstrated the uncoupling of oxidative
phosphorylation with aspirin and other salicylates, often apparent as an
increase in oxygen consumption (Fishgold et a!., 1951; Cochran, 1952; Sproull,
1954; Mackerer et a!., 1973; Jorgensen et a!., 1976a; Spenney and Bhown, 1977;
and Tomoda et a!., 1992).
Mechanism of Uncoupling
At first, the exact mechanism of uncoupling by salicylates was not known and
it was thought that these compounds, including aspirin, uncoupled by
increasing mitochondrial ATPase activity and decreasing phosphate uptake,
apparent as an increase in total inorganic phosphate. DNP was shown to be
100 times more potent than salicylate (Miyahara and Karler, 1965; Brody,1956;
and Falcone, 1959). Charnock and Opit (1962) suggested that salicylates
uncoupled by increasing the permeability of the mitochondrial membrane to
ATP, thus stimulating ATPase activity and ATP breakdown. Oxidative
phosphorylation was found to be uncoupled in the liver mitochondria of rats
fed dietary aspirin (in vivo) (Mehiman et al., 1972; and Mackerer et a!, 1973)
and also when aspirin was given in vitro (Mehlman et a!., 1972). However,
only the in vitro effects were thought to be attributed to a stimulation of
mitochondrial ATPase activity, whereas the mode of uncoupling in vivo was
perhaps more complex.
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It is now known that the uncoupling caused by salicylates is not primarily by
stimulation of ATPase activity, as was initially thought. This is because in the
presence of oligomycin, an F1 ATPase inhibitor, there is still an increase in
oxygen consumption with salicylate. Instead, salicylic acid acts as a proton
ionophore entering the mitochondrial matrix by nonionic diffusion and then
dissociating to yield salicylate and H (Gutknecht, 1990). Therefore, the
uncoupling caused by salicylates is by a similar mechanism to DNP (Brody,
1956; Jeffrey and Smith, 1959; Whitehouse, 1964a; and Aprille, 1977).
It must be noted that in vivo the uncoupling induced by aspirin has been
suggested to be due to salicylic acid, to which it is hydrolysed, and not the
parent compound itself (Thompkins and Lee, 1969). On absorption from the
gastrointestinal tract, aspirin is rapidly hydrolysed (t112 20mm) to form
salicylic acid and acetic acid (Needs and Brooks, 1985). The proposed inability
of aspirin to uncouple may be because the mitochondrial membrane is
relatively impermeable to this drug even in the protonated form, and so there
will be very little H uptake into the matrix by aspirin (Gutknecht, 1992).
Therapeutic Significance
Cochran (1954) first speculated that the uncoupling could be of fundamental
importance to the therapeutic action of salicylates as antiinflammatory agents
since, these drugs, together with phenylbutazone, showed strong
antiinflammatory efficacy and also uncoupled oxidative phosphorylation and
stimulated respiration. However, this idea was dispelled by the finding that
DNP, which strongly uncoupled and increased oxygen consumption, was not
antiinflammatory (Adams and Cobb, 1958). Despite the reports that DNP can
inhibit both ultraviolet erythema in guinea pigs (Winder et a!., 1958) and
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dextran/formation oedema in rats (Stenger, 1959), it is still unlikely that the
uncoupling activity of DNP is related to these antiinflammatory properties
since DNP is highly labile in biological systems and is rapidly metabolised in
the liver to 2-amino-4-nitrophenol which has no uncoupling activity (Cross
et al., 1949).
Reye's Syndrome
Reye's syndrome is an often fatal syndrome which occurs in children after a
prodormal viral illness and is characterised by fatty degeneration of the liver
and kidneys, rapid swelling of the brain, seizures, and loss of consciousness
(Reye et at., 1963; and Huebi et a!., 1987). In patients with Reye's syndrome, the
mitochondria are grossly swollen and deformed, with the matrix containing
coarsely granular materials, and cristae being few in number, widely spaced,
and fragmentary (Thaler et al., 1972). The greater the structural change the
more severe the illness. For example, in the comatosed patients the
mitochondrial alterations are profound (Lichtenstein et a!., 1983). Also the
persistent high fever and high overall metabolic rate would suggest
uncoupling of mitochondrial oxidative phosphorylation with elevated
respiratory rates but decreased ATP formation (Trost and Lemasters, 1996).
It is suggested that aspirin may be associated with outbreaks of the disease
since aspirin poisoning has many similarities to Reye's syndrome (You, 1983).
Also a decrease in the incidence of outbreaks of Reye's syndrome is paralleled
with a decrease in aspirin use in children (Pinsky et a!., 1988). Experimental
evidence suggests that it is salicylate, the principal metabolite of aspirin,
which is involved in the pathogenesis of Reye's syndrome. Salicylate-treated
mitochondria and mitochondria from Reye's syndrome patients are
ultrastructurally similar. Likewise, the uncoupling and inhibition of
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mitochondrial dehydrogenases by salicylate could explain the mitochondrial
injury caused by these drugs in Reye's syndrome (You, 1983).
2.3.2 Other NSAIDs
Although the earlier studies were mainly concerned with the salicylates, a
wealth of evidence that other NSAIDs also uncouple oxidative
phosphorylation, soon emerged. These studies were spearheaded by
Whitehouse and associates throughout the 60's and early 70's. Table 2.2
summarises the findings of Whitehouse and other investigators. In the
majority of the mentioned studies, the NSAIDs were compared to the classic
uncoupler 2,4-dinitrophenol and found to have similar characteristics, albeit
to varying degrees.
It has long been suggested that lipid solubility, pKa, and affinity for protein
amino groups are important determinants of the uncoupling activity of
NSAIDs (Whitehouse, 1965). Because NSAIDs are generally lipid-soluble
weak acids, they themselves will not inhibit specific enzymatic reactions in
the mitochondria, but probably act as protonophores in a manner similar to
DNP and FCCP (Famaey and Mockel, 1973). In fact, NSAIDs have a chemical
structure resembling that of typical uncouplers. They are usually
monocarboxylic acids with one or two aromatic rings. Such structures are
fairly lipophilic with varying degrees of membrane solubility. Protons are
carried across the 1MM by a continuous interchange, within the membrane, of
the protonated and deprotonated forms of an acidic group of the uncoupler.
Thus, an acid dissociable group is a prerequisite for uncoupling activity
(Terada et al., 1988). With NSAIDs, this is generally the carboxylic acid side
chain with the exception of the piroxicams and phenylbutazone.
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Table 2.2	 A summary of studies investigating the effects of NSAIDs on
mitochondrial function
NSAIDS tested	 Properties relating to uncoupling of Reference
oxidative phosphorylation
Phenylbutazone, 	 (i) Stimulate ATPase activity	 Whitehouse and
oxyphenbutazone,	 (ii)Inhibition of P1 incorporation Haslam, 1962
salicylic acid,	 into ADP (i.e. AlP biogenesis)
mefenamic acid,
flufenamic acid
Indomethacin,	 (i) Decreased PlO ratio	 Whitehouse, 1964b
phenylbutazone,	 (ii)Inhibition of P1 incorporation
salicylic acid into ADP (i.e. AlP biogenesis)
without inhibiting oxidative
metabolism and respiration
Flufenamic acid,	 (i) Inhibition of P1 incorporation	 Tokumitsu et a!., 1977
aspirin, ibuprofen	 into ADP
(ii) Stimulation of respiration
(iii) Stimulation of ATPase
activity
Indomethacin	 (i) Decreased PlO ratio	 Byczkowski and
(ii) Stimulation of ATPase	 Korolkiewicz, 1977
activity
(iii) Stimulation of respiration
Diflunisal, mefenamic (i) Stimulation of ATPase 	 McDougall et al.,
acid	 activity	 1983
(ii) Stimulation of respiration
followed by inhibition of this
stimulation at higher
concentrations
Butibufen	 (i) Reduction in ATP levels 	 MIguez et a!., 1986
(ii) Increase in oxygen consumption
Diflunisal, piroxicam, (i) Increase in oxygen consumption Baños and Reyes, 1989
indomethacin,	 followed by an inhibition of this
naproxen,	 stimulation at higher
phenylbutazone,	 concentrations
sodium diclofenac,	 (ii) Concentration-dependent





Timbrell (1991) has reported that uncouplers evoke contraction of the
mitochondria, and that prolonged contraction leads to a deterioration of the
inner membrane resulting in high amplitude swelling and eventually
membrane rupture. Mitochondrial swelling and disruption of its structure
often precedes cell death and necrosis. The NSAIDs indomethacin, flufenamic
acid, mefenamic acid, phenylbutazone, oxyphenbutazone, and aspirin have
been shown to induce mitochondrial swelling and, initially, it was thought
that this occurred at the same concentrations at which they uncoupled
oxidative phosphorylation (Famaey, 1973). However, more recently, it was
reported higher concentrations of the drugs diclofenac (sodium salt),
mefenamic acid, and salicylate were required to uncouple and/or inhibit
oxidative phosphorylation than to induce swelling (Mingatto et a!., 1996).
Therefore, this would suggest that the mitochondrial swelling precedes the
uncoupling and/or inhibitory effects of NSAIDs on oxidative
phosphorylation. Nevertheless, due to the relatively high concentrations of
NSAIDs required to induce such swelling, the relevance to their therapeutic
actions remains uncertain.
2.4 Aims of the Studies
In the studies of this thesis, as with most of the studies documented in table
2.2, rat liver mitochondria have been used rather than intestinal
mitochondria. This is simply because of the ease with which intact, pure,
coupled mitochondria can be prepared in high yields from liver (Rickwood et
a!., 1987). Coupled intestinal mitochondria are difficult to obtain for routine
use. The validity of using rat liver mitochondria as a surrogate for studying
uncoupling is, however, consistent with the universality of the chemiosmotic
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coupling mechanism between electron transfer and oxidative
phosphorylation (McLaughlin and Dilger, 1980).
Oxidative phosphorylation and the effect of agents which uncouple it, can be
assessed experimentally by measuring the rate at which a suspension of
mitochondria consumes oxygen. This is most conveniently done using an
oxygen electrode which can rapidly and continuously assay the respiratory
activity of small samples of mitochondria. When electron transport is
uncoupled from ATP synthesis, oxygen uptake proceeds at a higher rate even
in the absence of added ADP. Uncoupling can be achieved chemically, as
noted earlier, by compounds such as FCCP (Mathews and van Holde, 1996).
There follows a brief outline of various studies carried out on the effects of
NSAIDs on oxidative phosphorylation.
Study 1
The aim was to study the effect of the NSAIDs indomethacin, aspirin,
naproxen, piroxicam and ketoprofen on mitochondrial oxygen uptake. The
control was the analgesic paracetamol which has very little or no
antiinflammatory properties. The effect of these drugs were compared to the
classic uncoupler FCCP.
Study 2
To investigate if the acidic pro-NSAIDs sulindac and fenbufen had any
uncoupling effects on mitochondrial respiration. Both fenbufen and sulindac
need to be metabolised in vivo to exert antiinflammatory activity. It is the
suiphide metabolite of sulindac (Duggan et al., 1977) and the biphenylacetic
acid metabolite of fenbufen (Tolman and Partridge, 1975) which are important
for the drug's ability to inhibit cyclooxygenase. Likewise, the effect of the
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nonacidic prodrug nabumetone was studied and compared to its active
metabolite 6-methoxy-2-naphthylacetic acid (6-MNA).
The acid-dissociable group is an essential requirement for a compound to be
able to uncouple. Analogues of uncouplers, where the acid-dissociable group
has been replaced by a non-dissociable group, have no uncoupling activity
(Terada et al., 1988). Therefore, one would expect that the compounds
fenbufen, sulindac and 6-MNA to uncouple mitochondria in vitro since they
are acidic and nabumetone not to uncouple.
Study 3
To study the effect of the NSAID flurbiprofen and its nitroxylbutyl ester
derivative NO-flurbiprofen. It has been reported that NO-NSAIDs (including
NO-flurbiprofen) cause little or no gastrointestinal injury, whilst being
equally as effective as an antiinflammatory agent or cyclooxygenase inhibitor
as the native NSAID (Wallace et a!., 1994a,b). Moreover, NO-flurbiprofen has
been shown to accelerate the healing of experimental gastric ulcers (Elliot et
al., 1995) and to be associated with significantly less intestinal ulceration than
flurbiprofen (Somasundaram et a!., 1997). It is postulated that this is due to
the release of the nitric oxide (NO) group during drug absorption (Davies et
a!., 1997; and Reuter et a!., 1994, 1997). This is substantiated by the findings that
NO or other drugs that generate NO (e.g. sodium nitroprusside or glyceryl
trinitrate) reduce the severity of experimental gastric mucosal injury
(MacNaughton et a!., 1989; and Kitagawa et a!., 1990).
NO is an inorganic gaseous free radical, shown to possess a variety of
biological functions, including regulation of vascular tone, platelet
aggregation, leukocyte adhesion, and immune host defense (Moncada et a!.,
1991). Abnormalities of NO production may play a central role in the
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pathogenesis of many disease processes. For example, inhibitors of NO
synthesis appear to exacerbate gastric mucosal injury induced by
indomethacin by reducing mucosal blood flow, causing neutrophil adherence
to the vascular endothelium (Pique et al., 1989; and Kubes et al., 1991).
It is possible, therefore, that NO-flurbiprofen will not uncouple isolated
mitochondria, but flurbiprofen will.
The stability of NO-NSAIDs as supplied is stated in the manufacturer's data
on file as being greater than one year without deterioration. Whether the NO
moiety may be released in vitro, however, has not been assessed.
Study 4
To investigate if the orally active, synthetic prostaglandin E1 methyl ester
analogue, misoprostol, could prevent the uncoupling induced by
indomethacin in isolated mitochondria. Conventional antiulcer therapies,
such as H2 receptor antagonists, antacids, and sulcrafate, are ineffective in
preventing NSAID-induced ulceration and so are not approved for this use by
the US Food and Drug Administration (FDA) (Wallace, 1992). Prostaglandin
analogues, on the other hand, have been approved for the treatment of
NSAID-induced gastropathy.
In clinical trials, the prostaglandin misoprostol has been shown to reduce
NSAID-induced gastroduodenal injury both in the short and long term
(Silverstein et a!., 1995). Similar findings have been demonstrated in the rat
model (Davies et al., 1994). However, it is not clear if the protective effect of
misoprostol is a mitochondrial-, prostaglandin- or vascular-mediated effect.
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In order to assess the in vivo effects of indomethacin in the presence and
absence of misoprostol on the mitochondria, electron microscopy (EM)
studies was performed. 4 rats were given (1) control (solvent only), (2)
mdomethacin 10 mg/kg body weight, (3) misoprostoi 60 pg/kg body weight or
(4) indomethacin and misoprostol.
Study 5
To study the effect of a mixture of glucose and citrate on indomethacin-
induced mitochondrial uncoupling. In the whole animal, a similar glucose-
citrate formulation (containing sodium acid citrate) of indomethacin (in a
ratio of 15:15:1) has been shown to protect the gastrointestinal tract from the
deleterious effects of indomethacin (Rainsford and Whitehouse, 1980; and
Davies et al., 1994). In humans, administration of 15mg glucose and 15mg
sodium citrate to each mg of indomethacin, prevented the expected increase
in small intestinal permeability caused by indomethacin in the short-term
(Bjarnason et a!., 1992).
Likewise, a glucose-citrate-azapropazone mixture reduced the gastric mucosal
damage in rats and faecal red cell loss in human volunteers, when compared
to subjects treated with azapropazone alone (Rainsford et al., 1991). Though
glucose and citrate reduced the ulcerogenic properties of azapropazone, these
nutrients did not modify the ability of azapropazone to relieve pain and
inflammation. Therefore, it would appear that such an NSAID formulation
has great clinical potential as one which produces less gastrointestinal side
effects. However, long-term safety studies on these compounds have not been
performed.
In the experiments of this study, a glucose-citrate-indomethacin mixture (Na
salts) was made up in a ratio of 15:15:1 in accordance with the study carried
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out by Bjarnason et al. (1992). The effects of this mixture on indomethacin-
induced uncoupling was investigated in vitro in isolated mitochondria.
For in viva assessment, rats were orally administered (1) solvent only, (2) 450
mg/kg body weight glucose and 450 mg/kg body weight citrate, (3) 30 mg/kg
body weight indomethacin, or (4) indomethacin with glucose and citrate
(1:15:15). The intestinal mitochondria were then viewed by EM.
2.5 Materials and Methods
2.5.1 Animals
Throughout these studies male Sprague-Dawley rats (Charles River
Laboratories), 6-8 weeks old and weighing 200-250 g were used.
2.5.2 Materials
Reagents
The following were purchased from Sigma Chemical Company Ltd., Dorset,
England: the buffer ingredients 3- [N-morpholino]propanesulfonic acid
(MOPS), D-mannitol, fatty acid-free bovine serum albumin (BSA); substrates
sodium (Na) succinate, Na2 adenosine diphosphate (ADP); uncoupler
carbonyl-cyanide-p-trifluoromethoxyphenyl hydrazone (FCCP); drugs
indomethacin, aspirin, naproxen, piroxicam, ketoprofen, sulindac, fenbufen,
flurbiprofen, paracetamol.
British Drug House (BDH) Ltd., Poole, England, supplied the buffer
constituents sucrose, Na2 ethylenediamine tetraacetic acid (EDTA), potassium
106
chloride (KCI), tris[hydroxymethyl]aminomethane (tris), magnesium chloride
(MgC12), potassium dihydrogen orthophosphate (KH2PO 4); the substrates
glucose and sodium citrate; sodium hydroxide (NaOH) and concentrated
hydrochloric acid (HC1) required for neutralisation; the solvents dimethyl
sulphoxide (DMSO) and ethanol; and the reducing agent sodium dithionite
(Na2S2O4).
Misoprostol was obtained as a powder from Searle, High Wycombe, U.K.
Nitrobutyl-flurbiprofen was supplied by Nicox SA, Paris, France.
Instruments
Homogenisation of tissue was achieved by using a glass-Teflon motorised
Potter-Elvejhem homogeniser at a fixed speed. Centrifugation was performed
on a Beckman centrifuge with the JA-20 fixed rotor. Oxygen consumption
measurements were done using a Clarke-type oxygen electrode fitted with a
thermostatted Plexiglass reaction chamber (Rank Brothers, Cambridge, U.K.).
The electrode was connected to a chart recorder running at a speed of
1cm/minute. All glassware and centrifuge tubes were kept cool (4°C) prior to
use, and buffers and solutions were kept on ice throughout the experiment. In
order to prevent electrode poisoning and compounds attaching to the
chamber wall, the electrode was cleaned and the chamber soaked in ethanol
overnight then rinsed thoroughly, before each experiment.
2.5.3 Methods
Solubulisation of the Compounds
Succinate and ADP were prepared as 1M and 20mM stock solutions
respectively by dissolving in distilled water. The uncoupler FCCP was
prepared as a 1mM stock solution in 100% ethanol. Stock solution
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concentrations for the drugs were as follows: 50mM indomethacin, 100mM
aspirin, 100mM and 250mM paracetamol, 1M naproxen and 2mg/mi
misoprostol. Indomethacin, aspirin and paracetamol were prepared in 10%
DMSO and the pH adjusted to 7.4 with 1M NaOH. (The conventional method
of dissolving these drugs in sodium bicarbonate was not used as the high pH
of this solution would itself have affected mitochondrial respiration (Tobin et
a!., 1972)). Naproxen and misoprostol were soluble in water. Control
experiments containing either 10% DMSO or water, showed that these
solvents by themselves did not affect mitochondrial respiration at the
volumes used in the present studies.
Isolation of Rat Liver Mitochondria
This was essentially the same as Schneider and Hogeboom (1950) with a few
modifications. The rat was killed by cervical dislocation and the liver rapidly
dissected out. Using scissors, the tissue was chopped up in ice-cold saline
(0.9%) to approximately 1cm 3 pieces and the saline decanted off. The tissue
pieces were washed once more with fresh saline, which was again decanted,
in order to remove any excess blood.
The chopped liver was placed in 50m1 homogenising buffer consisting of 75
mM sucrose, 225 mM mannitol, 10 mM MOPS, 1mM EDTA, 5mg/ml BSA,
pH adjusted to 7.4 with 1 M NaOH. (BSA was included to remove the fatty
acids found in isolated mitochondria which may uncouple the mitochondria
(Matsuoka and Nakamura, 1979; and Soboll et a!., 1984)). The liver was then
homogenised by passing the teflon homogeniser up and down the tube 6
times.
The homogenised mixture was then divided equally into two precooled 5Oml
polythene centrifuge tubes, each made up to approximately 30 ml with
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homogenising buffer, then centrifuged at 500 g for 10 minutes. This sediments
the heavier particles, such as any unlysed cells, nuclei and large membrane
fragments. The supernatant was then carefully decanted into fresh tubes,
made up to 30 ml and centrifuged for 10 minutes at 12,000 g. A crude
mitochondrial pellet is sedimented but needs to be 'washed' as it contains
other components such as lysosomes, peroxisomes and membrane fragments.
Therefore, the supernatant was removed, and the pellet resuspended in 30 ml
buffer, then this mixture again spun at 12,000 g for 10 minutes. The
supernatant was discarded and the pellet resuspended in a minimal volume
of homogenising buffer. This yields a relatively pure mitochondrial
preparation (Rickwood et al., 1987), and takes no more than 1 1/2 hours.
Protein Determination
This was carried out using Pierce's protein assay kit (Pierce, Illinois, U.S.A.),
with BSA being used as the protein standard. Mitochondrial protein
concentrations could then be measured spectrometrically at an absorbance of
562nm.
Measurement of Oxygen Consumption
Electrode set-up
Mitochondrial respiration, hence the functioning of the electron transport
chain, was measured using a Clarke-type oxygen electrode (Clarke, 1956) as
first described by Chance and Williams (1956). The oxygen electrode consists of
a silver/silver chloride reference anode surrounding a platinum cathode
(Rickwood et al., 1987; and figure 2.5). These electrodes are immersed in
saturated KC1 solution and separated from the main chamber by a thin Teflon
















Figure 2.5 The oxygen electrode
This Clarke-type oxygen electrode enables direct measurement of the oxygen
content of solutions within its reaction chamber. Problems of measurement
can arise by uneven stirring and by back-diffusion of oxygen through the
Perspex walls of the chamber.
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At the platinum cathode, oxygen molecules are reduced by electrons to water:
4H + 4e +02 -> 21120
whilst the chloride anions migrate to the silver anode, releasing electrons:
4Ag + 4C1 -> 4AgC1 + 4e
The transfer of electrons from the cathode to the anode creates a current
between the two electrodes which can be measured in an external circuit.
With the electrodes polarised at 0.6 volts, the current generated is
proportional to the partial pressure of oxygen in the sample. This current is
also very temperature-sensitive and, therefore, it is important to operate the
electrode at a constant temperature by means of a water temperature jacket.
The oxygen electrode buffer comprising of 150 mM sucrose, 20 mM KC1, 10
mM tris, 5 mM MgC12.6H20, 1 mM KH2PO4, pH 7.4 with concentrated HC1, is
vigorously stirred with a magnetic stirrer. This ensures an equilibrium
between the oxygen dissolved in the solution and the gas diffusing through
the Teflon membrane of the electrode.
The electrodes are enclosed in a small chamber of imi capacity which is sealed
by a close fitting cap, except for a tiny aperture for addition of solutions, to
minimise the stirring in of oxygen from the surrounding air.
Calibration of the oxygen electrode
1. imi distilled water was added to the reaction vessel and stirred in order to
achieve maximum saturation with atmospheric oxygen at the measurement
temperature allowed 30°C and then the stopper inserted.
2. The pen of the chart recorder can be adjusted to full deflection using an
appropriate choice of sensitivity. This represents 250p.M oxygen (i.e.
atmospheric oxygen dissolved in distilled water at 30°C).
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3. On removal of the stopper, a few crystals of sodium dithionite (a strong
reducing agent) is added to the reaction chamber to purge the dissolved
oxygen, and the stopper reinserted. The pen rapidly drops to the bottom of the
chart paper and is adjusted to a zero mark, indicating 0% oxygen in the
mixture. Thus, two concentrations of oxygen, 0 and 250pM, are known from
which other concentrations can be determined assuming a linear response of
the electrode.
4. The chamber is washed out thoroughly with distilled water before
proceeding with any experiments, as the Plexiglass (plastic) vessel wall has an
avidity for dithionite (together with lipid soluble compounds), so any carry-
over to the next experiment may give spurious results (Estabrook, 1967).
Experimental procedure
lml of oxygen electrode buffer was added to the reaction chamber and allowed
to equilibriate with atmospheric oxygen for approximately 5 minutes, whilst
being stirred at 30°C.
On insertion of the stopper, mitochondria, substrates, drugs etc., were added
The general sequence of addition was as follows, for (a) the measurement of
phosphate/oxygen (PlO) and respiratory control (RCR) ratios: lOOp1 isolated
mitochondria, 1mM succinate, and 0.2mM ADP; and (b) the uncoupling
experiments: mitochondria, succinate, FCCP or drug, then ADP. Each
different concentration of drug was added to a fresh sample of mitochondria.
Solutions added never exceeded 200p1. After every addition a period of
approximately 1-2 minutes was allowed to elapse in order to observe
measurable rates for oxygen uptake on the chart recorder.
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Succinate was used as the substrate in these experiments because it gives a
good rate of respiration against which uncoupling can be compared. The fact
that succinate donates electrons specifically to complex II of the mitochondrial
respiratory chain was of no significance to the present experiments since
uncoupling is not substrate-dependent (Terada, 1981).
Measurement of PlO and respiratory control ratios
Respiratory control is generally regarded as an excellent index for the integrity
of isolated mitochondria (Hatefi et al., 1961). When 'tightly coupled'
mitochondria are added to an isotonic buffer a relatively slow rate of oxygen
consumption is measured with the oxygen electrode, caused by oxidation of
endogenous substrates. Addition of an oxidisable substrate such as succinate
increases the respiration rate. On addition of ADP, there is an immediate and
further increase in the rate of oxygen uptake, known as state 3 respiration
(Chance and Williams, 1956). State 3 respiration reflects the conversion of
ADP to ATP and its duration is dependent on the amount of ADP added. State
3 respiration will persist until all the ADP has been phosphorylated to ATP.
The rate of respiration then slows down again, and this is known as state 4
respiration (figure 2.6).
Since the concentration of oxygen utilised is proportional to the amount of
ADP phosphorylated to ATP, the ADPIO (or PlO) ratio can be directly
measured from the oxygen electrode traces. With succinate as the substrate,
the P/O ratio should be close to 1.6 for coupled rat liver mitochondria.
The RCR = rate of oxygen uptake in state 3
rate of oxygen uptake in state 4











Figure 2.6 Oxygen electrode trace demonstrating PlO and RCR
measurement
This is a typical trace of 'tightly coupled' mitochondria, obtained prior to
starting each of the experiments. The concentrations given are the final
concentrations in the electrode. The PlO ratio is the nanomoles of ADP
added, divided by the nanograms atoms of total oxygen consumed from the
start of state 3 respiration to its end. The RCR is calculated by dividing the
rate of oxygen uptake in state 3 by the rate of oxygen uptake in state 4 (see
main text). If by measuring the PlO and RC ratios, the mitochondria were
found not to be 'tightly coupled', then the mitochondria were not used.
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Therefore, before carrying out experiments with freshly isolated
mitochondria, it is essential to ascertain that the mitochondria are tightly
coupled i.e. their structure is intact, by measuring the PLO and RCR ratios
(Mathews and van Holde, 1996). Incomplete phosphorylation of ADP or
partial hydrolysis of ATP during the state 3 period, caused by damaged
uncoupled mitochondria, can be observed as a decrease in the expected PLO or
RCR values.
Electron microscopy studies
Two hours after drug administration an abdominal incision was made in the
rat under anaesthesia (hypnovail-hypnonorm), and the stomach was opened.
A catheter was placed in the second part of the duodenum and the whole of
the intestine flushed, avoiding distension, with a solution of gluteraldehyde
(3% v/v) in 0.1M sodium phosphate buffer pH 7.4. A 1cm length of jejunum
(10cm distal to the ligament of Trietz) was then excised, and placed in
gluteraldehyde for 3 days.
Sections from this tissue were made to 3jim width by an Ultratome-Richart
Ultracut-E, stained in Reynolds lead citrate medium for 10 minutes and
viewed with a Joel 1200cm electron microscope in transmission mode. In
particular, regions with well orientated cuts containing at least 10 consecutive
enterocytes for analysis, were studied.
For quantitative assessment, a total of 100 enterocytes from each animal was
examined for mitochondrial changes. Mild changes were only accepted as
results if they occurred in a cluster of 5 or more adjacent mitochondria.
Definition of mild mitochondrial abnormality is elongation with mild
swelling of the mitochondria. Severe abnormalities include distension,
ballooning, vacuolisation, and disruption of the outer and inner membranes
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of the mitochondria. All the samples were coded so that the morphological
assessment was performed with no knowledge of treatment.
2.6	 Results
Study 1: In vitro effects of NSAIDs on mitochondrial respiration
The NSAIDs indomethacin, aspirin, naproxen, piroxicam and ketoprofen all
stimulated oxygen uptake of mitochondria over the concentration range 0 to
3.75mM. Representative traces of the effects of the NSAIDs on mitochondrial
function are shown in figures 2.7a, b and c.
When the effect of the NSAIDs is expressed as a percentage of control,
i.e.
rate of oxygen uptake in the presence of drug 	 x	 100
rate of oxygen uptake in the absence of drug
over the concentration range of drug used, then a stimulation in oxygen
uptake can be seen by all the NSAIDs, followed by an inhibition of this
stimulation at higher concentrations of the drugs (figures 2.8a and b). These
figures show that the most potent uncoupler amongst the NSAIDs (defined as
the least drug concentration to achieve maximum stimulation of oxygen
uptake) was indomethacin, requiring ordy 0.25 mM. However, among the
NSAIDs, it was aspirin which stimulated mitochondrial respiration to the
greatest extent (294%).
The potency of and extent of respiration brought about by the classic
uncoupler FCCP was far greater than any of the other drugs. FCCP enhanced
mitochondrial respiration to more than 600°o at only 4 x iO4 mM. Table 2.3
summarises the concentrations of the various NSAIDs required to give





















Figure 2.7	 Oxygen electrode traces demonstrating uncoupling of
oxidative phosphorylation by NSAIDs
To mitochondria (1.2 to 4.2mg protein) was added succinate followed
by the NSAIDs (a) indomethacin, (b) aspirin and (c) naproxen, to the
final concentrations indicated. Mitochondrial oxygen uptake was
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	 A comparison of data from these studies with those of other
studies in isolated rat liver mitochondria




Indomethacin	 0-2.5	 0.25	 194	 This study
Aspirin	 0-25	 2.00	 294
Naproxen	 0-25	 3.75	 149
Ketoprofen	 0-2.8	 0.35	 220
Piroxicam	 0-2.0	 0.25	 250
Prot=1 .4-4.2mg
Aspirin	 0-0.5	 0.5	 163	 Tomoda et a!.,
Prot=4mg	 1992
Aspirin	 0.6	 0.6	 129	 Mehlman et a!.,
Prot=l5mg	 1972
Indomethacin 0.2




	 0.2	 320	 Famaey and
Prot=4.5mg	 Mockel, 1973
Indomethacin 0-1.25
	 0.25	 145	 Byczkowski and
Prot=7-lOmg	 Korolkiewicz,
1977
Indomethacin	 0.1	 0.1	 132	 Tokumitsu et
Aspirin	 1	 1	 273	 al., 1977
Prot=0.6-O.65mg
Aspirin	 0-900nmoles/mg 900nmoles/mg
	 125	 Leblondel and
protein	 protein	 Allain, 1979
Indomethacin	 0.05-0.3	 0,1	 154	 Baños and
Naproxen	 0.05-0.3	 0.05-0.1	 140	 Reyes, 1989
Prot=1-5mg




From figure 2.8 it is also apparent that the control drug paracetamol failed to
stimulate oxygen consumption and only inhibited with increasing
concentrations.
Study 2: The effect of the proNSAIDs fenbufen, sulindac and nabumetone,
and nabumetone's metabolite 6-MNA, on mitochondrial respiration
Figure 2.9a shows the effects of fenbufen and sulindac on mitochondrial
oxygen uptake. Both fenbufen and sulindac exhibited uncoupling, as shown
by a stimulation in mitochondrial oxygen uptake followed by inhibition.
Maximum stimulation of 165% by 1mM fenbufen and 190% by 4mM sulmdac.
From figure 2.9b, it can be seen that nabumetone failed to stimulate
mitochondrial oxygen consumption with concentrations reaching up to
2mM. However, the metabolite of nabumetone, 6-MNA, did uncouple in a
similar maimer to the conventional acidic NSAIDs, observed as a stimulation
of oxygen uptake to a maximum of 180% by 0.5 mM, followed by a decline in
oxygen uptake. Although this latter drop in oxygen uptake appears to be more
profound than those seen with the other acidic NSAIDs tested, this is not
relevant to these studies. Indeed, a less drastic inhibition of respiration may
have been seen had a concentration of 6-MNA between 0.5 mM and 0.8 mM
been used.
Study 3: Flurbiprofen vs NO-flurbiprofen
Flurbiprofen exhibited the characteristic stimulation in oxygen uptake,
reaching a maximum of 200% of control with 2.5mM, followed by a fall in
respiration. However, its NO derivative did not have such an effect over the
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Figure 2.9 Effect of prodrugs on mitochondrial respiration
To a mitochondrial suspension (protein concentration 1.6 to 6.5 mg) was
added 1mM succinate then increasing concentrations of the compounds (a)
sulindac and fenbufen, and (b) nabumetone plus its metabolite 6MNA.
Mitochondrial respiration was monitored at 30°C using an oxygen electrode.
Each point represents the mean ± SEM of 3 experiments (separate liver
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Figure 2.10 Effect of flurbiprofen and NO-flurbiprofen on mitochondrial
respiration
To a mitochondrial suspension (protein concentration 0.5 to 1 mg) was added
1mM succinate then increasing concentrations of flurbiprofen or nitroxy-
flurbiprofen. Using an oxygen electrode mitochondrial respiration was
recorded at 30°C . Data represents the mean ± SEM of 3 experiments (separate
liver preparations). * Significantly different from control, P < 0.05, Student's t-
test.
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Study 4: Effect of misoprostol on mitochondrial oxygen uptake &
u itras truct u re
In the experiments carried out on isolated mitochondria, the uncoupling (i.e.
stimulation followed by inhibition of oxygen uptake) by indomethacin, was
not prevented by misoprostol (figure 2.11a). Misoprostol itself had no effect on
mitochondrial oxygen uptake. Basal respiration rate (100%) was retained. It
must be noted, however, that despite these experiments being performed on 3
separate liver preparations as before, the data had relatively large error bars.
The reason for this is uncertain, but may have been decreased had more
experiments been done.
Figure 2.11b shows how the mitochondria were viewed under EM. It was
found that in the control rats and rats treated with misoprostol alone, less
than 5% of the enterocytes had abnormal mitochondria. Misoprostol itself
had no significant effect on intestinal mitochondrial morphology (figure
2.11bi). (Control mitochondria are not shown in this figure as the EM images
were identical to 2.11bi). In those rats treated with indomethacin alone 60-70%
of the cells contained abnormal mitochondria (EM image not shown). This
was not significantly different when indomethacin was coadministered with
misoprostol which had 50-70% of the cells containing damaged mitochondria.
As shown by severity of the damage seen in figure 2.11bii, addition of
misoprostol did not attenuate the mitochondrial structural changes caused by
indomethacin.
Study 5: Effect of glucose-citrate on mitochondrial oxygen uptake &
ultrastructure
In isolated mitochondria, the pattern of stimulation then inhibition of
respiration by indomethacin was similar when added in the presence or
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Figure 2.11a Effect of misoprostol on indomethacin-induced
uncoupling of oxidative phosphorylation
To mitochondria (1.2 to 1.7 mg) was added 1mM succinate then increasing
concentrations of either indomethacin or indomethacin mixed with 20J1g/ml
misoprostol. Mitochondrial respiration was monitored using an oxygen
electrode at 30°C. Results are mean ± SEM of 3 experiments (separate liver
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Figure 2.12a The effect of glucose and citrate on indomethacin-induced
uncoupling of oxidative phosphorylation
To mitochondria (1.1 to 1.5 mg) was added 1mM succinate then increasing
concentrations of either indomethacin or indomethacin mixed with 15 times
its weight of glucose and citrate. Mitochondrial respiration was monitored at
30°C using an oxygen electrode. Each point represents the mean ± SEM of 3
experiments (separate liver preparations). * Significantly different from
control, P < 0.05, Student's t-test.
127
Under EM, the amount of enterocytes containing abnormal mitochondria was
less than 5% in the control and glucose/citrate-treated rats (images not
shown). In the indomethacin-treated rats, 50-70% of the enterocytes had
abnormal mitochondria, exhibiting severe mitochondrial damage i.e.
ballooning, distension and vacuolisation (figure 2.l2bi). When indomethacin
was coadministered with glucose and citrate, 65% of the enterocytes had
abnormal mitochondria, although there was no significant attenuation of the
mitochondrial damage induced by indomethacin alone (figure 2.l2bii).
2.7	 Discussion
Study 1
All the conventional acidic NSAIDs studied uncoupled oxidative
phosphorylation. As with most 'inhibitory uncouplers', in isolated
mitochondria, this was observed as a characteristic biphasic response - an
initial stimulation followed by an inhibition of oxygen consumption. The rise
in oxygen uptake corresponded to the uncoupling effect of the drug, whereas
the fall related to an inhibition of electron transport.
Table 2.3 compares the data from this study with those of earlier work. In the
main, the concentrations required to give maximal stimulation in oxygen
uptake found by the present study, are very similar to those found by other
groups. In addition, concentrations of acidic NSAIDs have been measured in
vivo in the rat gastric mucosa and found to be approximately in the same
range as their uncoupling concentrations (Frey and El-Sayed, 1977).
Some groups have also reported that aspirin does not uncouple isolated rat
liver mitochondria (Thompkins and Lee, 1969; Spenney and Bhown, 1977;
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and Keller et a!., 1992). However, in the study by Spenney and Bhown (1977),
there was a slight stimulation of mitochondrial respiration with 5.6 mM
aspirin, albeit insignificantly (P = 0.10). In addition, Thompkins and Lee
(1969), showed up to a 30% reduction in PlO ratio with 3 mM aspirin, again
suggestive of an uncoupling of oxidative phosphorylation.
Paracetamol was used as the control in the present experiments since, though
as effective as many of the NSAIDs as an analgesic and antipyretic agent, it
lacks most of the side-effects of the NSAIDs and is non-acidic. The
analgesic/antipyretic properties of paracetamol may be due to its inhibition of
prostaglandin production in the central nervous system. However,
paracetamol is not antiinflammatory (Clissold, 1986), probably because it does
not inhibit peripheral prostaglandin synthesis (Marshall et a!., 1987).
The present experiments show that NSAIDs which are known to cause
gastrointestinal damage also uncouple oxidative phosphorylation, whereas
paracetamol neither causes GI lesions nor does it uncouple. Paracetamol also
failed to uncouple and induce swelling in rat kidney mitochondria (Mingatto
et a!., 1996; and Uyemura et al., 1997). Therefore, this would suggest a causal
connection between uncoupling and GI damage (see also study 2 below).
Other authors, however, have reported that paracetamol can impair
mitochondrial oxidative phosphorylation (Meyers et a!., 1988; aiid Katyare
and Satav, 1989).
Paracetamol does inhibit coupled mitochondrial respiration in these studies.
Similarly, 10 mM paracetamol has been shown to inhibit respiration by 60%
(Ramsay et al., 1989). In addition, in mouse liver mitochondria, 5 mM
paracetamol caused significant inhibition of respiration and this occurred
prior to the loss of cell membrane integrity (Burcham and Harman, 1991). In
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kidney mitochondria, paracetamol gave a small (95% of control) but
consistent inhibition respiration (Porter and Dawson, 1979). In all of the
above, the inhibition of state 4 respiration was similar in glutamate/malate-
or succinate-supported respiration. However, the biological significance of
this inhibition by paracetamol is uncertain as in all cases it only occurred to a
significant extent at relatively high concentrations.
Study 2
The suggestion that prodrugs produce less gastrointestinal side-effects than
conventional NSAIDs, was thought to be because the gastric or intestinal
mucosa is not exposed to high local concentrations of the active
antiinflammatory compound during drug absorption. However, a small
percentage of patients treated with the prodrugs (20% with sulindac and 12%
with fenbufen) do still have CI complaints (Brogden et al., 1981; and Insel,
1996). In fact, sulindac is only better tolerated than the other NSAIDs in short-
term endoscopy studies (Lanza, 1989): in the long-term it produces ulcers and
other complications (Larkai, 1987).
Thus, in theory, prodrugs may not reduce the "topical" damage if it is caused
by a separate mechanism (Insel, 1996), such as uncoupling of oxidative
phosphorylation (see section 1.6.1.1, chapter 1). This is substantiated by the
present study which showed that the prodrugs fenbufen and sulindac
uncoupled mitochondrial oxidative phosphorylation.
6MNA was also found to stimulate coupled respiration, whereas its parent
compound nabumetone did not. 6MNA, fenbufen and sulindac all possess a
carboxyl group unlike nabumetone. As previously mentioned the free acidic
group (generally the carboxylic acid group) of NSAIDs is required for
uncoupling activity. The acidic side chain appears not only to contribute to
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uncoupling but may also play an important role in the formation of
gastrointestinal lesions. This has been supported by the fact that altering the
acidic moiety of NSAIDs by esterification, appears to reduce the gastric toxicity
of these drugs without affecting their antiinflammatory activity (Whitehouse
and Rainsford, 1980). Nabumetone does not produce the GI damage seen with
other acidic NSAIDs in rats (Boyle et a!., 1982) and some studies in humans
also suggest greater gastrointestinal tolerability (Melarange et a!., 1992).
Study 3
This study was carried out not only to validate earlier in vivo findings, but
also to see the direct effect that modification of the NSAID carboxylic acid
group would have on uncoupling. As expected, flurbiprofen possessing an
acid side chain, uncoupled oxidative phosphorylation in isolated
mitochondria. NO-flurbiprofen did not uncouple possibly due to addition of
the NO group rendering the NSAID non-acidic and hence ineffective as a
protonophore (uncoupler).
However, in another study, electron microscopic examination revealed a
similar pattern of damage in mitochondria treated in vivo with either
flurbiprofen or NO-flurbiprofen (Somasundaram et a!., 1997). In addition, the
two compounds also increased intestinal permeability to the same extent. The
apparent discrepancy between these reports and the present in vitro findings
could be reasonably explained as due to the abundant presence of intestinal
esterases. These enzymes (absent in isolated mitochondria) can cleave the
ester bond in the NO compound yielding flurbiprofen, which would then be
free to exert its detrimental biochemical effects during drug absorption
(Somasundaram et al., 1997). The concomitant release of the NO group will
then help to prevent the reduction in mucosal blood flow and neutrophil
recruitment at a later stage of NSAID-induced gastrointestinal injury (figure
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2.13). It therefore appears that it is not only the release of nitric oxide from
NO-flurbiprofen which is important for its improved gastrointestinal
tolerability over flurbiprofen, but also the modification of the carboxylic acid
side chain.
Furthermore, in the present study, NO itself (added as a saturated aqueous
solution at 1mM stock) was found not to uncouple mitochondria (data not
shown). Interestingly, however, low (physiological) concentrations of NO
reversibly suppresses mitochondrial respiration probably by binding to
cytochrome a , producing a transient inhibition of electron flow (Cassina and
Radi, 1995). Then higher (cytotoxic) concentrations of NO irreversibly inhibit
respiration at complexes I, II and ifi. The latter effect is thought to be mediated
by peroxynitrite, the product of a reaction of mitochondrial superoxide with
NO. This ability to inhibit mitochondrial respiration could explain some of
the beneficial roles of NO; e.g. NO released under inflammatory conditions
may be useful for host defense by being able to suppress bacterial respiration
(Xie et al., 1996).
Study 4
It is suggested that uncoupling of mitochoridrial oxidative phosphorylation is
involved in the "topical" damage seen with NSAIDs (Somasundaram et al.,
1997). The present study demonstrates that misoprostol does not prevent
NSAID-induced uncoupling in vitro or in vivo, suggesting that uncoupling is
a prostaglandin-independent process. Indeed, prostaglandins do not prevent
the immediate widespread "topical" destruction of the surface epithelium
caused by irritants such as ethanol (Lacy, 1982). Instead, misoprostol protects
by retaining the integrity of the remaining layers of the mucosa. That is, the
compound enhances mucosal defense mechanisms and inhibits acid
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secretion, thereby preventing deeper necrotic and haemorrhagic lesions
(Konturek and Konturek, 1994).
Misoprostol has also been found to be ineffective at preventing ethanol-
induced inhibition of state 3 respiration in isolated rat liver mitochondria
respiring on succinate or ascorbate (Dlugosz et al., 1991). However, with
glutamate and malate as the substrates, there was partial protection with
misoprostol, probably because ethanol-induced inhibition is most profound at
complex I (Cederbaum et a!., 1974).
The present experiments also show that misoprostol alone does not uncouple
oxidative phosphorylation. Nevertheless, prostaglandin E1 given to rats does
appear to cause a reduction in the total number of mitochondria as well as an
increase in irregularly-shaped mitochondria (Ozeki et a!., 1987). One reason
for this discrepancy may be that naturally-occurring prostaglandins are acidic
whereas the synthetic derivative misoprostol is not, though this may be an
over-simplified explanation. This is because in another study, in accordance
with the present study, it was reported that the prostaglandins D2, E2, F2a and
E 1, had no effect on the respiratory activity of isolated rat brain mitochondria
(Takeuchi et a!., 1991).
Study 5
It has been suggested that the NSAID-induced increase in intestinal
permeability will expose the mucosa to luminal substances with subsequent
inflammation (Somasundaram et a!., 1995). Glucose and citrate
coadministered to human volunteers with indomethacin in a ratio of 15:15:1,
has been shown to reduce the permeability changes seen with indomethacin
alone (Bjarnason et al., 1992). In addition, indorise, a combination of
indomethacin, glucose and citrate, given to rats, completely prevents
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permeability changes and ulcer formation induced by indomethacin (Hayllar
et a!., 1991).
The underlying biochemical mechanism for this protection is unclear. One
possibility is that salicylate inhibits some of the steps in the TCA cycle (Kaplan
et a!., 1954). It is possible, therefore, that salicylates and other NSAIDs may
competitively inhibit enzymes in glycolysis and the tricarboxylic acid (TCA)
cycle, causing a reduction in ATP production and hence cell death (Rainsford
and Whitehouse, 1980). The presence of glucose and citrate in the intestinal
lumen would provide the enterocytes with substrates for glycolysis and the
TCA cycle, thereby overcoming the competitive effects of the NSAIDs.
However, the structural diversity of NSAIDs, make it unlikely though not
impossible. NSAIDs certainly competitively inhibit cyclooxygenase despite
their chemical diversity, although this may be due to the interaction between
the carboxyl group on the NSAID with the NH3 -arginine group on
cyclooxygenase (Picot et a!., 1994).
An alternative explanation is that citrate, being a potent inhibitor of
phosphofructokinase, a rate-controlling enzyme of glycolysis, may divert
glucose metabolism along the hexose monophosphate pathway (see figure 4.6,
chapter 4). This would provide reducing power to prevent NSAID-induced
oxygen radical damage, a mitochondrial-independent process (Bjarnason et
al., 1992). In this case, glucose and citrate might protect against some NSAID
damage, but not by any effect on NSAID uncoupling of oxidative
phosphorylation.
A controlling factor of the activity of the TCA cycle is the NADH/NAD ratio.
Thus when uncouplers, including NSAIDs, accelerate mitochondrial
respiration, the decrease in NADH/NAD ratio would produce a
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compensatory stimulation of the TCA cycle (Fromenty et al., 1993). In
addition, uncoupling mitochondria would lower AlP levels and stimulate
glycolysis to produce the necessary AlP for the cell. Numerous NSAJDs have
been found to stimulate glycolysis (Brass and Garrity, 1985; Kemmelmeier and
Bracht, 1989; Salguiero-Pagadigorria et a!., 1996a; and Petrescu and Tarba,
1997). This is in sharp contrast to the earlier suggestion that NSAIDs inhibit
the TCA cycle and glycolysis. Addition of glucose and citrate in the present
experiments did not affect the uncoupling induced by indomethacin
suggesting, as above, that the protective effect of glucose and citrate is not a
direct protection at the mitochondrial level but an effect related to whole cell
metabolism. However, these arguments do not explain why glucose and
citrate needed to given together in order to have a protective effect.
Cooney and Dawson (1977) found that when D-glucose was added as the sole
exogenous substrate, 2,4-DNP stimulated oxygen uptake, consistent with its
uncoupling activity. However, indomethacin, at concentrations previously
shown to uncouple oxidative phosphorylation in isolated mitochondria
(Whitehouse, 1964b; Famaey and Mockel, 1973; and Byczkowski and
Korolkiewicz, 1977), inhibited oxygen consumption. Cooney and Dawson
(1977) went on to demonstrate that this inhibition of oxygen uptake was not
caused by direct inhibitory effects of indomethacin on the TCA cycle (as
previously mentioned) but by the inhibition of the transfer of reducing
equivalents (e.g. NADH) from the cytoplasm to the mitochondria. They
showed that the effect of indomethacin on glucose metabolism was
independent of its ability to uncouple oxidative phosphorylation. This again
is consistent with the findings of the present studies, since glucose and citrate
failed to have any effect on the uncoupling induced by indomethacin.
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Finally, with the intestinal enterocyte, it is possible that not all the
mitochondria will be uncoupled by NSAIDs. Any remaining intact
mitochondria will still be able to utilise glucose and citrate for glycolysis and
TCA cycle activity, thereby alleviating the deleterious effects of NSAIDs.
Justifying the Use of Rat Liver Mitochondria
As the purpose of this study was to investigate one of the underlying
mechanisms of NSAID-induced gastrointestinal lesion, the use of
mitochondria isolated from rat liver may be questioned. However, it has been
shown that mitochondria isolated from various sources and species have
generally similar properties with respect to electron transport and oxidative
phosphorylation (Brody, 1955). For example, NSAIDs also uncouple oxidative
phosphorylation of rat brain and kidney mitochondria (Brody, 1956; and
Mingatto et al., 1996). The extent to which the NSAIDs diflunisal, flufenamic
acid and mefenamic acid stimulate respiration in liver mitochondria isolated
from rat, mouse, rabbit and guinea-pig is similar in all four species
(McDougall et a!, 1983). In addition, aspirin uncouples mitochondria isolated
from the gastric mucosa of pigs at a similar concentration range to the studies
of this thesis (Jorgensen et a!., 1976). Aspirin has even been found to cause an
increase in oxygen consumption in whole tissue, such as rat liver slices, at the
lower concentrations of 1.49mM and 2.97mM, and a progressive decrease in
oxygen uptake at the higher concentrations of 5.94mM and 7.45mM (Fishgold
et al., 1951). These experimental findings closely parallel those of the present
study using aspirin and isolated rat liver mitochondria.
Several attempts to prepare mitochondria from gut (jejunal) tissue were
made but were unsuccessful with regard to coupling ability. Problems of
preparation due to the action of endogenous proteases and the high
concentrations of mucus in intestinal preparations have been previously
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noted (Sherratt, 1963). One advantage of using kidney mitochondria would be
the high content of epithelial tissue. However the majority of previous work
on NSAIDs and mitochondria had used liver mitochondria and/or liver
slices (see tables 2.3 and 3.1). It was therefore decided, for the present work, to




ELECTRON TRANSPORT BY NSAIDS
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The in vitro studies on the effects of NSAIDs on mitochondrial function
(chapter 2), suggest that these compounds may uncouple oxidative
phosphorylation and/or inhibit the respiratory chain. Either action would, in
theory, cause changes to mitochondrial ultrastructure in vivo, and a decrease
in mucosal ATP which, in turn, would lead to an increase in intestinal
permeability. Such effects are key steps in the proposed pathogenesis of
NSAID-induced damage to the gastrointestinal tract. This chapter looks
specifically at the action of NSAIDs on the respiratory chain.
Electron transport and oxidative phosphorylation can be envisaged as two
separate processes, required to be tightly coupled for the purpose of ATP
generation. Hence, in order to investigate selectively the effects of NSAJDs on
the electron transport, the mitochondria were first uncoupled with FCCP so
that no oxidative phosphorylation could take place. To localise the possible
site(s) of inhibition along the respiratory chain by the drugs, specific
respiratory chain substrates and inhibitors were used. Inhibitors, unlike
uncouplers of oxidative phosphorylation, act on a specific component of the
respiratory chain (Spenney and Bhown, 1977).
3.1	 Exogenous Respiratory Chain Substrates
3.1.1 Glutamate and Malate
NADH produced by glycolysis, cannot readily cross the mitochondrial
membrane (Mathews and van Holde, 1996). In order for NADH to donate
electrons to the respiratory chain it must somehow be able to transfer
reducing equivalents into the mitochondrion for reoxidation. This process
occurs through the "malate-aspartate shuttle" and is particularly active in the
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heart and liver (figure 3.1). In short, in this shuttle, NADH reduces
oxaloacetate to malate in the cytoplasm. Malate then enters the mitochondria,
where it is reoxidised, regenerating NADH and oxaloacetate. Because
oxaloacetate cannot cross the mitochondrial membrane to pass out of the
mitochondria, it is transaminated to aspartate, which is then transported out
into the cytoplasm for reconversion to oxaloacetate, beginning the cycle again.
The involvement of transamination in this shuttle means that a-
ketoglutarate must be continuously transported out of mitochondria and
glutamate continuously transported in.
The presence of glutamate is also important for this shuttle to proceed since,
like malate, it too can pass across the mitochondrial membrane into the
mitochondria and be transaminated to aspartate. Therefore, in isolated
mitochondria, as endogenous substrates are used up, glutamate and malate
are provided in equal amounts to generate NADH within the matrix, thereby
reducing complex I of the electron transport chain. Electrons are then
transferred from complex I to complex III and eventually to complex IV,
resulting in the reduction of molecular oxygen to water (see figure 2.2, chapter
2).
3.1.2 Succinate
Addition of succinate elicits FAD-linked oxidation. Therefore, electrons are
donated to complex II, from where they are passed onto complex Ill and then
complex IV (see figure 2.2, chapter 2).
3.1.3 Ascorbate and TMPD

















































transfers electrons directly to cytochroine c bound to cytochrome oxidase
(complex IV). But only when TMPD is given together with ascorbate is
cytochrome oxidase activity fully saturated since ascorbate maintains TMPD
in the reduced state (Kimelberg and Nicholls, 1969) (figure 3.2). However,
TMPD, a purple-coloured free radical, has itself also been found to uncouple
oxidative phosphorylation at a concentration of 0.2 mM (Park et a!., 1957).
3.2	 Exogenous Respiratory Chain Inhibitors
3.2.1 Rotenone
Rotenone is a powerful insecticide and fish poison, extracted from the roots of
the Derris plant found in South America (Mayes, 1993). The compound is a
specific, non-competitive and high affinity inhibitor of complex I, blocking
electron flow from the iron-sulphur centres of complex I to coenzyme Q
(ubiquinone, UQ), possibly by acting as UQ analogues. The inhibitor is
believed to bind near the site of ubiquinone reduction in the distal portion of
complex I (Greenamyre et al., 1992). A concentration of 30 nmoles/gram
protein of rotenone is sufficient to inhibit respiration in rat liver
mitochondria and higher concentrations do not uncouple succinate or
ascorbate/TMPD-supported respiration. Rotenone, being hydrophobic, is
normally dissolved in ethanol for use (Slater, 1967).
3.2.2 Antimycin A
Antimycin A is a family of fungicidal antibiotics produced by a species of
Streptomyces , comprising of a mixture of at least four closely related
















Figure 3.2 Ascorbate and TMFD
Ascorbate reduces TMPD which can then transfer electrons directly to






Figure 3.3 Structure of antimycin A
Antimycin A blocks electron transport at complex III of the respiratory chain.
In antimycin A 1 : R = n-hexyl; antimycin A2 : R = n-butyl.
144
is a potent inhibitor which specifically inhibits the respiratory chain between
cytochrome b and cytochrome Cl of complex III (figure 3.3; and Slater, 1973).
Maximal inhibition by antimycin A occurs after 1 minute (Slater, 1967). The
literature also suggests that antimycin A be dissolved in ethanol and that no
more than 0.2 i.tmole be used per gram of mitochondrial protein be used in
inhibition studies, since higher concentrations of the compound will
uncouple ascorbate /TMPD-supported respiration.
3.2.3 Cyanide
The classic poison cyanide is a powerful reversible inhibitor of oxidised
cytochrome oxidase (complex IV), totally arresting respiration (Mayes, 1993).
Cyanide reacts specifically with the sixth coordinate of the haem a iron of
cytochrome a, the terminal electron carrier of the respiratory chain.
3.3	 Aims of the Studies
Inhibition of mitochondrial respiration by NSAIDs was investigated using
FCCP-uncoupled mitochondria. In addition, an attempt was also made to
pinpoint the site along the respiratory chain where the NSAIDs may be
binding. In order to achieve this three different techniques were employed:
the oxygen electrode, the ferricyanide reductase system and electron
paramagnetic resonance (EPR).
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3.4 Oxygen Electrode Studies
3.4.1 Materials and Methods
Materials and methods are essentially the same as in section 2.4 (chapter 2),
with the addition of:
Reagents
The substrates sodium (Na) glutamate, Na malate; inhibitors rotenone and
antimycin A were purchased from the Sigma Chemical Company Ltd., Dorset,
U.K. The inhibitor Na cyanide was supplied by the Aldrich Chemical
Company, Inc., Wisconsin, U.S.A.
Solubulisation of the Compounds
The substrates glutamate and malate, and the inhibitor cyanide, were
prepared as 1M stock solutions in distilled water. The inhibitor rotenone was
prepared as a 10mM stock solution and antimycin A as a 1mg/mi stock
solution, by dissolving in 100% ethanol. To see effective inhibition, higher
concentrations of stock solutions for indomethacin and aspirin were used,
250mM and 500mM respectively (prepared as before).
Experimental Procedure
Isolation of rat liver mitochondria, oxygen electrode calibration and PlO and
RCR measurement were carried out as before. The following studies were
then performed:
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Study 1 - Effects of mitochondrial substrates and inhibitors
This was carried out to establish the order of electron flow through the
complexes of the respiratory chain and the positions blocked by various site-
specific inhibitors. This also served to test that the electron transport chain of
this mitochondrial preparation was operating adequately.
To imi suspension mixture was added 100il isolated mitochondria (protein
concentration 5.2mg) then the following sequence of substrates and inhibitors
to give the final concentrations:
(i) 10mM glutamate plus 10mM malate (complex I substrates),
(ii) 20pM rotenone (complex I inhibitor),
(iii) 1mM succinate (complex II substrate),
(iv) 10pM antimycin A (complex H inhibitor),
(v) 2mM ascorbate and 2ORM TMPD (complex IV substrates) and
(vi) 1mM cyanide (complex IV inhibitor).
Study 2 - Effect of drugs on complex I
The effect of the drugs on electron transport from complex I to Ill and finally
to IV was measured by using a mixture of glutamate and malate to stimulate
mitochondrial respiration at complex I, and FCCP to uncouple the
mitochondria. The additions were: lOOp.1 mitochondria (2.9 to 6.7 mg), 10mM
glutamate plus 10mM malate, 0.1 iM FCCP then the drugs indomethacin,
aspirin, naproxen and paracetamol with final concentrations ranging from 0
to 115mM.
Study 3 - Effect of drugs on complex II
The effect of the drugs on electron transport from complex II to complex III
through to complex IV was monitored using succinate as substrate. Rotenone
was used to prevented any electrons from being transferred from complex I
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and FCCP again ensured the mitochondria were uncoupled prior to addition
of the drug. The additions were: 100tl mitochondria (2.9 to 6.7 mg), 2OjxM
rotenone, 1mM succinate, 0.1 p.M FCCP then 0 to 190mM of the drugs
indomethacin, aspirin, naproxen and paracetamol.
As before, each different concentration of drug was added to a fresh sample of
mitochondria and solutions added never exceeded 200jil. After every addition
a period of approximately 1-2 minutes was allowed to elapse in order to
observe clear rates for oxygen uptake on the chart recorder. FCCP is a specific
and potent uncoupler of mitochondrial oxidative phosphorylation whose
concentration was kept deliberately low, since addition of too much would
itself result in inhibition of respiration (Slater, 1967).
3.4.2 Results
Study 1
Figure 3.4 shows the oxygen electrode trace of how the different substrates and
inhibitors affected mitochondrial oxygen uptake. The rate of respiration given
by each compound is denoted on the trace. The addition of 100 p.1
mitochondria (protein concentration 5.2mg), gave a relatively slow basal rate
of respiration, recorded as slight reduction in oxygen uptake.
(i) Injecting a mixture of glutamate and malate into the chamber, enabled
NADH generation within the mitochondria, thereby donating electrons to
complex I. This caused an slight but further increase in respiration.




















Effect of site-specific substrates and inhibitors on
mitochondrial oxygen uptake
Oxygen electrode trace obtained when substrates and inhibitors are
injected, to the final concentrations shown, into the sample chamber
containing mitochondria. Arrows indicate the various additions.
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(iii) By adding succinate supplied electrons to complex II, therefore oxygen
consumption was again enhanced. The fact that electrons from FADH2 are
still able to reduce 02 in the presence of rotenone indicate that electrons from
FADH2 enter the electron transport chain after the rotenone-blocked step
(Voet and Voet, 1995).
(iv) Antimycin A inhibited the succinate-stimulated respiration as expected
from its known action on cytochrome bc1.
(v) Addition of ascorbate and TMPD to the antimycin A-inhibited mixture
resulted in a resumption of oxygen consumption since ascorbate and TMPD
can directly reduce complex IV.
(vi) Oxygen uptake was arrested by adding cyanide to the system, inhibiting
complex IV activity.
Study 2
All the drugs inhibited mitochondrial respiration in a concentration-
dependent manner when electron entry through complex I was used. Figure
3.5 shows how the inhibition was observed on the oxygen electrode trace.
Only (a) indomethacin and (b) aspirin are represented since a similar picture
was seen with naproxen and paracetamol (not shown). In figure 3.6 these
changes have been converted to percentage of control. According to their
IC5Ø's (mM), the potency of the drugs at inhibiting electron transport,
initiating from complex I, was:
indomethacin (0.3) >> paracetamol (10.7) aspirin (11) ' naproxen (13).
Study 3
The drugs also inhibited mitochondrial respiration with increasing
concentration when electron entry was via complex II using succinate as a
substrate. All the drugs again inhibited in a similar manner and, as an
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Figure 3.6 Effect of drugs on glutamate/malate (complex I) - stimulated
mitochondrial respiration
To a mitochondrial suspension (protein concentration 2.9 to 6.7 mg) was
added 10mM glutamate, 10mM malate, 0.ljiM FCCP then increasing
concentrations of the drugs indomethacin, aspirin, naproxen and
paracetamol. Mitochondrial respiration was monitored at 30°C using an
oxygen electrode. Results are mean ± SEM of 3 experiments (separate liver
preparations). IC50 values (mM) were indomethacin = 0.3, aspirin = 11,
naproxen = 13 and paracetamol = 10.7. All points differed significantly from
control, P < 0.05, Student's t-test, except for first measurement at 0 mM of all









Figure 3.7	 Inhibition of complex-Il mediated mitochondrial
respiration by paracetamol
Oxygen electrode trace showing paracetamol effect on succinate-
supported mitochondrial oxygen consumption. Arrows indicate additions
made to the mitochondria (2.9 to 6.7 mg protein). Rotenone was added to
eliminate electron transport from complex I and FCCP to uncouple the
mitochondria.
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the oxygen electrode trace. In figure 3.8 effects of all the drugs have been
converted to percentage of control. The inhibitory potencies of the drugs
according to their 1050's were:
indomethacin (0.35) naproxen (7.5) aspirin (13) paracetamol (23.9).
3.4.3 Discussion
This study showed that the drugs indomethacin, aspirin, naproxen and
paracetamol all concentration-dependently inhibited uncoupled
mitochondrial respiration (FCCP-induced state 3 respiration), whether the
electrons were being fed in from complex I or from complex II. The 1050 of
naproxen at inhibiting complex I-mediated respiration was slightly greater
than its 1050 against complex 11-mediated respiration, suggesting perhaps that
naproxen was more effective at inhibiting respiration when electrons were
being fed into complex II.
Unlike the results of the effects of the various drugs on uncoupling (chapter
2), both the NSAIDs and the non-NSAID paracetamol brought about
inhibition. The 1050 for paracetamol at inhibiting complex Il-mediated
respiration was, however, two-fold greater than its 1050 at inhibiting complex
I-mediated respiration. This would suggest that paracetamol was more
effective at inhibiting respiration when electrons were
being fed in from complex I.
The fact that paracetamol inhibits electron transport would, at first, suggest
that inhibition of respiration by NSAIDs might not be important in the
pathogenesis of NSAID enteropathy. However, an increase in intestinal
permeability and inflammation caused by paracetamol cannot be ruled out, as














Figure 3.8 Effect of drugs on succinate (complex II) - stimulated
mitochondrial respiration
To a mitochondrial suspension (protein concentration 2.9 to 6.7 mg) was
added 20pM rotenone, 1mM succinate, 0.1iM FCCP then increasing
concentrations of the drugs indomethacin, aspirin, naproxen and
paracetamol. Mitochondrial respiration was monitored at 30°C using an
oxygen electrode. Each point represents the mean ± SEM of 3 experiments
(separate liver preparations). IC50 values (mM) were indomethacin = 0.35,
aspirin = 13, naproxen = 7.5 and paracetamol = 23.9. All points differed
significantly from control, P < 0.05, Student's t-test, except for the first
measurement at 0 mM of all drugs, and second of aspirin and paracetamol at
2.5mM and 6.25mM respectively.
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levels caused by the inhibition of mitochondrial respiration by paracetamol,
could possibly bring about such deleterious effects in the intestine, in a similar
manner to NSAIDs. In addition, although ulcers are not generally observed
with paracetamol, this does not necessarily mean that there is no increase in
permeability with this drug. The driving force in converting the intestinal
damage to ulcers may be the concomitant inhibition of cyclooxygenase-1. This
would effectively reduce the synthesis of mucosal prostaglandins, which are
important for the regulation of blood flow, leading to vasoconstriction,
ischaemia and eventually ulcer formation (Anthony et al., 1995). Therefore,
although paracetamol appears to inhibit the respiratory chain at high
concentrations, which might possibly cause an increase in intestinal
permeability, the drug is without effect on cyclooxygenase perhaps explaining
the lack of ulcer formation.
The following compares the results from other studies with that of the
present work.
Glutamate /Malate-Supported Respiration
Table 3.1 compares the present data with those of others using glutamate and
malate as substrates. Byczkowski and Korolkiewicz (1977) suggested that
indomethacin inhibited the electron transport chain sites before cytochrome c.
Later, the same authors postulated that the inhibition of state 3 respiration by
indomethacin was caused by a collapse of the mitochondrial cationic gradient,
since the drug has a higher ionophoretic potency than that for classic
uncouplers (Byczkowski and Korolkiewicz, 1978). In the study by Porter and
Dawson (1979), on the other hand, the inhibition by paracetamol was shown
to be due to partial blockage of mitochondrial electron transport between
NADH dehydrogenase and cytochrome b.
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Table 3.1	 The concentrations of the NSAIDs causing 50% inhibition of
glutamate/malate-supported respiration : a comparison of the data from this
study with those of others
Drugs tested	 1050 (mM) Mitochondria Notes	 Reference
Indomethacm	 0.3	 Rat liver	 FCCP-induced	 This study
Aspirin	 11	 state 3 respiration
Naproxen	 13
Paracetamol	 10.7
Indomethacin	 0.25	 Rat liver	 DNP-induced state Byczkowski &
3 respiration; only Korolkiewicz,
glutamate used as 1977
substrate.
Indomethacin	 0.25	 Rat liver	 ADP-induced state Byczkowski &
3 respiration; only Korolkiewicz,
glutamate used as 1978
substrate
Indomethacin	 0.04	 Rat liver	 ADP-induced state Kawai et al.,
3 respiration	 1985
Indomethacin	 0.2	 Rat liver	 ADP-induced state Bãños & Reyes,
3 respiration	 1989
Indomethacin	 0.24	 Guinea pig	 ADP-induced state Priess &
gastric mucosa 3 respiration 	 Sewing, 1985
Paracetamol	 1.8	 Mouse liver	 ADP-induced state Ramsay
3 respiration	 et al., 1989
Paracetamol	 9.7	 Rat kidney	 DNP-irtduced state Porter &




Mingatto et a!. (1996) found that 2-4 mM aspirin and 5-7 mM paracetamol
inhibited state 3 respiration in rat kidney mitochondria, whether induced by
ADP or the uncoupler carbonyl cyanide m-chlorophenylhydrazone (CCCP).
They noted that the pattern of inhibition by aspirin paralleled that of the
respiratory chain inhibitors of complex I (rotenone), complex III (antimycin
A), and complex IV (potassium cyanide); since the inhibition of state 3
respiration by aspirin could not be released by CCCP. However, paracetamol
inhibition could be released by CCCP; therefore, paracetamol showed a pattern
similar to that expressed by the inhibitors of the F 0F1 ATPase (oligomycin) and
the ADP/ATP carrier (atractyloside). (The effects of the drugs on succinate
oxidation were similar to those mentioned here on glutamate/malate
oxidation). In contrast to the present results using aspirin, Petrescu and Tarba
(1997) showed that 2mM aspirin failed to inhibit ADP-induced state 3
respiration.
Succinate-Supported Respiration
As with the findings of the present study, Mehiman et a!. (1972) showed that
0.6 mM aspirin could significantly inhibit DNP-uncoupled respiration up to
66%. Similarly, when state 3 respiration was induced by ADP, 0-0.7 ilmoles
aspirin/mg protein (approximately 0-2.5 mM) inhibited respiration
concentration-dependently by up to 60% of control (Leblondel and Allain,
1979) whilst in another study, aspirin gave an 1050 of 4.5mM (Keller et a!.,
1992). However, Tokumitsu et a!. (1977) failed to show any inhibition in
oxygen uptake with 1mM aspirin, in mitochondria uncoupled with DNP.
Perhaps in this case, a higher drug concentration may have inhibited, as in
the present study.
Nevertheless, Tokumitsu et a!. (1977) did find that 0.1 mM indomethacin
inhibited oxygen uptake to 33% of control. Likewise, Priess and Sewing (1985)
158
showed that indomethacin inhibited ADP-induced state 3 respiration in
guinea pig gastric mucosal mitochondria, giving an 1050 of 0.18mM. These
authors postulated the site(s) of inhibition in the vicinity of complexes I and
III of the respiratory chain. Byczkowski and Korolkiewicz (1977) reported an
1050 of 0.3mM indomethacin of DNP-uncoupled respiration in rat liver
mitochondria. Again in rat liver mitochondria, both Kawai et a!. (1985) and
Baños and Reyes (1989) also demonstrated inhibition with indomethacin, but
when state 3 respiration was stimulated with ADP. In the former study, the
IC50 was estimated to be > 0.2mM. In the latter study, naproxen was also
studied and 0.3 mM inhibited respiration to only 80% of control, contrary to
the present findings. Baños and Reyes (1989), however, failed to explain why
amongst the 10 NSAIDs they studied, naproxen appeared to be alone in its
anomalous effects on rat liver mitochondrial oxygen uptake.
In contrast to their findings with glutamate/malate-supported respiration,
both Ramsay et a!. (1989), using mouse liver mitochondria, and Porter and
Dawson (1979), using rat kidney mitochondria, found no inhibition by
paracetamol when succinate was used as the substrate. This would suggest
that paracetamol preferentially blocks electron transport at complex I, though
this has not been studied further.
Overall, there appeared to be a close correlation between the present study and
others when comparing the relative potency of the drugs at inhibiting
mitochondrial respiration. Although the actual 1050 values varied amongst
the different studies, this could have been due to, for example, different
experimental conditions especially problems with drug solubility. These
compounds being lipophilic may have, in some cases, been used in
suspension and not in solution. Thus, the effective drug concentration per
mg mitochondrial protein would possibly be less than previously estimated.
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Other NSAIDs including diflunisal and diclofenac, have also been found to
inhibit ADP-driven state 3 respiration in a concentration-dependent manner
when glutamate plus malate or when succinate were used as substrates
(McDougall et a!., 1983; Baños and Reyes, 1989).
3.5	 Ferricyanide Studies
Studies on electron transport in isolated mitochondria can be carried out
using terminal electron acceptors other than oxygen, enabling shorter sections
of the respiratory chain to be studied. One of most extensively used of such
reagents is potassium ferricyanide (Caswell and Pressman, 1969), an artificial
electron acceptor which can draw off electrons from specific sites in the
respiratory chain. Ferricyanide, together with respiratory inhibitors, can be
used to determine both the sequence of electron carriers and also the effects of
various compounds on the individual respiratory complexes. The use of
ferricyanide as an artificial electron acceptor is preferred since it is able to
operate at substrate concentrations with little deleterious effects to the
mitochondria.
3.5.1 Materials and Methods
Principle of the Assay
On accepting an electron, ferricyanide is reduced to ferrocyanide. Ferricyanide
possesses an absorption peak at 420 nm, which on ferricyanide reduction
disappears (Pressman, 1955). Thus, it is possible to monitor the rate of
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Figure 3.9 Ferricyanide assay system
Schematic representation of electron transport chain. To assay complex I, the
substrates NADH, glutamate, malate and the inhibitor rotenone were used,
and electrons were drawn off complex I to reduce ferricyanide. For complex II,
the substrate succinate in the presence of the inhibitors antimycin A and
rotenone were used, and electrons were tapped off from complex H to reduce
ferricyanide. Ferricyanide reduction was measured spectrophotometrically at
420 nm.
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Ferricyanide can not penetrate the inner mitochondrial membrane (1MM)
(Mitchell and Moyle, 1969). In intact mitochondria the major site of
ferricyanide reduction is cytochrome c which is located in the outer face of the
1MM (Klingenberg, 1970). Therefore, the mitochondria need to be sonicated
for the assay, to enable access of ferricyanide to the matrix-facing side of the
1MM.
Assay of Electron Transport from Complex I to Ferricyanide
Isolated rat liver mitochondria were sonicated for 5 to 10 minutes using a
pulse sonicator (Branson) at power setting 3. lOOp.1 sonicated mitochondria
was added to 3m1 of a reaction mixture containing 2.5mM potassium
ferricyanide dissolved in: 150mM sucrose, 10mM potassium chloride, 5mM
magnesium chloride and 1mM potassium dihydrogen phosphate (pH 7.0). In
order to study electron transfer specifically from complex I, 2mM NADH,
1mM glutamate and 1mM malate (complex I substrates), and 0.1 mM
rotenone (complex I inhibitor), were included in the reaction mixture.
Ferricyanide reduction was determined by measuring the change in
absorbance at 420 nm. NSAIDs indomethacin, aspirin and naproxen were
added sequentially at different concentrations, as was the analgesic
paracetamol.
Assay of Electron Transport from Complex II to Ferricyanide
Assay carried out as above, with the exception that 1mM succinate, 1mM
rotenone and lp.M antimycin A were included in the reaction mixture, to
assay electron transport specifically from complex H to ferricyanide.
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3.5.2 Results
Figures 3.10 and 3.11 show the effect of the NSAIDs indomethacin, aspirin
and naproxen on electron transport from complex I and complex II
respectively. From these figures it can be seen that all the NSAIDs
concentration-dependently inhibited both complex I and complex Il-mediated
electron transport. However, the non-NSAID paracetamol did not inhibit
electron transport from either complex (results not shown). The estimated
1050's (mM/mg protein) for the NSAIDs for complex I and complex II-
mediated electron transport were:





The present results show that indomethacin was the most potent drug in
terms of requiring the least concentration to substantially inhibit ferricyanide-
dependent electron transport from both complex I and II. This is in accordance
with the previous findings using the oxygen electrode (section 3.3). In
addition, indomethacin seemed to be more effective at inhibiting complex II-
mediated electron transport, as seen by its lower 1050 for complex II. However,
the other two NSAIDs aspirin and naproxen had significantly higher IC50's
for complex II, suggesting that they are less effective at inhibiting electron
transport from complex II than from complex I. The use of sonicated
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Figure 3.10 Effect of NSAIDs on ferricyanide-dependent electron
transport from complex I
To sonicated mitochondria suspended in a reaction mixture containing
potassium ferricyanide (see main text), was added 2mM NADH, 1mM
glutamate, 1mM malate and 0.1mM rotenone. The rate of complex I-mediated
ferricyanide reduction was monitored spectrophotometrically at 420nm.
Increasing concentrations of the NSAIDs indomethacin, aspirin and naproxen
were then added to observe their effects on complex I-mediated ferricyanide
reduction. Each point is the mean of 3 experiments ± SEM (3 separate rat liver
preparations). Except for the first measurement at 0mM, all points were
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Figure 3.11 Effect of NSAIDs on ferricyanide-dependent electron
transport from complex II
To sonicated mitochondria suspended in a reaction mixture containing
potassium ferricyanide (see main text), was added 1mM succinate, 1mM
rotenone and 1tM antimycin A. The rate of complex 11-mediated ferricyanide
reduction was monitored spectrophotometrically at 420nm. Increasing
concentrations of the NSAIDs indomethacin, aspirin and naproxen were then
added to observe their effects on complex I-mediated ferricyanide reduction.
Each point is the mean of 3 experiments ± SEM (3 separate rat liver
preparations). Except for the first measurement at 0mM for all the drugs and
the second measurement of indomethacin at 0.025mM and aspirin at 1.5mM,
all points were significantly different from control, P <0.05, Student's t-test.
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eliminates the possibility that the inhibitory effect of the drugs may have been
on substrate transport into the matrix.
The fact that paracetamol did not inhibit electron transport, in contrast with
the findings of the oxygen electrode studies, suggest that paracetamol
inhibition of electron transport occurs beyond complexes I and II in the
respiratory chain, i.e. at complex III or IV or that paracetamol inhibits
substrate entry.
In summary, all the NSAIDs studied inhibited ferricyanide-dependent
electron transport. This has not previously been reported. Despite the
different 1050 values, the range of potencies was similar for complex I and
complex 11-mediated electron transport:
indomethacin > aspirin > naproxen.
3.6 EPR Studies
Present within each of the complexes of the respiratory chain are multiple
forms of iron-sulphur (Fe-S) clusters which can be detected by electron
spin/paramagnetic resonance (ESR/EPR). Figure 3.12 shows the electron
transport system in more detail, with the components of complexes I to IV. As
can be seen from this figure, complex I contains, along with its other
prosthetic group flavomononucleotide (FMN), five separate Fe-S clusters,
termed FeSN1a, FeSN1b, FeSN2, FeSN3 and FeSN4 according to the
nomenclature of Ohnishi (Ohnishi, 1979). Likewise, complex II has together
with its other prosthetic groups flavin adenine dinucleotide (FAD) and
cytochrome b560, three Fe-S centres known as FeSsi, FeSS2 and FeSS3.
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person who discovered it (Rieske et a!., 1964). Although complex IV has no
Fe-S centres, it does contain EPR-detectable iron from the haem centre of
cytochrome oxidase (also known as cytochrome aa3).
The respiratory chain contains 3 types of Fe-S clusters each with a different
ratio of iron to sulphur; these are the [2Fe-2S], the [4Fe-4S], and the [3Fe-4S]
clusters (figure 3.13). For the last two types of cluster, the Fe atoms are each
coordinated by four acid-labile S atoms arranged tetrahedrally around them.
The majority of the Fe-S clusters are coordinated by four cysteine residues
from the protein backbone of the respiratory complex. However, in the
Rieske-type centre, the ligands are 2 cysteines and 2 histidines. The iron atom
in these clusters undergoes oxidoreduction between the reduced (Fe2+) and
oxidised (Fe3 ) states, enabling the proteins to function as one-electron
carriers.
3.6.1 The Theory of EPR
There is extensive and detailed literature on the theory of EPR, which is
summarised well by Beinert and Palmer (1965). For the purpose of this thesis
the rationale of EPR spectroscopy can be simplified.
The majority of stable molecules are held together by bonds in which electron
spins are paired; in this situation there is no net electron spin, no electronic
magnetic moment, and hence no interaction between the electron spins and
an applied magnetic field. Some atoms and molecules, however, do contain
one or more electrons with unpaired spins, and these molecules exhibit
electron spin resonance (ESR). Since the molecules detected are paramagnetic,
this type of spectroscopy is often termed electron paramagnetic resonance
(EPR). EPR spectroscopy essentially detects the transitions between two energy
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Figure 3.13 3D chemical structure of iron-sulphur clusters
A. [2Fe-2S] B. [4Fe-4S]
Source: McGilvery (1979).
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levels, induced by the application of an external magnetic field and an
appropriate frequency radiation.
EPR spectra are recorded as a series of peaks and troughs of characteristic
shapes with characteristic g values (g is a spectroscopic splitting factor). In
principal, the relative intensities of the signals are proportional to the relative
number of unpaired electrons in the system (Ebsworth et a!., 1987). The
temperature at which EPR spectra are measured can be important. For Fe-S
centres, low temperature EPR, as opposed to EPR at ambient (room)
temperatures, results in increased sensitivity, an improved signal-to-noise
ratio, making quantitative measurements more reproducible. In contrast,
some free radicals are detected more readily at room temperature.
With the exception of the S3 Fe-S cluster of complex II, all the other Fe-S
clusters of respiratory complexes I to III have paired electrons and are
therefore "diamagnetic". However, in order to be detected by EPR, they need
first to be made paramagnetic by one-electron reduction so that they contain
an unpaired electron. In the reduced state, these Fe-S centres exhibit an EPR
spectrum at low temperature that is characterised by a prominent signal (gy)
with maximal absorption at g=1.85 to g=1.95, and two lower intensity features
(g and gz). Table 3.2 summarises the properties of the Fe-S centres of the
respiratory chain, as found by EPR.
3.6.2 Aims of the EPR Studies
The aim of the studies in this section was to see if any of these components of
the respiratory chain were affected by the NSAIDs, which could explain the
inhibitory properties of these drugs. The appearance or disappearance of EPR
signals, or a decrease in the peak-to-trough (PU) value when compared to
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Complex	 Cluster	 g,	 gy	 g	 Fe:S type
I	 FeSN1a	 1.91	 1.95	 2.03	 [2Fe2S]
I	 FeSN1b	 1.92	 1.94	 2.02	 [2Fe-2S]
I	 FeSN2	 1.92	 1.92	 2.05	 [4Fe-4S]
I	 FeSN3	 1.86	 1.93	 2.04	 [4Fe-4S]
I	 FeSN4	 1.87	 1.93	 2.10	 [4Fe-4S]
II	 FeSsi	 1.91	 1.93	 2.03	 [2Fe-2S]
II	 FeSS2	 1.91	 1.93	 2.03	 [2Fe-2S]
II	 FeSS3*	 1.99	 2.01	 2.02	 [3Fe-4S1
ifi	 FeSm**	 1.81	 1.89	 2.025	 [2Fe-2S]
* EPR active in oxidised state; rest are EPR active in reduced state. ** Also
known as the "Rieske" centre. Based on data from Orme-Johnson et a!. (1974)
and Ohnishi (1979).
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control, were used as indices of drug effect. The control was the solvent, 10%
(v/v) DMSO.
The experiments were carried out using beef heart submitochondrial particles
(SMP), because these contain higher concentrations of redox proteins in the
inner mitochondrial membrane than isolated rat liver mitochondria, and the
corresponding EPR signals were found to be greater. SMP's prepared from
sonically disrupted mitochondria essentially consist of sealed inner
mitochondrial membrane vesicles, where the 1MM has been turned inside
out. In addition, the matrix enzymes are removed so only signals from the
membrane-associated respiratory complexes are seen. An added advantage is
that the substrate NADH, which reduces complex I but cannot cross the 1MM,
can now be used as a reductant.
The experiments were carried out first on oxidised SMPs (as prepared), in
order to detect the EPR signals from centre S3 of complex II, and CUA of
cytochrome oxidase, and then in the reduced state to study the remaining Fe-S
clusters. Although there are two centres Nia and Nib, only one of these
centres is usually detected, and is termed centre Ni.
As with the oxygen electrode and ferricyanide inhibition experiments, specific
substrates were used to reduce the individual complexes, to study each
complex in isolation. Dithionite was used to reduce the sample, in order
record an EPR spectrum of all the centres, except centre S3 which is EPR-silent
when reduced. NADH was used to reduce complex I and succinate was used
for complex H.
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With all the experiments the temperature was varied from 8K to 40K. This is
because different signals become apparent at different temperatures,
summarised as:
Temperature (helium)	 Fe-S clusters observed by EPR
8 to 15 K	 [4Fe-4S]; [3Fe-4S]
20 to 77 K	 [2Fe-2S]
40K	 CUA3 of cytochrome oxidase;
Rieske
3.6.3 Materials and Methods
Materials
Beef hearts were provided by the University of Essex, Essex, England. Sorbitol,
trypsin, trypsin inhibitor, disodium adenosine triphosphate (Na2ATP),
reduced nicotinamide adenine dinucleotide (NADH) were supplied by the
Sigma Chemical Company Ltd., Dorset, U.K. N-[2-hydroxyethyl]piperazine-
N'-[2-ethanesulfonic acid] (HEPES) was supplied by Fluka Chemicals, Dorset,
England.
Isolation of Beef Heart Mitochondria
A modification of the protocol described by Rickwood et al. (1987) for the
isolation of rat liver mitochondria, was used for isolating coupled
mitochondria in large scale from bovine heart tissue. This modified
procedure is particularly suited for EPR studies.
Fat and connective tissue was removed from fresh hearts, and the muscle
minced finely. The mince was suspended in an equal volume of a buffer
containing 50mM EDTA, 10mM Tris, 210mM sorbitol, 70mM sucrose, 0.1%
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BSA, pH 7.6 (high-EDTA buffer), and washed with a minimum of 6 changes
to remove blood and fat impurities.
The tissue was incubated with trypsin (0.5mg/g tissue) for 30 minutes, to aid
digestion of the tough connective tissue that prevents successful
homogenisation. To prevent further digestion, trypsin inhibitor (1.5mg/g
tissue) was added to the incubation, and the preparation washed with several
changes of high-EDTA buffer. The tissue was homogenised, a little at a time,
using a MSE Atomix blender at medium speed, with two 5 second bursts
interrupted by 30 second intervals. The homogenate was distributed into pre-
cooled 500m1 Sorvall centrifuge tubes and centrifuged at 1,500g for 5 minutes.
The supernatant was decanted off carefully and filtered through four layers of
muslin to remove fat. The filtrate was centrifuged at 13,000g for 10 minutes,
and the resultant dark-brown mitochondrial pellet washed and resuspended
in a buffer comprising of 100pM EDTA, 10mM Tris, 225p.M sorbitol, 75mM
sucrose, 0.1% BSA, pH 7.6 (low-EDTA buffer). This material was recentrifuged
as above at 13,000g and the final pellet resuspended in low-EDTA buffer. The
prepared sample was kept frozen at 77K until required.
Preparation of Beef Heart Submitochondrial Particles
The beef heart mitochondria (BHM) was diluted to a final concentration of
10mg protein/mi in 10mM HEPES, 1mM MgC12, 1mM ATP, 5mM succinate,
0.2mM NADH and 1% BSA, pH 7.1 (Medium A). The mitochondriai
suspension was centrifuged at 26,000g for 10 minutes at 4°C and the
supernatant decanted. The pellet was resuspended in Medium A and
sonicated in 3m1 aliquots on ice, with eight 15 second bursts, interrupted by 15
second intervals, at 18 amps, using a microtip probe. The sonicated
suspension was then centrifuged at 26,000g for 10 minutes at 4°C.
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The supernatant was removed and kept on ice whilst the remaining
mitochondrial pellet was again resuspended in Medium A, then sonicated
and centrifuged as before. The supernatants were combined and spun in a
Pegasus Ultracentrifuge at 130,000g for 1 hour at 4°C.
The supernatant was removed and the remaining red-brown pellet was
resuspended in 40m1 of 250mM sucrose and 50 mM HEPES, pH 7.5, and
recentrifuged at 130,000g for 1 hour. The supematant was again discarded and
the final pellet, containing the submitochondrial particles, was resuspended
in a minimal volume of the sucrose solution.
Sample Preparation for EPR
Oxidised samples
lOi.d of solvent or NSAID was added to 901fl SMP in a quartz EPR tube (3mm
internal diameter). For measurement under oxidised conditions, mixing of
the sample on the bench for approximately 1 minute was sufficient. The
sample was frozen by gradually immersing the EPR tube into liquid nitrogen
(-70°C), and stored until required for measurement.
Reduced samples
Preliminary experiments were performed to find out how much reductant
was required to give optimum reduction of the respiratory complexes. The
general sequence of additions was:
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90p1 SMP + lOp1 solvent/NSAID*
+ Dithionite / + NADH	 / + Succmate
4mM, 2mm / 4mM, 2mm / 60mM, 10mm
mix and leave bubbling under
argon for 10 mins**
Immerse in liquid nitrogen, transfer to EPR chamber
& measure EPR signals
*The final concentrations of the NSAIDs added were: 25mM indomethacin,
50mM aspirin and 100mM naproxen. These were the minimum
concentrations required to show an effect, based on preliminary experiments.
The solvent was 10% DMSO or distilled water and preliminary experiments
showed that the EPR signals were unaffected by these solvents.
**Argon gas was introduced into the EPR tube just above the level of the
mixture, in order to exclude atmospheric oxygen from the system.
EPR Measurement
A Bruker ESP 300 spectrometer fitted with an ESR900 liquid helium flow
cryostat (Oxford Instruments) was used to carry out EPR measurements.
X-band EPR spectra of the samples were recorded at various temperatures.
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3.6.4 Results and Discussion
Oxidised Samples
8K: wide scan
This wide scan spectrum (figure 3.14) reveals the complex II centre S3 (at
3,400G or g=2.02), g=6 signal from haem-Fe3 , and g=4.3 signal from
mononuclear non-haem Fe3+. The presence of all these signals in the control
indicates that this mitochondrial sample is undamaged by the preparation
procedure. No significant change was observed in the low field signals on
addition of the solvent 10% DMSO or of the NSAIDs. However, this may be
due to low spectral resolution in the g=2 region.
8K : narrow scan
This spectra (figure 3.15) focuses on the most prominent peak observed when
BHM SMP's are viewed by EPR as prepared. This signal corresponds to the
[3Fe-4S1 centre (centre S3) of complex II. From this figure, it can be seen that
the NSAIDs indomethacin, aspirin and naproxen, decreased the EPR signal






Such an effect was also seen in vivo in rat intestinal homogenates treated
with indomethacin for 1 hour (Somasundaram et a!., in preparation). This
would initially suggest that the NSAIDs may bind to complex II of the
respiratory chain. However, the fact that in vitro 10% DMSO also decreased
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Figure 3.14	 Wide scan EPR trace of oxidised BHM at 8K
EPR was performed at 8K on BHM as prepared (i.e. oxidised) which was
either untreated (control) or incubated with solvent (DMSO),
indomethacin (indo), aspirin (asa), or naproxen (nap), at the concentrations
shown. See main text for experimental details. S3 = [3Fe-4S] cluster of
complex II; * = artefact due to dust contamination. This trace represents an
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Figure 3.15	 EPR trace of oxidised BHM at 8K
EPR was performed at 8K on oxidised BHM which was either untreated
(control), or incubated with solvent (DM50), indomethacin (indo),
aspirin (asa) or naproxen (nap) at the concentrations shown. See main
text for experimental details. S3 [3Fe-4S} of complex II; ** =
ubiquinone interaction with centre S3. This trace represents an average
of 4 scans performed on a single BHM sample.
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solvent effect or due to dilution of the sample, since the treated sample was
9Ojil SMP + 10tl drug/solvent, whereas the control contained lOOiil SMP.
Also observed in this spectra were 'wings' on either side of the EPR signal
from centre S3 were observed. During electron transfer, reduction of




The 'wings' correspond to a spin-spin interaction of the S3 centre with
ubiquinone, (i.e. as electrons are transferred from complex II to ubiquinone).
The wings were abolished by indomethacin, aspirin and naproxen but not by
10% DMSO. This is, therefore, most likely an NSAID-induced effect. These
drugs may be exerting their action by either reducing or oxidising the
semiquinone, or by interfering with the reaction of centre S3 with
ubiquinone.
40K
At a higher temperature of 40K, the EPR spectrum (figure 3.16) exhibited by
the control is typical of CUA2 of cytochrome oxidase. 10% DMSO revealed a
similar, but slightly decreased, signal, again possibly due to dilution. 50 mM
aspirin also seemed to have no effect on the EPR signal. With 100 mM
naproxen, a nitrosyl NO signal (at g=2.04) was seen and with 25 mM
indomethacin treatment there appeared to be a free radical.
NO reacts with a variety of metal complexes to form high affinity,
paramagnetic nitroso complexes. Therefore, NO can be specifically measured
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Figure 3.16	 EPR trace of oxidised BHM at 40K
EPR was performed at 40K on oxidised BFIM which was either untreated
(control), or treated with solvent (DMSO), indomethacin (indo),
aspirin (asa) or naproxen (nap) at the concentrations shown. See main
text for experimental details. g = spectroscopic splitting factor; FR = free
radical; FeS/NO = nitroxyl complex with FeS cluster. This trace
represents an average of 4 scans performed on a single BHM sample.
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main, are iron-containing proteins such as haem proteins and those with
iron-sulphur complexes (e.g. the respiratory complexes). Indeed, the
inhibition of mitochondrial respiration seen with NO (see section 2.7, chapter
2) is thought to be via nitrosylation of the iron-sulphur centres of complexes I
and II, of aconitase (a key enzyme of the Krebs cycle) (Lancaster and Hibbs,
1990), and by interacting with the haem group of cytochrome c oxidase
(Cleeter et al., 1994).
However, the question arises as to how NO appeared in the beef-heart SMP's
in the presence of naproxen. In biological systems, NO is synthesized by NO
synthase (NOS) of which, until recently, there was thought to be three
isoforms: endothelial NOS (eNOS), neuronal NOS (nNOS), and inducible
NOS (iNOS) (Venema et a!., 1997). (Induction of iNOS by cytokines has been
implicated in the pathogenesis of a number of inflammatory diseases,
including inflammatory bowel diseases and arthritis (Moncada et a!., 1991)).
The cellular location for nNOS and iNOS is cytosolic (Marletta, 1994), whereas
eNOS is membrane-associated (Busconi and Michel, 1993).
The presence of NOS within mitochondria has only recently come to light.
Using isolated rat liver mitochondria, the existence of a functional NOS was
shown, associated with the inner mitochondrial membrane but not with the
mitochondrial matrix (Ghafourifar and Richter, 1997). NOS activity was
detectable in both intact mitochondria and SMP's. Interestingly, this
mitochondrial NOS (mtNOS) exerted considerable control over
mitochondrial respiration, probably by virtue of its close proximity to the
respiratory complexes. So perhaps in the present study, naproxen activates
mtNOS to produce NO.
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Importantly, NO has also been demonstrated to stimulate the production of
the radical superoxide (Of), a by-product of mitochondrial respiratory
electron transport, catalysed by NOS in the presence of certain substrates and
cofactors (Pfeiffer et al., 1997).
Activation of mtNOS
	 NO	 0f
This, however, is not very surprising considering that other mitochondrial
inhibitors such as rotenone, antimycin A and cyanide, also increase the
production of Of (believed to be within complexes I and III) (Knowles, 1997).
Perhaps, therefore, the results seen with indomethacin in the present study,
was a result of activation of mtNOS, producing NO then, in turn, a
superoxide radical. Indeed, oxygen-derived free radicals have been implicated
in the pathogenesis of NSAID gastropathy (Del Soldato et al., 1985; Pihan et
a!., 1987; and Vaananen et a!., 1991), although other reports have suggested
that NSAIDs behaved as free radical scavengers as part of their
antiinflammatory mechanism (Bodaness and Chan, 1980; Hiller and Wilson,
1983; Sagone Jr. and Husney, 1987). Maybe in the present study, the
concentration of naproxen used was not cytotoxic enough to activate mtNOS
beyond the formation of NO. However, this still fails to explain why aspirin
had no apparent effect on mtNOS.
Nevertheless, as with the present study, the appearance of a haem-nitric oxide
signal by EPR was previously seen in vivo in rat jejunal homogenates
following indomethacin treatment for 24 hours (Somasundaram et a!., in
preparation). Pretreatment with an inhibitor of inducible NO synthase, 2,4-
diaminohydroxy pyrimidine (DAHP), decreased the intensity of this NO
signal significantly. DAHP also prevented indomethacin-induced ulcer
formation but did not significantly affect intestinal permeability. These
findings suggest that during NSAID enteropathy, NO is released which is
somehow involved in the later stages of pathogenesis.
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Samples Reduced by Dithionite
8K: wide scan
In the control, all the expected [2Fe-2S] and [4Fe-4S] EPR signals can be
observed, namely from centres Ni, N2, N3, N4 of complex I, and possibly
centre Si of complex II (figure 3.17). Although, in theory, dithionite is a
relatively strong reducing agent with a standard reduction potential (E'o) of
approximately -O.53V, in practice it reduces only complex I and complex II
partially. Neither 25mM indomethacin nor 50mM aspirin exhibited any affect
on these centres. However, with i0OmM naproxen, a free radical signal
appeared at g=2.0), and the intensity of the Fe-S signals was less when
compared to the control, with a corresponding increase in the g=4.3 signal
characteristic of free Fe3+.
8K : narrow scan
This spectrum focuses on the Fe-S centres of the respiratory chain (figure
3.18). At the higher resolution, an additional small free radical is observed
with the control. Indomethacin and aspirin were without effect on the EPR
signals from the [2Fe-2S] and [4Fe-4S] clusters. Naproxen, on the other hand,
seemed to produce a more prominent free radical signal and less intense Fe-S
signals.
18K
At this temperature, it is apparent that in the naproxen-treated sample there
is a significant decrease in the signal intensity of the N3 and N4 complex I
centres, plus an emergence of a free radical (figure 3.19). This would suggest
that naproxen prevents electron transport from complex I, since it prevented
the full reduction of centre N3 by dithionite. Indomethacin and aspirin,









Figure 3.17 Wide scan EPR trace of dithionite-reduced BHM at 8K
EPR was carried out at 8K on BHM reduced by 4mM dithionite which
was either untreated (control) or incubated with indomethacin (indo),
aspirin (asa), or naproxen (nap), at the concentrations indicated. See main
text for experimental details and abbreviations. This trace represents an
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Figure 3.18	 EPR trace of dithionite-reduced BHM at 8K
EPR was carried out at 8K on beef heart submitochondrial particles
reduced by 4mM dithionite which were either untreated (control) or
incubated with indomethacin (indo), aspirin (asa), or naproxen (nap),
at the concentrations indicated. See main text for experimental
details and other abbreviations. g = spectroscopic splitting factor;
FR = free radical. This trace represents an average of 4 scans














Figure 3.19	 EPR trace of dithionite-reduced BHM at 18K
EPR was carried out at 18K on BHM reduced by 4mM dithionite which
were either untreated (control) or incubated with indomethacin (indo),
aspirin (asa), or naproxen (nap), at the concentrations indicated. See main
text for experimental details and other abbreviations. g = spectroscopic
splitting factor; FR = free radical. This trace represents an average of 4
scans performed on a single BHM sample.
187
Samples Reduced by 4mM NADH
8K
Signals corresponding to centres Ni, N2, N3 and N4 are beginning to appear
since NADH donates electrons specifically to complex I (figure 3.20). The
prominent signal of S3 is also still apparent since it is not reduced by NADH,
therefore remaining oxidised and EPR-active. Specific reduction of complex I
suggests the Fe-S clusters of complex I seem to be greatly affected by 25mM
indomethacin, less so by 100mM naproxen and not at all by 50mM aspirin, in
stark contrast to the dithionite spectrum.
18K
By increasing the temperature slightly, centres Ni to N4 can be seen more
clearly as can the effects of the drugs (figure 3.21). Signals from all centres, in
particular centres 3 and 4, were affected by indomethacin and to a lesser extent
by naproxen, but not by aspirin.
40K
At this temperature, signals from CUA2+ of cytochrome oxidase, centre Ni,
and the Rieske centre are all observed (figure 3.22). Cytochrome oxidase
copper can be seen as it remains oxidised and EPR-active in the presence of
NADH. In the control, however, there is an additional free radical signal
which was also present in duplicate experiments; quite typical of
mitochondrial preparations. With indomethacin and naproxen, there was no
Rieske signal, suggesting that these drugs may block forward electron
transport between complex I and complex III. However, aspirin has no effect
on any of the signals. This would suggest that naproxen and indomethacin act
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	 EPR trace of NADH-reduced BHM at 8K
EPR was performed at 8K on BHM reduced with 4mM NADH which
were either untreated (control) or incubated with indomethacin (indo),
aspirin (asa), or naproxen (nap), at the concentrationsindicated. See
main text for experimental details and other abbreviations. UQH=
interaction of centre S3 with semiquinone. This trace represents an















Figure 3.21	 EPR trace of NADH-reduced BHM at 18K
EPR was carried out at 18K on beef heart submitochondrial particles
reduced by 4mM NADH which were either untreated (control), or
incubated with indomethacin (indo), aspirin (asa), or naproxen (nap), at
the concentrations shown. See main text for experimental details and
abbreviations. This trace represents an average of 4 scans performed on













Figure 3.22	 EPR trace of NADH-reduced BHM at 40K
EPR was carried out at 18K on BI-IM reduced by 4mM NADH which were
either untreated (control), or treated with indomethacin (indo), aspirin
(asa), or naproxen (nap), at the concentrations shown. See main text for
experimental details and other abbreviations. FR = free radical; Cyt Ox =
cytochrome oxidase. This trace represents an average of 4 scans
performed on a single BI-IM sample.
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Samples Reduced by 60mM Succinate
Controls at 8, 18 and 40K
Control samples were run at 8, 18 and 40K. The clearest signals were seen at
40K (figure 3.23). Therefore, the drug effect was not tested at the lower
temperatures following succinate reduction.
40K
Succinate reduces complex II and can sometimes also reduce complex III due
to forward electron transfer by the respiratory chain. Signals from centre Si
and the Rieske centre are observed. A signal corresponding to the CUA2 of
cytochrome oxidase is also apparent since it remains oxidised, thus EPR-
detectable, in the presence of succinate (figure 3.24). A free radical signal could
also be seen. With aspirin and indomethacin the Si signal intensity is
decreased. With naproxen, however, this Si signal is not present at all and
there appears to be a very intense NO signal instead.
Table 3.3 summarises the effects of the NSAIDs on the various Fe-S centres.
Overall, these studies showed an interaction of the NSAIDs with Fe-S clusters
of complex I, II and III. No one complex in particular was targeted by the
drugs, in agreement with the oxygen electrode studies. Also, more than once,
a free radical signal appeared, in accordance with the idea that reactive oxygen
species may play a part in NSAJD-induced gastrointestinal damage. Similarly,
naproxen appeared to evoke the release of an NO group, a finding also







	 EPR trace of succinate-reduced BHM
EPR was carried out at 8, 18 and 40K on beef heart submitochoridrial
particles reduced with 60mM succinate. See main text for experimental
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Figure 3.24	 EPR trace of succinate-reduced BHM at 40K
EPR was carried out on BHM at 40K reduced by 60mM succinate
which were either untreated (control) or incubated with aspirin
(asa), indomethacin (indo), or naproxen (nap), at the concentrations
indicated. See main text for experimental details. Si [2Fe-2S]
cluster of complex II; Cyt Ox = cytochrome oxidase; FR = free
radical; g = spectroscopic splitting factor. This trace represents an

















































































DECREASE IN MITOCHONDRIAL ATP
PRODUCTION BY NSAIDS
196
ATP (figure 4.1) is a compound with a relatively high free-energy of
hydrolysis used by a large number of cellular pathways. The process of
oxidative phosphorylation is responsible for the synthesis of at least 90% of
the total ATP formed in most aerobic cells containing mitochondria. The
remaining AlP is generated during glycolysis and the citric acid cycle via GTP
(Mayes, 1993). For the majority of ATP synthesis, the phosphate required for
ADP phosphorylation is imported into the mitochondria by a phosphate
carrier, and the ATP generated is exported to the cytosol in exchange for ADP
by the adenine nucleotide carrier (ANC) (figure 4.2). The turnover of ATP is
very high, being continuously regenerated from ADP. This is because it acts as
an immediate donor, rather than long-term storage form, of free energy. In
the cell, an ATP molecule is consumed within a minute following its
formation (Stryer, 1988).
Depletion of ATP is caused by many compounds, resulting in a variety of
biochemical changes. Perhaps the most common mechanism of ATP
depletion in the cell is by interference with oxidative phosphorylation,
inhibition of electron transport, or depletion of NADH. Excessive ATP
utilisation or sequestration, or DNA damage which causes the activation of
poly(ADP-ribose)polymerase, are other mechanisms which may reduce ATP
levels.
A lack of ATP in the cell would mean that active transport, into, out of and
within the cell, is compromised or arrested, resulting in changes in Na+, K±
and Ca2+ ion concentrations in particular compartments. In addition, there
may be a decrease in certain synthetic biochemical processes such as protein
synthesis, gluconeogenesis and lipid synthesis. At the tissue level, this could



















Figure 4.1 The structures of ADP and ATP
Figure 4.2 Carrier systems in the mitochondrial membrane
ANC = adenme nucleotide carrier; PC = phosphate carrier; ADP = adenosine
diphosphate; ATP4 = adenosme triphosphate; H2PO4 = phosphate; and OH- =
hydroxyl. Adapted from Mayes (1993).
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proximal tubules will not actively reabsorb essential amino acids and glucose
(Timbrell, 1991).
As shown by the studies of chapters 2 and 3, NSAIDs uncouple oxidative
phosphorylation and inhibit mitochondrial electron transport. Both of these
effects would result in an inhibition of ATP synthesis. This would entail a
series of events, which could ultimately play a part in the gastrointestinal
damage seen with these drugs. The aim of the present section is to directly
measure the effect of NSAIDs on mitochondrial ATP content.
4.1 Materials and Methods
For measuring oxygen consumption, the materials and methods were the
same as before (chapter 2, section 2.4). For measuring ATP levels:
4.1.1 Materials
-mercaptoethanol, potassium hydroxide (KOH), nicotinamide adenine
dinucleotide phosphate (NADP), glucose-6-phosphate dehydrogenase (G-6-
PD) and hexokinase were supplied by the Sigma Chemical Company Ltd.,
Dorset, England. Perchioric acid 70% (PCA) and D-glucose were obtained from




Mitochondria from rat liver were isolated as before. The PlO and respiratory
control ratios of the mitochondria were measured to ensure they were tightly
coupled.
On adding 0.67mM ADP to 2.1 to 8.9 mg mitochondria respiring on 1mM
succinate, it took approximately 5 minutes for all the ADP to be converted to
ATP i.e. for state 3 to go back to state 4 respiration. Therefore, 1 minute after
addition of ADP there should still be sufficient ATP synthesis taking place.
The effect of increasing concentrations of the NSAIDs indomethacin, aspirin
and naproxen, the analgesic paracetamol, and the uncoupler FCCP, were
tested on ATP levels. The concentrations of the drugs were approximately in
the same range as that used previously for oxygen uptake studies. The
concentrations of FCCP used were those shown previously to strongly
stimulate oxygen uptake. Also tested were the respiratory inhibitors
antimycin A (0.01mM) and cyanide (1mM). Again, these concentrations of the
inhibitors were based on those shown previously to strongly inhibit oxygen
consumption.
PCA Extraction
To measure the effects of compounds on ATP synthesis, the following were
incubated for 1 minute at 30°C: oxygen electrode buffer, coupled mitochondria
(2.1 to 8.9 mg), 1mM succinate, 0.67mM ADP, and increasing concentrations of
the drug or solvent. The reaction was stopped by the addition of ice-cold PCA
(final concentration of 200o) which precipitates proteins, leaving cytosolic
elements in the supernatant. This cloudy white suspension was spun in a
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microcentrifuge (MSE; Medical and Scientific Equipment Ltd) for 5 minutes
and the supernatant transferred to fresh vials.
1.5M KOH was added to this supernatant, producing a cloudy mixture, and
spun again for 5 minutes in the microcentrifuge to precipitate and remove
potassium perchiorate. The supernatant was then neutralised by adding solid
FIEPES, and stored at -70°C until assayed.
ATP Assay
An enzymatic assay was used to assess ATP levels.
Principle
ATP phosphorylates glucose via hexokinase:
hexokinase
Glucose + ATP	 - Glucose-6-Phosphate + ADP
Mg2+
The glucose-6-phosphate (glucose-6-P) is then converted to glucose-6-
phosphate dehydrogenase (G-6-PD):
G-6-PDGlucose-6-P + NADP	 - 6-PGA + NADPH + H
The change in absorbance at 340nm, resulting from the reduction of NADP to
NADPH, can be measured. In the presence of excess glucose, this change in
absorbance is proportional to the amount of ATP in the mixture (Beutler,
1975).
Experimental Procedure
The PCA extracts were thawed and kept on ice. The following solutions
were then added to a 2m1 cuvette at the volumes shown below:
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Solution	 Volume (jil)










(Note, both G-6-PD and hexokinase were made up in a stabilising solution
comprising of 20% J-mercaptoethanol in Na2EDTA:Na4EDTA (1:1)).
The cuvettes were warmed on a water bath to 37°C, then 200p1 of the PCA
extract was added. This was mixed and the absorbance at 340nm was read
using a doubie beam spectrophotometer (Cecil Instruments) to give a baseline
reading. lOjil hexokinase (400units/ml) was then added, mixed, incubated for
30 minutes at 37°C, and the absorbance again measured.
Therefore,
200u1 PCA added to imi
in cuvette = 1/5 dilution
(	 (	 ol




overall dilution factor = final volume/ original volume
original vol (jil)=buffer^succinate+ADP+drug / solvent+mitochond na
final vol (tl)=original vol+PCA+KOH
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4.2	 Results
4.2.1 Effect of NSAIDs on ATP Production
Figure 4.3a shows how all three NSAIDs tested, with increasing
concentrations (0 to 17mM), were associated with a decrease in ATP
production. The drug giving the greatest reduction in ATP production with
the lowest concentration was indomethacin > naproxen > aspirin.
Paracetamol did not reduce ATP production. FCCP (0 to 10pM) decreased ATP
production to a maximum of 66% of control (figure 4.3b).
4.2.2 Effect of Respiratory Inhibitors on ATP Production
Figure 4.4 shows the effect of the antimycin A (0.01mM) and cyanide (1mM)
on ATP formation. Antimycin A only inhibited to 88% of control and cyanide
to 78% of control.
4.3 Discussion
Although the uncoupling of oxidative phosphorylation implies inhibition of
ATP formation, a direct measure of ATP production is necessary in order to
definitely state AlP production is inhibited by NSAID action. The present
experiments show that all the NSAIDs studied decreased ATP production.
This is logical since oxidative phosphorylation is responsible for ATP
generation. Indomethacin was again the most potent at inhibiting ATP
production as it was at uncoupling oxidative phosphorylation and inhibiting
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Figure 4.3 Effect of drugs on mitochondrial ATP production
To mitochondria (2.1-8.9 mg) was added 1mM succinate, 0.67mM ADP, then
(a) NSAIDs / paracetamol or (b) FCC?. After 1 minute incubation at 30°C, the
reaction was stopped by the addition of PCA. Neutralisation with
KOH/HEPES, followed by addition to a reaction mixture (see main text),
enabled measurement of AlP production by the samples by reading
absorbance at 340nm. Results are mean of 3 experiments ± SEM (3 separate

















Figure 4.4 Effect of respiratory inhibitors on mitochondrial AT? production
To mitochondria (2.1-8.9 mg) was added 1mM succinate, 0.67mM ADP, then
antimycin A (0.01mM)! cyanide (1mM)! solvent. After 1 minute incubation
at 30°C, the reaction was stopped by the addition of PCA. Neutralisation with
KOH/HEPES, then addition to a reaction mixture (see main text), enabled
measurement of ATP production by the samples by reading absorbance at
340nm. Each result represents the mean of 3 experiments ± SEM (3 separate
liver preparations). * Significantly different from control, P < 0.05, Student's t-
test.
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The fact that paracetamol did not reduce ATP formation at concentrations
previously shown to inhibit electron transport by approximately 50% (see
chapter 3) was surprising and revealing. Though this drug does not uncouple
oxidative phosphorylation, it does inhibit respiration as shown by a decrease
in mitochondrial oxygen consumption, which would also decrease ATP
production. It would appear that sufficient activity remains in the remaining
uninhibited electron transfer components to maintain ATP production over
the time period of these measurements. The conclusion from these studies,
therefore, is that it is the uncoupling action of the NSAIDs which is primarily
responsible for a decline in ATP generation in mitochondria, rather than an
inhibitory action.
ATP measurement as an indicator of uncoupling effect has previously been
reported with these drugs. As with the present study, others have measured
ATP levels as an indicator of ATP synthesis. For example, the mucosal ATP
content of the human jejunum (Arvanitakis et al., 1977) and also in bullfrog
stomach (Spenney and Bhown, 1977) is decreased by exposure to aspirin. A
depletion in AT? production has also been observed in human neutrophils
by the NSAIDs indomethacin, piroxicam and sodium salicylate (Cronstein et
al., 1994), and in human lymphocytes, used as a model for testing drug effect
on human mitochondria, by the drug ibuprofen (Fromenty et al., 1993).
A stimulation of ATPase activity by NSAIDs, which causes a decrease in AT?
synthesis, has also been well documented (Byczkowski and Korolkiewicz,
1977; Tokumitsu et al., 1977; Baños and Reyes, 1989; and Salguiero-
Pagadigorria et al., 1996). Contradictory findings, however, have been
demonstrated by Chatterjee and Stefanovich (1976), where indomethacin (1050
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0.55mM) and aspirin (IC5Ø 13mM) appeared to inhibit rat liver mitochondrial
ATPase, the reason for this inconsistency is unclear.
Mingatto et a!. (1996) measured actual ATP synthesis and found, in accordance
with this study, that aspirin and other NSAIDs piroxicam, diclofenac,
dipyrone, mefenamic acid, inhibited the rate of ATP synthesis. Unlike the
present study however, paracetamol also inhibited AlP synthesis, though
requiring higher concentrations. A drop in ATP generation by paracetamol
was similarly demonstrated by Porter and Dawson (1979) in kidney cells. In
the study of Mingatto et al. (1996) the drugs were incubated for 10 minutes
with the mitochondria before measuring ATP synthesis, and with the study of
Porter and Dawson (1979) the incubation period was 1 hour. This would
suggest that, had paracetamol been incubated for longer than 1 minute in the
present study, it too may have brought about a decrease in ATP production.
The importance of incubation time is highlighted in the present study by the
FCCP results and those of the inhibitors antimycin A and cyanide. FCCP,
being a highly potent uncoupler of oxidative phosphorylation, and antimycin
A and cyanide being strong inhibitors, would be expected to cause a drastic
decrease in mitochondrial ATP synthesis. However, these compounds gave
no more than a 35% drop in ATP production. It would suggest that 1 minute
incubation with the compounds was not sufficient to fully deplete ATP
production. Alternatively, higher concentrations may be required, since in
another study it was found that 37RM FCCP caused an 80% reduction
spontaneous AlP production (Nassberger, 1990).
Nassberger (1990) also found that the solvent DMSO caused an increase in
ATP output by about 20%, though the mechanism by which this occurred was
not investigated. Despite the final concentration of DMSO never exceeded 2°
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in my experiments and drug effect being calculated as a percentage of solvent
effect, the ATP-promoting effect of DMSO may explain why ATP production
never reached zero.
4.3.1 Significance of Decreased ATP Production
It can be envisaged, therefore, that a lack of ATP generation caused by the
action of NSAIDs in uncoupling oxidative phosphorylation or possibly even
by inhibition of dehydrogenase enzymes in the tricarboxylic acid cycle (Smith
and Dawkins, 1971), could play a part in some of the gastrointestinal side-
effects seen with these drugs. Reduced ATP production would cause calcium
ions (Ca2 ) to leak out of the mitochondria (Carafoli, 1987). Increased cytosolic
Ca2+ may lead to activation of Ca2+ sensitive enzymes such as proteases,
endonucleases and phospholipases (Tuena de Gomes-Puyou et al., 1980).
Phospholipase A2 activation would result in the release of reactive oxygen
species from membrane phospholipids (Jam and Shohet, 1981). Protease
activation could evoke microtubule depolarisation, affecting the cytoskeleton
(Tada et al., 1974), which could in turn be responsible for the increase in
intestinal permeability seen with NSAJDs (Somasundaram et al., 1995).
Another consequence of reduced ATP production, would be a compensatory
stimulation of glycolysis (see chapter 2, section 2.6). However, enterocytes
have low phosphofructokinase (PFK), and high glucose-6-phosphate (G-6-P)
dehydrogenase and phosphogluconate dehydrogenase, activities, and may not
be able to increase their glucose consumption as much as other cells by
glycolysis.
A possible consequence of stimulated glycolysis in enterocytes, is that the
pyruvate formed in glycolysis is converted into lactate instead of acetyl CoA
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(figure 4.5), due to the low activity of pyruvate dehydrogenase in these cells
(Jongab et a!., 1992). This would result in intracellular acidosis. If there was a
prevalent reduction in blood flow, cell viability would be further
compromised.
By inhibiting AlP generation, the NSAIDs would deprive the organism of
the numerous other ATP-dependent reactions. For example, an inflammatory
stimulus initiates many energy-dependent reactions such as vasodilatation,
histamine release, movement of leukocytes into the inflamed area. This
requires a continuous supply of ATP to sustain the inflammatory response
(Whitehouse, 1968). This is one explanation of why, in inflamed areas of
tissue, ATP content is higher since ATP synthesis is occurring more rapidly,
than the adjacent "normal" tissue (Kalbhen, 1963). Decreasing ATP synthesis
would significantly affect the rate at which the whole inflammatory response,
including the ultimate reparative processes, will occur (Whitehouse, 1968).
A distinct correlation between decreased ATP production and NSAID-
gastrointestinal damage has been demonstrated. For example, decreased ATP
production has been measured in the areas of the gastric mucosa most prone
to ulceration by aspirin ingestion, the corpus and pyloric gland regions
(Jorgensen et a!., 1976b). Also, the appearance of gastric mucosal damage
induced by aspirin has been associated with an increase in ATP breakdown to
ADP. In indomethacin-induced damage, the changes in tissue ATP
metabolism have actually been shown to precede the development of
macroscopic gastric mucosal injury (Mózsik et a!., 1992).
Paradoxically, the decrease of AlP synthesis by antiinflammatory drugs, was
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Figure 4.5 Fate of glucose in enterocytes
In the enterocyte most of the glucose-6-phosphate is metabolised by the
hexose monophosphate (HMP) pathway or is transported out by specific
carriers (C) at the basolateral borders. If glycolysis is stimulated, then lactate is
formed. 1 = glucose-6-phosphatase. Adapted from Somasundaram et al. (1995).
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inflammatory disease, connective tissue proliferation and polymer
biosynthesis involved in the pathogenesis of joint stiffness, are inhibited by
these drugs presumed to be because they diminish the energy supply
supporting these reactions in these tissues.
But it must be emphasised that decreased ATP generation alone is not in itself
a biochemical indication of gastrointestinal damage. For example, when
mucosal damage is induced by pylorus ligation, stress, ethanol, or reserpine,
there is a significant decrease of tissue ATP at the early stage of ulcer
development, but its level is later elevated (Mózsik and Jávor, 1988; and
Mózsik et al., 1990). This would tie in with the suggestion that mitochondrial
disturbances together with inhibition of prostaglandin synthesis are both




EFFECT OF NSAIDS ON INTESTINAL CELL
MONOLAYERS
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Small intestinal injury caused by NSAIDs is more common than those in the
stomach or duodenum, affecting 60-70% of patients taking these drugs for
more than six months (Bjarnason et al., 1993). Inflammation in the small
intestine caused by NSAIDs may be complicated by mild bleeding and protein
loss, which may lead to iron deficiency anaemia and hypoalbuminaemia
(Bjarnason et a!., 198Th). Diaphragmatic-like strictures may also occasionally
affect patients, which could require surgery, though relatively uncommon
(Bjarnason et a!., 1988). In the stomach or duodenum, on the other hand, the
pattern of NSAID-induced damage is different and often more dramatic,
whereby ulcers may perforate and bleed.
Numerous factors have been implicated in the pathogenesis of NSAID
enteropathy, such as impaired epithelial barrier function (Somasundaram et
al., 1995), bile, luminal bacteria (Yamada et at., 1993), and enterohepatic
recirculation of the NSAID (Wax et a!., 1970). The relative importance of these
factors in the pathogenesis, has still not been determined (Reuter et a!., 1997).
In addition, inhibition of prostaglandin synthesis seems not to be of major
importance in the pathogenesis of small intestinal injury caused by these
drugs (Whittle, 1981; Davies et a!., 1993; Rooney and Jenkins, 1990; and
Somasundaram et a!., 1995).
Nevertheless, it is suggested that the change in intestinal permeability is the
central mechanism in the whole framework of NSAID-induced enteropathy
(Somasundaram et a!., 1995). The increase in intestinal permeability caused by
NSAIDs, enables the biochemical damage (e.g. the mitochondrial changes), to
be converted into the macroscopic damage, by facilitating mucosal exposure to
luminal aggressive factors thereby eliciting neutrophil chemotaxis.
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5.1	 Structure and Function of Tight Junctions
The intestinal wall is lined by a layer of epithelial cells. The apical membrane
of this polarised monolayer is in contact with the luminal space of the
intestine, while the basolateral (or serosal) membrane is in contact with the
body fluid which provides nutrients for the cell (Simons and Fuller, 1985).
The function of the normal healthy gastrointestinal epithelium is to permit
the absorption of nutrients, electrolytes, and water, whilst at the same time
restricting the passage of larger potentially toxic compounds from the lumen
into the systemic circulation (Salzman et al., 1995). This "selective
permeability" of the intestinal mucosa is mediated by intercellular tight
junctions ("zonula occiudens") (Madara, 1989).
The tight junction is a narrow belt-like structure, measuring between 0.1 and
0.7 im in width, on the plasma membrane of transporting epithelial cells
(Madara et aL, 1988a; and Schneeberger and Lynch, 1992). The junction
generally resides near the apex of the cell, forming a continuous
circumferential seal between adjacent cells, thereby selectively restricting the
permeation of ions and nonelectrolytes, according to their charge and size,
between the lumen and the basolateral space.
There are only two pathways by which molecules can cross the epithelium:
the paracellular or the transcellular route (figure 5.1). At least 85% of passive
ion flow across the mammalian small intestine takes the paracellular route
(Frizzell and Shultz, 1972). Tight junctions restrict flow through the
paracellular pathway. Tight junctional permeability is thought to be under
cytoskeletal control, since an increase in paracellular permeability to small
molecules may involve contraction of the perijunctional actinomyosin ring
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Figure 5.1 Passage of molecules through epithelial cells
The tight junctions reside between the cells, toward the apical side. Molecules
can pass through the cells (transcellular) or in between the cells (paracellular).
Modified from Madara (1988).
Magnified grid area
Figure 5.2 Cell counting chamber
The haemocytometer is a modified microscopic slide engraved with two
identical grids of known area. Each of these grids comprise of 5 identical,
smaller sets of grids 1mm 2 square and 0.1mm depth. Therefore, when cell
suspension is introduced by a Pasteur pipette and the coverslip correctly
positioned, the volume of liquid per grid is 0.1mm 3. If the total no. of viable
cells in one of these grids are counted, then when n = no. of cells in 1mm3,
the no. of cells in 1cm3 (i.e. imi) = n x iO4 and cells/cm2 = n x	 Obtained
from Butler (1996).
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(Madara and Pappenheimer, 1987). Cytoskeletal components, in turn, appear
to be partially regulated by All? which elicits contraction (Burgess, 1982).
Therefore, perturbed ATP formation (e.g. by uncoupling of oxidative
phosphorylation) may bring about an increase in intestinal permeability, as
hypothesised in this thesis.
5.2 Advantages of Using Cell Lines
Traditionally, investigations of intestinal permeability have used in situ or in
viva animal models which are not only expensive, but time-consuming,
require large amounts of sample, and can show great variability due to
luminal contents, mucus layer, hepatic clearance, and animal-to-animal or
species-to-species differences (Cogburn et al., 1991). Ex viva transport models
have also been used with everted intestinal sacs, mucosal tracts mounted in
Ussing chambers (Schultz and Zalusky, 1964), luminally or vascularly
perfused intestine (Hartmann and Plauth; and Schumann and Strugala, 1989),
or brush border membrane vesicles (Kessler et a!., 1978). However, such
techniques have proved to be laborious, difficult to reproduce, and limited by
rapid tissue degradation following removal from the body. Moreover,
although looking at effects on brush border membrane vesicles is simpler
than using whole-tissue models and have a larger capacity, they can only be
used to study the effects on the cell membranes (Anderberg et al., 1992). No
information about the possible effects on the permeability across tight
junctions can be obtained from such systems.
Another major difficulty in measuring the effect of compounds on intestinal
function is due to the complex geometric structure and cellular heterogeneity
of this organ (Grasset et al., 1984). As a result, access to the apical (luminal) or
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basolateral (serosal) surfaces of the epithelium is impaired by the presence of
subadjacent tissues. The use of cultured intestinal cells will overcome these
difficulties, while at the same time maintaining polarised morphological and
functional characteristics typical of their role in vivo. The availability of
human cells, the low variability between replicates, the necessity for small
sample and drug volumes, the ability to examine large numbers of samples,
and clearer interpretation of results due to cellular homogeneity, are all
additional advantages of using cultured cells to those techniques formerly
used to measure intestinal permeability (Hilgers et al., 1990; and Cogburn et
a!., 1991).
The use of cells directly isolated from intestinal epithelium (primary cells)
would be the ideal choice, and although some advances toward this goal has
been made (Quaroni et a!., 1979), they are not yet available. This is because
these cells are difficult to culture, have limited viability (-30 to 40 minutes),
and there is a risk of contamination by microorganisms normally found in
the gastrointestinal tract (Pinkus, 1975; Moyer, 1983; and Dharmsathaphorn
and Madara, 1990). Moreover, during isolation of mucosal cells, a loss of
polarity together with substantial damage of the cells may occur. The use of
cell lines are preferred since their uniformity in culture eliminates the
problems created by mixed cell types and different degrees of viability, which
occurs when isolated intestinal cells are studied (Dharmsathaphorn et a!.,
1984).
Human adenocarcinoma cell lines reproducibly exhibit a number of structural
and functional properties characteristic of differentiated intestinal epithelial
cells (Pinto et a!., 1983). Therefore, these cell lines provide an excellent means
of studying intestinal function, such as paracellular permeability.
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These cell lines can be seeded onto to permeable filter supports. Under
appropriate culture conditions, the surface of the cells adherent to the filter
forms the basolateral side, while the nonadherent surface forms the apical
side. As in vivo, tight junctions can develop between cells grown on filters,
and similarly are responsible for their impermeability and polarity (Cereijido
et al., 1989).
5.3 The Caco-2 Cell Line
The Caco-2 cell line is obtained from human colorectal adenocarcinoma (Fogh
et al., 1977). Despite its colonic origin, when cultured the Caco-2 cell line
grows as a monolayer which, at confluency, undergoes spontaneous
differentiation into polarised, columnar cells, more representative of the
small intestine (Pinto et a!., 1983). These cells exhibit characteristics typical of
those found in absorptive small intestinal epithelial cells in vivo (Ranaldi et
al., 1992; and see figure 2.1, chapter 2). These features include brush border
with well-developed microvilli, tight apical junctions, a polarised distribution
of membrane components such as enzymes, receptors, ion channels, and lipid
molecules (Grasset et al., 1984), and vitamin uptake (Vincent et a!., 1985). In
addition, several active transport systems that are located in small intestinal
cells, such as those for sugars, amino acids, dipeptides, bile acids, and
cobalamine intrinsic factor, are also expressed in Caco-2 cells (Wilson et a!.,
1990; Hu and Borchardt, 1990; Dantzig and Bergin, 1990; and Lahey et a!., 1991).
Also, the permeability of a substance across Caco-2 monolayers has been
shown to give a fair assessment of its in vivo absorption regardless of the
mechanism of transport (Yee et a!., 1997). The presence of tight junctions in
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Caco-2 cells can be demonstrated by an inability of permeability markers to
pass across the cell monolayers (Wilson et al., 1990).
5.4 The T84 Cell Line
The human colonic epithelial cell line T84, originates from a lung metastasis
of a well-differentiated adenocarcinoma (Murakami and Masui, 1980). This
cell line grows on permeable supports, soon again becoming well
differentiated when reaching confluence (Dharmsathaphorn et a!., 1984; and
Madara et a!., 1987a). The resultant monolayers have a columnar appearance,
morphologically resembling foetal colon crypt epithelial cells, with distinct
apical and basolateral surfaces. Though these cells do not form well-
developed brush borders, they do form tight junctions between cell. The latter
has been determined by electrical resistance measurements and the presence
of a prominent actin-rich perijunctional microfilament ring, similar to that
seen in native intestinal epithelia, which controls tight junction structure
(Madara et al., 1988).
hi addition, there is evidence to suggest that T84 cells behave like intestinal
tissue in situ with respect to inflammation. This is because in the lumen and
mucosa of patients with inflammatory bowel disease, there are elevated
prostaglandin levels (Rampton and Sladen, 1984). Likewise, in tissue and
cultured cell preparations, numerous inflammatory mediators have been
shown to stimulate the synthesis and/or release of prostaglandins (Lawson
and Powell, 1987; Hong and Levine, 1988; and Bern et a!., 1989). Pretreatment
of T84 cells with indomethacin (1 jiM) inhibits such prostaglandin release
(Berschneider and Powell, 1992).
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5.5	 Measurement of Transepithelial Resistance (TER)
When cells are grown on a permeable support they form a monolayer.
Measurement of electrical resistance across the cellular monolayer is a
relatively sensitive measure of its integrity and permeability (von Bonsdorff
et al., 1985). The TER is inversely proportional to paracellular permeability,
reflecting resistance predominantly across tight junctions and not the cell
membrane (Madara, 1983) since firstly, in leaky epithelia, such as in the
intestine, up to 85% of the electrical current flows between the cells via the
paracellular route (Frizzell and Schultz, 1972), and secondly, paracellular
resistance increases logarithmically with increasing number of junctional
strands. Relatively minor alterations in junctional permeability produces
substantial changes in the TER, attesting to the high sensitivity of this method
of permeability measurement (Madara, 1983). Treatments which disrupt the
tight junctions, such as removing Ca2 from the medium (Collares-Buzato et
a!., 1994) or inhibiting actin filament formation with cytochalasins (Madara et
a!., 1983), cause the monolayers to lose their electrical resistance properties.
Furthermore, changes in the TER will reflect structural as well as functional
changes of the tight junctions, whereas electron microscopic evaluation can
only detect structural changes (Milton and Knutson, 1990).
TER is generally expressed in cm2, which is the resistance measured in
multiplied by the area of the filter in cm 2. For Caco-2 monolayers, the TER is
usually between 150 and 400 acm2 (Grasset, 1984; Hidalgo et a!., 1989; and
Wilson et a!., 1990). This is similar to that of colonic cells (whole rat colon -
30O.cm 2 ) yet higher than that of small intestinal cells (whole rat small
intestine - 60^.cm2) (Frizzell and Schultz, 1972), indicating the formation of
220
tighter epithelia. Monolayers of T84 cells typically have an even higher TER
of —1,500 icm2 (Madara and Dharmsathaphorn, 1985).
The TER can be measured by several means. The most established technique
employs the use of the Llssing chamber (Ussing and Zehran, 1951). Cells
grown on permeable filters are mounted in between two compartments of the
U-shaped chamber, bathed in the appropriate buffer, and resistance measured
across the cell monolayer.
Another technique to determine the TER involves using the Millicell. This
involves passing a potential difference across the cell monolayer using
specially designed electrodes, and measuring the resistance.
5.6 Materials and Methods
5.6.1 Materials
The cell lines Caco-2 and T84 were obtained from European Collection of
Animal Cell Cultures (ECACC), Salisbury, England.
Gibco BRL, Paisley, Scotland, supplied modified eagles medium (MEM),
Dulbecco's modified eagles medium (DMEM), non-essential amino acids
(NEAA), 1-glutamine, heat-inactivated foetal bovine serum (FBS), trypsin-
EDTA (0.25%-lmM), Ca 2 /Mg2 -free phosphate-buffered saline (PBS) and
trypan blue 0.4% (w/v). 51Chromium-labelled ethylenediaminetetraacetic acid
( 51 CrEDTA) was obtained from Amersham Life Science Ltd,
Buckinghamshire, England. The sterile plastic instruments were purchased




Crucial to all cell culture experiments is the avoidance of microbial infection.
This is because the cells, being in vitro, have no resistance against such
invasion and easily become contaminated, resulting in the loss of function.
Therefore most of the plastics used were sterile and disposable and almost
everything (including gloves) was sprayed with 70% ethanol before coming
into contact with the cells. The use of a class 3 laminar flow cabinet (Holten
LaminAir) also helped prevent contamination
Passaging Cells
Passaging was performed in the flow cabinet. When not being used the flask
of cells was kept in an aerated (95% 02 and 5% CO2) incubator (Heraeus) at
37°C, with the lid of the flask slightly loosened to enable the cells to receive
sufficient oxygen and carbon dioxide for growth.
The cells were grown in lOml prewarmed (37°C) medium. For the Caco-2 cells
the culture medium comprised of MEM containing 1% NEAA, 1% glutamine
and 20% FBS, and for the T84 cells the medium was DMEM: nutrient mix F12
(1:1) with 1% glutamine and 10% FBS. In both cases, the culture medium was
a red-coloured solution since it contained the indicator phenolphthalein red.
This medium turns purple when alkaline, such as when the cells have
exhausted the nutrients from the medium, and orange when acidic, for
example during bacterial contamination.
The cells were examined each day under a microscope to check for confluency
and any signs of microbial contamination. Every alternate day, the medium
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was poured off and replaced with fresh medium, known as "refeeding". This
ensured the cells always had adequate nutrients for growth.
When the cells were confluent they were "passaged" either for experimental
use or for propagation. This involved pouring off the culture medium and
washing the cells gently with prewarmed PBS three times. imi prewarmed
trypsin-EDTA was then added. Both Caco-2 and T84 cells attach very strongly
to the flask wall so both a protease (trypsin) and a chelating agent (EDTA) are
required to detach the cells from the flask wall. The lytic action of trypsin is
prevented by the serum in the medium, so it is important for the cells to be
washed well for trypsin to work. The flask was reincubated for approximately
2-3 minutes for Caco-2 and 10-15 minutes for T84 cells, to enable the trypsin to
work. (T84 cells require relatively vigorous trypsinisation because these cells
attach extremely firmly to the culture flask and the cells tolerate it well
(Dharmsathaphorn and Madara, 1990)). The side of the flask was then gently
tapped to increase detachment.
9ml of culture medium was added to counteract the action of trypsin. By
gently pipetting up and down several times, a homogenous suspension of
cells was obtained. imi of this suspension was transferred to a new flask
containing 9m1 fresh medium, and this new flask then returned to the
incubator until the cells were confluent again. Both Caco-2 and T84 cells take
approximately 5 days to reach confluency.
Counting the Cells
When culturing a new cell line, it is practice to count the cells to estimate
how many viable cells are present per cm 2 area of attached surface. In short,
this involved mixing the cell suspension with equal volumes of trypan blue,
and loading a haemocytometer (Improved Nebauer) with 2Opi of this
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mixture. Viable cells can exclude trypan blue but those which are dead cannot
and so take up a distinctive blue coloration (figure 5.2).
Measurement of TER Using the Ussing Chamber
The cell suspension, obtained from passaging, was concentrated down to 2 x
106 cells/ml by resuspending in the appropriate volume of medium. 0.5m1 of
this cell suspension (i.e. 1 x 106 cells) was added to the inner (apical) well of
the culture plate and 4m1 of medium to the outer (serosal) well. The cells
were incubated with the wells being refed every other day.
The 12mm diameter, polycarbonate filter (0.4.tm pore size) of the inner well
was purpose built so that it could be snapped out and assembled in the Ussing
chamber (World Precision Instruments, mc). This was done so with the
bottom of the "snapwell" (serosal side) facing the left hand side of the
chamber. Both halves of the chamber were filled with 20m1 Ringer's solution
comprising 114mM NaC1, 5mM KC1, 1.65mM Na2HPO4, 0.3mM NaH2PO4,
25mM NaHCO3, 1.25mM CaC12.2H20, 1.1mM MgSO4.7H20, 10mM D-glucose,
pH 7.4 with 1M NaOH. This was then gently oxygenated and the temperature
maintained at 37°C by a temperature jacket (figure 5.3).
Electrodes, embedded in 3% agar and 150mM KC1, were connected to both
chambers. Resistance (R) measurements were made by damping the potential
difference to a known voltage (V) and measuring the current (I) necessary to
produce this deflection. Resistance could then be calculated using Ohm's law
(V=IR). Similarly, it was also possible to clamp the current at required values
and measure the voltage. The voltage was initially measured at lOOp.A for
approximately 30 minutes to get a stable baseline. The voltmeter allowed for
compensation of fluid resistance. That is, by subtracting the resistance



















Figure 5.3 Ussing chamber set up
1x106 cells were plated out onto specialised snapwells. Following cell growth,
the snapwells were snapped out of the plate and placed at the bottom of the U-
shaped Ussing chamber and a voltage passed across it. Drugs were added to
the right hand bath (the apical side of the monolayer), and their effect on the
TER are observed.
225
fluid through when the filter was present, an accurate resistance
measurement across the filter is achieved.
Measurement of TER Using the Millicell Electrode
Using 12mm diameter polycarbonate transwells (0.4jim pore size), 0.75m1 cell
suspension was added to the inner well and 1.5m1 medium to the outer well.
The cells were incubated for 48 hours in order to attach to the filter.
Before taking a reading, the Millicell-ERS electrode (Millipore (U.K.) Ltd) was
immersed in 70% ethanol for 15 minutes, to rid it of any contaminants, air-
dried, then dipped in serum-free medium to equilibriate for a further 15
minutes. The two-probed electrode was positioned over the cells such that the
longer probe was immersed in the outer well and the shorter probe in the
inner well, making sure there was no physical contact with the filter to avoid
cell or filter damage. By passing a current between the electrodes, i.e. across
the monolayer, the potential difference was automatically measured and the
resistance across the cell monolayer calculated, giving a reading in kilo-ohms
(ku) on the meter (figure 5.4). After obtaining a reading, the cells were refed
with fresh medium.
This process of measuring TER then refeeding was repeated every alternate
day until a maximum resistance was measured. Preliminary experiments
revealed that for Caco-2 cells the average maximum TER was —800fl.cm2 and
was achieved after approximately 17 days, and for T84 cells it was —1200^.cm2
after approximately 7 days. It is worth noting that the time it took for the cells
to give maximum TER in the transwell plate did not correlate with the time it
took for them to reach confluency in the culture flasks. Thus, the progressive
rise in epithelial resistance most likely reflects the continued maturation and











Figure 5.4 Millicell set-up
1.4 x 106 cells were seeded onto transwells and grown for 2 days. The Millicell
electrodes were then appropriately positioned in the wells and a potential
difference passed across the electrodes, giving a resistance reading in kilo-
ohms of the cell monolayer. The monolayers were then replenished with
fresh medium and the process of measuring their resistance and refeeding
was repeated every other day.
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1992).
Therefore, subsequent experiments looking at NSAID effect on the TER were
performed on T84 cells 7 days after seeding onto transwells, since its greater
TER meant that drug effect would be easier to detect than in Caco-2 cells. If the
time-interval between each reading was greater than 5 minutes, the plate was
returned to the incubator to ensure that the temperature of the medium did
not drop below 37°C.
5.7 Aims of the Studies
Ussing Chamber Experiments
Experiment 1 - Resistance over varying currents
Ideally, the resistance across the monolayer should remain constant with
varying current. This was tested by clamping the current at set values and
calculating the resistance (in ohms). This was carried out in Caco-2 cells 2, 3, 6
and 7 days after seeding onto the wells. The effect of indomethacin on the
TER of 2, 3 and 7 day old cells was then studied by adding 0.125mM
indomethacin to the apical side of the cell monolayer (RHS chamber). In the 6
day old Caco-2 cells, the effects of 0.015 and 0.045mM dinitrophenol were
observed.
Experiment 2 - Resistance over time
A decrease of TER would indicate a loosening of the tight junctions. The TER
was measured over time to assess firstly how long the monolayers retained
their junctional integrity for a certain length of time, and secondly how long
it took for indomethacin to have an effect on the TER. This was carried out by
clamping the current at lOOp.A and measuring the change in resistance over
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time in 4, 5, 13, 14 and 17 day old Caco-2 cells, and also in 8, 9 and 10 day old
T84 cells. In the 4 day old Caco-2 cells the effect of 0.125 and 0.375mM
indomethacin was tested and found to have very little effect. Therefore, in the
remaining groups of cell monolayers a higher concentration of indomethacin
(2.5mM) was used.
Millicell Electrode Experiments
Study 1 - Effect of indomethacin on TER of T84 cells
The effect of 0.5 to 2mM indomethacin was tested on the cells at regular
intervals over 6 hours then again 24 hours later. This was done by adding 7.5,
15, 22.5 and 3Opi of 50mM indomethacin (made up in 10% DMSO) to the
inner well, then measuring the TER at the set time time-points.
Study 2 - Effect of 10% DMSO on TER of T84 cells
In order to rule out a dilution effect caused by adding different volumes of
indomethacin or DMSO, experiment 1 was repeated but with (a) 10% DMSO
added to the wells at the same volumes as indomethacin and also with (b)
7.5p.l of different strengths of DMSO.
Study 3 - Effect of NSAIDs (same volume, different stocks)
It was then decided to keep the volume of drug added constant throughout to
rule out dilution of the medium having an effect on the TER. Therefore,
indomethacin and aspirin were now prepared in different strengths of DMSO
and 7.5jil of the different stocks added to give a final concentration range from
0.05 to 2.5mM for indomethacin and 0.001 to 1mM for aspirin. Similarly,
different stock solutions of naproxen were made up in water so that addition
of 7.5p.l gave a concentration range of 0.0001 to 1mM. (7.5p.l water was found
to have no effect on the TER).
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Study 4 - Effect of DNP on TER of T84 cells
Different stock solutions of DNP were made up in 0.5% ethanol. Either 7.5 or
15p.l was added to the cells to give a final concentration range of 0.001 to
0.04mM, and the resistance measured over time. Corresponding volumes of
only 0.5% ethanol were also tested.
Study 5 - Effect of pH on TER of T84 cells
Maintaining a pH of 7.4 in the bathing medium is important since alterations
in pH will alter cell growth and an alkaline pFi, particularly, will markedly
reduce cell viability (Wilson, 1987). In the previous experiments, although all
the original drug solutions were adjusted to pH 7.4 with 1M NaOH, the cell
culture medium itself was not buffered. To investigate if the TER changes
previously seen with the drugs were as a result of pH changes in the medium
following drug addition rather than a drug effect per Se, the effect of pH on the
TER was tested by adding different volumes of 1M HC1 or 1M NaOH to the
cells to vary the pH between 4 and 10.
Study 6 - Effect of indomethacin in HEPES-buffered medium
Due to their being an effect of pH changes on the TER, HEPES-buffered
medium was used for all subsequent experiments. The effect of indomethacin
(0.2 to 1mM) on the TER was measured in this new medium at regular
intervals between 5 and 240 minutes. It was found that by the first reading at 5
minutes, the TER of the cells was already significantly reduced by
indomethacin. Therefore, in order to follow this decrease more closely, the
TER was then measured at 5 second intervals until 30 secs, then at 60 secs,
then every minute until 5 minutes had elapsed.
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Study 7 - Effect of aspirin and naproxen on TER of T84 cells
A range of concentrations of aspirin between 0.4 and 20mM and naproxen
between 1 and 10mM were used, and the TER measured over time.
Study 8 - Effect of misopros to! on TER of T84 cells
A range of concentrations of misoprostol from 0.4 to 4mM were used, to see
the effect of this prostaglandin derivative on the TER.
Study 9 - Effect of naproxen on 51 CrEDTA flux
As well as measuring the TER, addition of hydrophilic permeability markers
such as 51chromium-labelled ethylenediaminetetraacetic acid (51CrEDTA) to
cellular monolayers will enable paracellular permeability to be measured.
Therefore, to the inner well was added either (a) 10mM naproxen with 30111
51CrEDTA (3p.Ci), (b) naproxen alone or (c) 51CrEDTA alone. Then at regular
intervals for 4 hours, the resistance was measured. Then the contents of the
inner and outer wells transferred to scintillation vials in order to measure
their respective counts per minute (cpm) using a gamma counter (Wallac,
LKB 1262). An increase in the cpm of the outer well and a decrease in the
inner well, would suggest 51 CrEDTA flux through the monolayer by a
loosening of intercellular tight junctions.
Study 10 - Effect of NSAIDs pre-dissolved in the medium
Up till now, all the drugs tested had been added directly to the cells. Often
duplicate experiments gave different results. These discrepancies may have
arisen from the 'location' the drug was pipetted with respect to the cells, as
many of the drug solutions were fairly viscous and tended not to disperse
readily in the medium. (It was not possible to use a plate shaker to disperse
the drug solution due to the fragility of the cells). Thus, if the drug solution
was pipetted very near to the monolayer, the cells would be exposed to a
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higher (more toxic) concentration sooner than if the drug was pipetted near
the top of the well (see figure 5.4). For this reason it was decided to prepare the
drugs indomethacin and naproxen as before, then to mix the required
volume to 750ii1 prewarmed medium in a sterile vial rather than add to the
well directly. Then, in order to see the effect of the drug on the TER, the pre-
existing medium from the inner well was removed and replenished with the
freshly-prepared drug-treated medium.
5.8	 Results
5.8.1 Ussing Chamber Results
Experiment 1 - Resistance over varying currents
The Caco-2 cells gave a TER between 10 and 100 flcm 2. Such readings were
much lower than expected and did not correlate with the age of the cells.
However, the TER remained fairly constant with increasing current.
Addition of 0.125mM indomethacin did not bring about any significant
change in the TER. In the 3 day old Caco-2 cells (figure 5.5a), there appeared to
be a 30% drop in TER after a 30 minute incubation with indomethacin.
However, results with the 7 day old cells (figure 5.5b), revealed that this
decrease occurred in untreated cells as well and, therefore, probably
represented loss of cellular integrity after 30 minutes rather than a drug effect.
This was substantiated in the 2 day old cells (figure 5.5c), when after
indomethacin had been washed out and the cells left for one hour, a decrease
in the TER was again observed. The suggestion is that the cells do not remain
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Figure 5.5 Effect of indomethacin on TER of Caco-2 cells over increasing
current using the Ussing chamber
1x106 Caco-2 cells were grown in snapwells for a period of (a) 3, (b) 7 and (c) 2
days before being assembled in the Ussing chamber. The TER (expressed as
acm2 = resistance measured x area of the filter) of untreated (control) or
treated (0.12mM indomethacin) cells was measured over increasing current.
Each data point represents one experiment.
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0.015 or 0.045mM DNP did not appear to affect the TER of 6 day old Caco-2
cells (figure 5.6). As with indomethacin, when the cells had been washed free
of drug, there was a marked decrease in the TER. It was found that control
resistance measurements were not consistent between preparations.
Experiment 2 - Resistance over time
In Caco-2 (figure 5.7) and T84 (figure 5.8) cells, there was a consistent decline
in the TER over time, irrespective of the age of the cells. Addition of
indomethacin did not further reduce the TER but showed the same pattern of
decrease over time, indicating that this was not a drug effect but due to loss of
cellular viability.
5.8.2 Millicell Results
Study 1 - Effect of indomethacin
Figure 5.9 shows that concentrations of indomethacin between 0.5 and 2mM
decreased the TER of T84 cells. The highest concentration of indomethacin
used, 2mM, caused the maximum decrease to approximately 35% of control.
With all the concentrations used, the initial sudden drop in the TER was
followed by a gradual rise over 30 minutes and then a decrease again. As TER
measurements were done every 5 minutes for the first half an hour, it was
unfeasible to return the plate to the incubator in between readings.
Consequently, the increase in TER seen over this time period may actually
correspond to the temperature of the cells falling below room temperature
and not a drug effect per Se, since a similar rise in the TER was seen in
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Figure 5.6 Effect of DNP on TER of Caco-2 cells over increasing current
using the Ussing chamber
1x106 Caco-2 cells were grown in snapwells for a period of 6 days then placed
in the Ussing chamber. The TER of cells treated with DNP (0.015mM or
0.045mM) or untreated cells (control) was monitored over increasing current.
Each data point represents one experiment. TER was expressed as cm2
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Figure 5.7 Effect of indomethacin on TER of Caco-2 cells over time using
the Ussing chamber
1 x 106 Caco-2 cells were seeded onto snapwells and grown for (a) 13, (b) 14; or
(c) 17 days. The filters were then assembled into the Ussing chamber and
2.5mM indomethacin added to right-hand bath feeding the apical side of the
monolayer. Control monolayers were untreated. The TER was then measured
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Figure 5.8 Effect of indomethacin on TER of T84 cells over time
1.4 x 106 184 cells were plated out in snapwells for a period of (a) 8; (b) 9; and
(c) 10 days then positioned in the Ussing chamber. The cells were either
treated with 0.25mM DNP by adding to the right hand half of the chamber or
untreated (control). Their TER was then observed over time. TER was
expressed as acm2 (resistance measured multiplied by the area of the filter).
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Figure 5.9 Effect of indomethacin on TER of T84 using the Millicell
1.4 x 106 T84 cells were grown in transwells for 1 week. Using the Millicell
electrode the TER of the monolayers were monitored every alternate day
before being refed, until their TER had reached —1000.cm 2. The monolayers
were then treated with 0.5 to 2mM indomethacin and the TER measured at
set time-points and compared to control. The TER was expressed as percent of
(resistance in presence of drug / resistance in absence of drug). Each point
represents the mean of 2 experiments.
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Study 2 - Effect of 10% DM50
Figure 5.lOa shows that different volumes of 10% DMSO between 7.5 and
30p1, all appeared to give a TER greater than 100%. Figure 5.lOb shows that
when 7.5l DMSO of different strengths was used, the TER remained at
approximately 100%, indicating this volume of the solvent (irrespective of
final concentration) had no effect on the TER and so would be favourable to
use for experiments.
Study 3 - Effect of NSAIDs (same volume, different stocks)
Figure 5.11a shows how over approximately 24 hours, 0.005 and 0.05mM
indomethacin had a negligible effect on the TER. 0.5mM reduced TER by a
maximum of 50%, whereas 5mM indomethacin decreased the TER by 95%
within 5 minutes. Therefore, the effect of indomethacin on the TER appears
to be concentration-related.
From figure 5.11b it can be seen that 0.0001 to 1mM aspirin had very little
effect on the TER. Over 6 hours, the TER remained at approximately 100% of
control.
Figure 5.11c shows that over a concentration range of 0.0001 to 1mM,
naproxen did not reduce the TER by more than 30%. The decrease was not
related to the concentration of the drug since maximum decrease was
obtained by 0.01mM naproxen.
Study4 -EffectofDNP
There was very little effect of 0.002 to 0.04mM DNP, or of corresponding
volumes of its solvent 0.5°c ethanol, on the TER. This can be seen in figure
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Figure 5.10 Effect of DMSO on TER of TM cells using the Millicell
1.4 x 106 T84 cells were seeded onto transwells. After growing for
approximately 1 week, the TER had reached —10O0icm2
 as determined by the
Millicell electrode. The cells were then treated with (a) different volumes of
10% (v/v) DMSO or (b) 7.5j.tl of different strengths of DMSO. The TER of the
monolayers was monitored over time and compared to untreated cells
(control). TER is expressed as percent of (resistance in presence of DMSO /
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Figure 5.11 Effect of NSAIDs on TER of T84 cells using the Millicell
When 1.4 x 106 T84 cells were grown in transwells for 1 week they gave a TER
of —1000.cm2 when measured by the Millicell electrode. The monolayers
were then incubated with 7.5p1 of different stocks of (a) indomethacin, (b)
aspirin or (c) naproxen. The TER of the cells were observed at various times
after treatment and compared to control (untreated cells). TER expressed as
percent of (resistance in presence of drug / resistance in absence of drug). Each










0	 100	 200	 300	 400	 500
Time (minutes)
Figure 5.12 Effect of DNP on TER of TM cells using the Mihicell
1.4 x 106 TM cells were grown in transwells. Using the Millicell electrode, the
TER of the monolayers was monitored every alternate day before being refed,
until their TER had reached —1000.cm 2. The cells were then treated with
7.5pl of different stocks of DNP and their TER measured at various time
points and compared to untreated cells. TER expressed as percent of
(resistance in presence of drug / resistance in absence of drug). Each point
represents mean of 2 experiments.
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Study 5 - Effect of pH
The effect of different pH's on the TER can be observed in figure 5.13. In the
currently used unbuffered medium, a pH of 4 to 7 and pH 10, gave TER values
below that of control, with pH 10 reducing the TER the most. A pH of 8 gave a
TER similar to the control value, indicating at this pH the cell viability would
not be compromised.
However, even with the drugs being prepared at pH 7.4, their addition to the
medium may still change the pH slightly. Therefore, a culture medium
buffered with FIEPES was subsequently used. (The existence of such a medium
prior to starting the experiments was unknown and previously published
reports have not mentioned pH changes as a problem).
Study 6 - Effect of indomethacin in HEPES-buffered medium
Figure 5.14a show that 0.2 to 1mM indomethacin significantly decreased the
TER within 5 minutes of addition. 10% DMSO had no effect.
Following the decrease in detail over 5 minutes, it can be seen from figure
5.14b that the decrease is time-dependent. The reduction is also related to the
concentration of indomethacin since at 5 minutes the TER (% of control) by
0.2mM indomethacin is 60%, 0.5mM is 30%, and 1mM is 18%.
Study 7 - Effect of aspirin and naproxen in HEPES-buffered medium
Figure 5.15a shows the effect of aspirin on the TER (in HEPES-buffered
medium). Only the highest two concentrations 10 and 20mM significantly
reduced the TER to approximately 600 o of control. The lower concentrations













Figure 5.13 Effect of pH on TER of TM cells
1.4 x 106 T84 cells were plated out in transwells and grown until the TER of
the monolayers had reached -1000.cm2 as asceratined by the Millicell
electrode. Using 1M HC1 or 1M NaOH, the pH of the inner well was varied as
shown, and the TER was measured after a 30 minutes incubation period. The
TER was expressed as cm2 (resistance measured multiplied by the area of
the filter). Each result represents 1 experiment.
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Figure 5.14 Effect of indomethacin on TER of T84 cells using the Millicell
1.4 x 106 T84 cells were plated out in transwells using HEPES-buffered culture
medium. After 1 week, the TER of the monolayers was -l000Licm 2 when
measured by the Millicell electrode. 0.2 to 1mM indomethacin was then added
to the monolayers and their TER monitored over either (a) 1200 minutes or
(b) 300 seconds and compared to untreated cells. TER expressed as percent of
(resistance in presence of drug I resistance in absence of drug). Each point
represents mean of 2 experiments.
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Figure 5.15 Effect of aspirin and naproxen on TER of T84 cells using the
Millicell
In HEPES-buffered culture medium, 1.4 x 106 T84 cells were seeded onto
transwells. These were grown until their TER had reached —10001.cm 2 as
ascertained by the Millicell. The monolayers were then incubated with (a)
aspirin or (b) naproxen at the concentrations indicated. The TER of the cells
was measured at various time intervals and compared to untreated cells. TER
is expressed as percent of (resistance in presence of drug / resistance in absence
of drug). Each point represents the mean of 2 experiments.
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In figure 5.15b, it can be seen that both the solvent (water) and the lowest
concentration of naproxen used (1mM), had no effect on the TER over 2
minutes. At the higher concentrations, maximum reduction in the TER was
achieved more or less within 30 seconds, the greatest decrease being caused by
the highest concentration of naproxen (10mM) to 26% of control.
Study 8 - Effect of misoprostol
From figure 5.16 it can be seen that 0.4 to 4mM misoprostol did reduce the
TER by a maximum of 35%. However, this decrease was not concentration-
related since the maximum reduction was seen with 2mM misoprostol.
There was a rise in the TER above 100% with water (the solvent of
misoprostol) in the first 10 seconds of readings. This again may have
corresponded to a temperature-effect since the water had not been prewarmed
to 37°C, therefore causing the temperature of the cells to drop below 37°C.
Study 9 - Effect of naproxen on 51 Cr.EDTA flux
The TER of T84 monolayers treated with 51CrEDTA alone, remained around
100% of control over 4 hours (figure 5.17), suggesting this marker did not
adversely affect cell function during this time. When the radioactivity of the
outer well was compared to total radioactivity as a percentage to measure
51 CrEDTA flux, it was seen that virtually no 51CrEDTA passed through the
monolayer. On addition of naproxen, the TER was decreased within 30
minutes (as seen previously). There was also a time-dependent increase in
51CrEDTA flux through the monolayer, observed as a gradual rise in the outer
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Figure 5.16 Effect of misoprostol on TER of T84 cells using the Millicell
1.4 x 106 T84 cells were grown in transwells using HEPES-buffered culture
medium. Using the Millicell electrode, the TER of the monolayers was
monitored until a value of —1OOO.cm 2 had been obtained. These were then
incubated with 0.4 to 4mM misoprostol and the TER observed over 3600
seconds and compared to untreated cells. TER expressed as percent of
(resistance in presence of drug / resistance in absence of drug). Each point
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Figure 5.17 Effect of naproxen on the 51CrEDTA flux of TM cells
In HEPES-buffered culture medium, 1.4 x 106 T84 cells were grown in
transwells for approximately 1 week so that their Millicell TER reading was
-1000.cm2. The monolayers were then incubated with 3pCi 51CrEDTA (Cr)
in the presence or absence of 10mM naproxen (Nap). The TER of the cells was
then observed over 4 hours and compared to untreated cells as a percentage.
At the same time-points, the counts per minute (cpm) of the outer and inner
wells were also measured using a gamma counter, to assess 5 -CrEDTA flux.
This was expressed as a percentage of the cpm of the outer well over total
cpm. Each point represents mean of 2 experiments.
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Study 10 - Effect of drugs dissolved in the medium
The effects of replacing the culture medium in the wells with indornethacin-
or naproxen-treated medium can be seen in figures 5.18a and b respectively. In
both cases, the reduction in the TER by the drugs can be observed gradually
over 4 hours, rather than occurring within minutes as happened when the
drugs were added directly to the wells (see figures 5.14 and 5.15b).
5.9	 Discussion
5.9.1 Optimising Experimental Conditions
The use of intestinal cell lines to monitor the effects of NSAIDs would, in
theory, be highly preferable to whole tissue because altered prostaglandin
production has a major effect on blood flow and the effect of this is not a
problem in cell lines. Therefore, one can observe the effects of NSAJDs on
tight junctions in isolation of their effects on blood vessels. However, as the
experiments of this chapter demonstrated, getting the right technique and
conditions is very important in avoiding artefactual results.
The Ussing chamber was initially introduced to distinguish between active
and passive ion movement by using a short-circuit current technique, i.e.
voltage-clamping (Ussing and Zehran, 1951). It has since been adapted for the
investigation of transport of many markers, being most commonly used in
gastrointestinal pharmacology (Grass and Sweetana, 1988). It has the
advantage of allowing continuous resistance measurement, so that active
transepithelial transport of electrolytes can be monitored. However, when
adding small quantities of drug, it is fairly 'hit and miss' as to whether the
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Figure 5.18 Effect on TER of T84 cells when medium replaced with
indomethacin- or naproxen-treated medium
Using HEPES-buffered medium, 1.4 x 106
 T84 cells were grown in transwells
until the Millicell TER measurement was -1000.cm 2. The medium in the
wells was then replaced with (a) indomethacin- or (b) naproxen-treated
medium at the concentrations indicated. The TER of the cells was observed
over 4 hours and compared to untreated cells. TER expressed as percent of
(resistance in presence of drug / resistance in absence of drug). Each point
represents mean of 2 experiments.
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This could have explained the variable results of the present studies. Grass
and Sweetana (1988), found that by reducing the volume capacity of the
reservoir, quantifying substances with low permeabilities was more accurate.
The present experiments also showed a decrease in the TER over time
indicating a loosening of tight junctions. This may have resulted from
damage to the cells due to excessive physical manipulation, since the filter
had to be removed from its surrounding medium, 'snapped' out of the inner
well, then positioned in the chamber. Moreover, the cells were bathed in
Ringer's solution and not their original culture medium, perhaps another
reason why their viability was challenged.
This lack of success in attaining adequate TER with the Ussing chamber was,
however, in sharp contrast to the studies carried out by Madara and
colleagues, who consistently reported a TER with T84 cells of —1,5OOL.cm2
(Madara and Dharmsathaphorn, 1985; and Dharmsathaphorn and Pandol,
1986). The discrepancy may have arisen from the fact that the latter group
worked on cells grown on collagen-coated ifiters, which increases the ability of
T84 cells to attach and confluently spread over the substrate surface
immediately after plating, as compared to uncoated filters (Madara et a!.,
198Th). The advantage of collagen-coated filters was also seen with Caco-2
cells, which reached confluency more rapidly and achieved higher cell
densities in, the same length of time, than those on uncoated filters as
reported by Grasset et a!. (1984). This suggests that the collagen matrix may
promote cell attachment as well as cell growth (Hidalgo et al., 1989). However,
when Hilgers et al. (1990) compared Caco-2 cell monolayers grown in the
absence to those in the presence of collagen, they concluded that the collagen
matrix was unnecessary for the establishment of confluent monolayers.
Moreover, the collagen appeared to promote cell migration through the filter
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at earlier times in culture, resulting in functional depolarisation of the
monolayer. Artursson (1990) even demonstrated a higher TER of Caco-2 cells
grown on uncoated filters than that previously reported for collagen-coated
filters (Hidalgo et al., 1989). The major discrepancy is that filters of 3i.tm pore
size were used in the studies where collagen was reported to be essential,
whereas the pore size was 0.4j.Lm in those studies where collagen was not
necessary. Perhaps, therefore, collagen facilitated the formation of confluent
monolayers by covering the relatively large pores (Artursson, 1990).
Furthermore, in the studies of Madara's team, the Ussing chamber was
modified such that the water turbulence created by oxygenation of the
Ringer's solution was minimised, thereby enabling the monolayer to remain
intact for more than 2 hours. Pressure to the monolayer was avoided by not
clamping the filter into the chamber, rather growing the cells directly on
Lexan rings with a collagen-coated Nitex mesh support, which serves as a
component of the Ussing chamber itself (Dharmsathaphorn et al., 1984). The
Lexan rings, made of rubber, also ensured no damage occurred to the edge of
the monolayer. Grasset et al. (1984), reduced edge damage by using silicone
paste.
Nevertheless, for the purpose of these studies, the Millicell electrode was
preferred to the Ussing chamber since the TER could be measured in the
original growing environment of the cell monolayers without requiring
movement of the cells. Also, with the Millicell, the TER of the cells was
higher and it gave reproducible results, indicating the cell monolayer was not
greatly perturbed by this means of measurement. However, this technique
gave only static measurements, so drug effect could only be monitored at set
time points and not continuously.
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Another disadvantage was that measurement by the Millicell electrode
needed to be performed at room temperature, so there was a risk that the
temperature of the culture medium would fall below 37°C. The drop in
medium temperature was observed as a steady rise in the TER. A similar
finding has been reported previously in Caco-2BBe monolayers (Menconi et
al., 1997) and by other investigators (Madara, 1983; and Riehi and Stenson,
1994), where the TER increased at 4°C, possibly as a result of temperature-
dependent closing of tight junctions. Likewise in Madin-Darby canine kidney
(MDCK) monolayers, a drop in the temperature from 37°C to 3°C resulted in a
306% increase in the TER (Gonzalez-Mariscal et al., 1984). However, the
suggestion that the sealing capacity of the tight junctions increased with a fall
in temperature, was refuted by the absence of morphological changes. In
addition, paracellular transport of fluorescein isothiocyanate (FITC) and
mannitol in Caco-2 cell monolayers, showed very little change when the
temperature fell below 37°C (Cogburn et al., 1991). Perhaps, therefore, this
increase in TER with decrease in temperature is not a tight junctional effect,
rather an effect on cell physiology.
The problem then arose of optimising the conditions for measurement of
drug effect on the TER by the Millicell. Firstly, as the inner well volume was
only 750ji1, it was important not to dilute it too much by the addition of drug
solutions. Therefore, the drug were prepared in stock solutions of increasing
strengths, and 7.5.t1 added to each well. Any change in TER was, therefore,
due to the drug and not a dilution effect.
It was then discovered that, although the drug solutions were at pH - 7.4, and
added to a medium also at pH - 7.4, there was still a slight change in the pH,
observed as a change in medium coloration. In the main, the NSAIDs made
the medium slightly acidic. This may have been due to the NSAID itself.
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Alternatively it may have occurred due to intracellular acidification caused by
increasing the paracellular conductance of the apical cell membrane to H+, as
shown previously with aspirin in isolated Necturus antral mucosa
(Kivuluoto et al., 1989). The direct effect of different pH's on the TER was then
investigated and pH 4 to 7, and pH 10 greatly reduced the TER, with only pH 8
giving a TER similar to control. Similarly, in Caco-2 (Parisi et a!., 1993) and
Caco-2BBe monolayers (Menconi et al., 1997), and rat jejunum (Capurro and
Parisi, 1992), acidification of the culiure medium to pH <7.4 resulted in an
increase in paracellular permeability. The effect of pH on the paracellular
pathway (i.e. TER) was shown to be via an effect on tight junctions since these
were dilated and appeared to contain less of the tight junction-associated
protein ZO-1 (Menconi et a!., 1997), which is known to diffuse away from the
cell periphery in response to a decrease in cellular pH (Li and Poznanasky,
1990). In contrast to the present findings, however, another study showed that
184 and other epithelial cell monolayers, gave an increased TER at pH <4.5
(Chan et al., 1989). This, therefore, indicated that resistance to acid as a general
phenomenon of epithelial layers. This is reflected in vivo, where the gastric
mucosal barrier withstands a luminal pH <1 via acid-induced reduction in
the paracellular shunt pathway (Powell, 1981). Other factors which could
maintain normal epithelial integrity in the face of acidic challenges include
Na+/H+ -exchangers in the apical membrane, membrane proton permeability
and/or intracellular buffering (Chan et a!., 1989). Nevertheless, in order to
avoid a possible pH effect, a culture medium buffered with HEPES was used
for subsequent experiments in this chapter.
5.9.2 Effect of NSAIDs on Intestinal Cells
Using the HEPES-buffered medium a series of experiments were performed
with the NSAIDs indomethacin, aspirin and naproxen, and the prostaglandin
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analogue misoprostol. Indomethacin decreased the TER in a concentration-
dependent manner within 5 minutes. With naproxen and aspirin, only
concentrations greater than 5mM and 10mM respectively, reduced the TER.
This would indicate that the potency range of the drugs, that is, the drug
which required the least concentration to significantly reduce the TER, was
indomethacin > naproxen> aspirin.
In addition, the effect of naproxen on paracellular permeability was assessed
using the marker 51 CrEDTA. Like [ 14C}mannitol, 51CrEDTA is a very
hydrophilic marker which does not partition into cell membranes and its
transport across the epithelial layer takes place around the cells through the
tight junction-mediated paracellular pathway. Although the use of
[ 14Clmannitol is more conventional in cellular monolayers (Madara and
Dharmsathaphorn, 1985; and Cogburn et a!., 1991), 51CrEDTA use is well
established for in vivo measurements of intestinal permeability (Bjarnason et
a!., 1995). Also, it has been suggested that due to the smaller molecular size of
mannitol (M 182), it may even cross the epithelial barrier via the
transcellular pathway, whereas 51 CrEDTA is a larger probe (M 358) so can
only cross via the paracellular pathway (Menzies, 1983). The present
experiments demonstrated that as the TER decreased over time on treatment
of T84 cells with naproxen, the permeability to 51 CrEDTA concomitantly
increased. This would, therefore, validate the assumption that the decrease in
the TER seen with the NSAJDs, is caused by a loosening of intercellular tight
junctions. Indeed, increased permeation of 51 CrEDTA via the paracellular
route has been demonstrated when NSAIDs have been given in vivo to
human volunteers (Bjarnason et a!., 1991) and to experimental animals
(Davies et a!., 1994).
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To date, there is no other documented study of the effect of NSAIDs on the
TER with a view to investigating their effects on intestinal permeability.
Effects of these compounds on cell lines have been studied for other purposes;
the most relevant work will be outlined here.
Damage to Caco-2 monolayers has been demonstrated by subjecting them to
0.5mM indomethacin (Tang et a!., 1993). There was a significant reduction in
the TER after 1 hour incubation with indomethacin, which was even greater
after 12 hours. EM studies revealed that indomethacin induced gross
intracellular damage (characterised by granulation), plus damage and/or
reduction in the number of microvilli. Indomethacin also significantly
increased the flux across the monolayer of [3H]methoxyinulin (which passes
through the paracellular pathway), but not [14C]testosterone (which undergoes
transcellular transport). Therefore, it can be seen that indomethacin increases
paracellular permeability and induces damage in intestinal cells. It is possible
in vivo that the former will lead to the latter effect.
Although the present studies also showed a reduction in the TER, that seen by
Tang et a!. (1993) was not as profound. In the former studies, the maximum
TER decrease with 0.5mM indomethacin was seen within 5 minutes (to 7% of
control), whereas with Tang et al. (1993) the same concentration of
indomethacin gave a maximum reduction in the TER (to only —50% of
control) after 12 hours. Such a discrepancy may have arisen due to the use of
different cell lines. Perhaps T84 cells, as used in the present studies, are more
sensitive to NSAID effect than Caco-2 cells used by Tang et a!. (1993). Indeed,
the higher TER of the T84 cells will mean that slight changes in the TER are
more readily detected.
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Another difference was the means of drug addition. In the present
experiments, drug solution was added directly to the well, and if pipetted near
to the monolayer itself, may have subjected the monolayer to higher than
desired drug concentrations. In the experiments of Tang et a!. (1993), however,
the medium bathing the apical chamber was replaced with drug-treated
medium. To validate if the method of drug addition could affect the rate at
which the drugs decreased the TER, in one set of experiments for the present
work, the medium was replaced with drug-treated medium rather than
adding drug directly to the wells. This was found to markedly slow down the
rate at which indomethacin and naproxen decreased the TER; it was now
observed over hours rather than within seconds.
Another study demonstrated the passage of salicylic acid, the active metabolite
of aspirin, across Caco-2 monolayers (Hilgers et a!., 1990). This, however, was
speculated to be by carrier-mediated transcellular transport rather than
paracellular transport since exposure to 40mM salicylic acid for 15 minutes did
not alter the TER nor the flux of the [3H]mannitol (Takanaga et a!., 1994).
The effect of salicylic acid on resistance has also been investigated in isolated
bullfrog gastric mucosa (Kasbekar, 1973). Here, salicylic acid decreased the
transmucosal resistance as well as mucosal ATP levels. Furthermore, in
accordance with the present hypothesis, it was suggested that uncoupling of
oxidative phosphorylation was responsible for the decline in electrical
functions of the mucosa. Salicylic acid was also found to induce an increase in
paracellular permeability to sucrose.
Several other studies have been carried out in isolated bullfrog gastric
mucosa, investigating resistance changes by aspirin. In one study, exposure to
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5 and 10mM aspirin for 1 hour or more, reduced mucosal resistance and
increased its paracellular permeability to dextran molecules (Flemström and
Marsden, 1973). These effects persisted even after removal of aspirin and
appeared to be related to aspirin concentration.
In another study, subjecting bullfrog gastric mucosa to 10 or 20mM aspirin
caused an initial increase in the transmucosal resistance in the first 35
minutes, followed by a decline to near zero at 70 to 150 minutes (Spenney and
Bhown, 1977). Interestingly, mucosal permeability to [ 14C]mannitol only
increased when the resistance had begun to decrease (- 90 minutes after
aspirin addition). However, the possible mechanism for the initial rise in
resistance was not speculated upon.
The present work also demonstrated that the prostaglandin analogue
misoprostol did not to greatly affect the TER. Although the prostaglandin-
mediated protection against epithelial damage seen in vivo is also seen in
gastric cells cultured in vitro (Terano et al., 1982a,b), the present findings
indicate that the cytoprotection afforded by prostaglandins is not mediated by
alterations in tight junctions. This is consistent with the finding by Weinstein
et a!. (1986), who reported that intragastrically administered misoprostol had
no effect on epithelial-cell tight junctions in rat stomach. Indeed, exogenous
16, 16,-dimethyl prostaglandin E2 (PGE2) did not prevent the permeability
increase caused by aspirin in isolated bull frog gastric mucosa (Spenney and
Bhown, 1977).
In contrast, however, results of another study speculated that exogenous PGE2
did affect intestinal intercellular tight junctions (Krugliak et al., 1990). Such a
conclusion was made when PGE 2 was shown to inhibit water absorption in
rat intestinal perfusates, possibly by stimulating cyclic 3' 5' -AMP (cAMP).
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cAMP increases the TER and, therefore, is thought to be important in the
orientation of tight junctional intramembranous strands (Duffey et a!., 1981;
and Madara, 1988). This, in turn, would affect the paracellular transport of
water molecules. However, the study by Krugliak et al. (1990), also showed
that the NSAIDs indomethacin (2.5 and 5 mM) and aspirin (5 mM) both
increased water transport, indicating a 'loosening' of tight junctions. This is
in agreement with the present findings.
Lastly, in all the present studies, the final concentration of DMSO as a solvent
never exceeded 0.4% and was shown not affect the TER. Even a final
concentration of 0.5% has been found to have no effect on tissue resistance or
structure (Madara, 1983). Generally, a minimum dilution factor of 1000 is
recommended to avoid solvent toxicity (Wilson, 1987). Thus, for TER
measurement, DMSO was a highly suitable solvent since any change in the
TER was almost certainly caused by the drug and not the solvent.
5.9.3 Effect of Decreased ATP Production on Structure and Function of
Tight Junctions
The present work postulates that it is the depletion of mitochondrial ATP
production by NSAIDs (by uncoupling and/or inhibition of respiration),
which is responsible for the tight junctional changes and thus increase in
intestinal permeability. This is compatible with findings that show that
proinflammatory oxidants similarly increase paracellular conductance of
epithelial monolayers by decreasing ATP levels in the cells (Winter et a!.,
1990). Moreover, diminished ATP levels are known to evoke profound
changes in the organisation of the microfilament-based cytoskeleton
(Kellerman and Bogusky, 1992; and Hinshaw et al., 1993). This is substantiated
by the in vitro finding that filamentous actin assembly from actin monomers
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has been shown to be an AlP-requiring biochemical process (Hinshaw et a!.,
1993). Furthermore, ATP depletion has been shown to rapidly increase
transepithelial permeability in T84 monolayers (Mathews et a!., 1994) and to
lead to a loss of epithelial polarity (Molitoris et a!., 1989). Another study
demonstrated that the depletion of AlP actually preceded the decrease in TER
(Mandel et a!., 1993). Such findings indirectly provide evidence for the
hypothesis that biochemical changes, such as uncoupling of oxidative
phosphorylation, may lead to an increase in intestinal permeability.
Consistent with this is the finding that the respiratory chain inhibitors,
cyanide and antimycin A, caused a rapid decrement of ATP levels in MDCK
epithelial cells and a decrease in the TER (McCoy et a!., 1988; and Mandel et
al., 1993). Bacallao et a!. (1994) extended these observations by reporting that
the antimycin A-induced decrease in ATP levels caused significant alterations
in the cytoskeleton and tight junctions and that the fall in ATP preceded the
drop in the TER. Likewise, in LLC-PK 1 epithelial monolayers, antimycin A
depleted ATP levels to <10% of control during which time the TER linearly
decreased, and paracellular permeability of [3H]mannitol increased, indicating
loss of tight junction integrity, which was then morphologically confirmed
(Canfield et a!., 1991). When the uncoupler DNP reduced ATP levels, there
was a reduced rate of tight junction formation and a rearrangement of tight
junction fibrils in HT 29 adenocarcinoma cells (Mückter et a!., 1987). The
authors stressed, however, that ATP levels required to be reduced severely to
- 2% of control for an effect, since a drop to 20% was not associated with any
tight junctional changes.
In contrast, the uncoupler FCCP was able to induce an abrupt (within 4
minutes) decrease in the TER of MDCK monolayers and open tight junctions,
without changes in AlP levels (Li and Poznansky, 1990). Therefore, it appears
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that rather than reduced AlP levels being responsible for changes in tight
junctional permeability, it is probably due to the breakdown of the proton
gradient and the subsequent change in intracellular pH caused by uncoupling
of oxidative phosphorylation. Alternatively, it may simply have been that in
order for the ATP stores to begin to be depleted, the cells needed to be
incubated with FCCP for longer than 4 minutes. This is indicated in the study
by Mückter et al. (1987), where ATP levels were seen to be reduced after 30
minutes with DNP. Moreover, in the study of Li and Poznansky (1990), a
compensatory increase in energy production via glycolysis, may have
maintained intracellular ATP concentrations. Indeed, all the former studies
mentioned, employed the use of a glucose-free medium and/or 2-
deoxyglucose to inhibit glycolysis (Muckter et al., 1987; McCoy et a!., 1988;
Canfield et a!., 1991; Mandel et a!., 1993; and Baccallao et a!., 1994).
5.9.4 Abnormal Tight Junctional Structure and Function in
Disease
Abnormal intestinal permeability caused by perturbation of tight junctions,
may be important in the pathogenesis and pathophysiology of a number of
diseases including rheumatoid arthritis (Jenkins et al., 1987), indomethacin-
associated enteritis (Bjarnason et a!., 1987a), and Crohn's disease (Jenkins et
a!., 1986). Intestinal diseases, where the tight junctional barrier function has
been severely altered, are often characterised histologically by small erosions
or macroscopic ulcers (Madara, 1989).
During intestinal inflammation, neutrophils (PMN's) migrate out of
subepithelial microvasculature, through the paracellular pathway of
epithelial cells and accumulate intraluminally to form crypt abscesses. It is
thought that it is the adhesion plaques between the PMN's and the epithelial
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cells, which form prior to transmigration, that mechanically open the tight
junctions (Nash et al., 1987). Simultaneous with their migration, the
neutrophils release a plethora of inflammatory mediators, including oxygen
metabolites and proteases. These latter agents induce cytoskeletal
reorganisation in epithelial cells which, in turn, may also affect tight
junctional structure and function (Schneeberger and Lynch, 1992), though this
is disputed by Madara (1989). Nevertheless, it is possible that the tight
junctional barrier defect might actually enhance the migration of PMN's out
of vessels into the intestinal epithelium, where activation of these
inflammatory cells would ensue (Hecht et al., 1988).
One such inflammatory mediator is platelet-activating factor (PAF),
implicated in ulcerative colitis (Eliakim et a!., 1988), Crohn's disease (Kald et
a!., 1990) and infective colitis (Chaussade et a!., 1991). These diseases are all
associated with diarrhoea, thought to be caused by PAF-induced increase in
paracellular epithelial transport to sodium and water (Travis and Jewell,
1992).
In addition, gamma-interferon (yIFN), a mediator released from lymphoid
cells, has been found to substantially reduce intestinal epithelial barrier
function by increasing the permeability of tight junctions in T84 monolayers
(Madara and Stafford, 1989). Therefore, in chronic inflammatory conditions
such as in coeliac sprue and idiopathic inflammatory bowel disease, where the
density of lymphoid cells underlying intestinal epithelial cells is particularly
prominent (Sleisenger and Fordtran, 1978), 'yIFN may be partially responsible
for the permeability changes seen in the intestine.
Insulin-like growth factor is yet another mediator which highlights a link
between increased paracellular permeability and chronic inflammation
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(Petruson et a!., 1988; and Rom et al., 1988). McRoberts and Riley (1992) have
also demonstrated the ability of this factor to mediate an increase in
permeability, via the paracellular pathway, in 184 monolayers.
Perturbation of the tight junctional barrier function is a feature of many other
disease states with the factors causing these being well documented. These
include biologically important factors such as C3a and C5a (Bjork et a!., 1985),
leukotrienes (Dahien et a!., 1981), histamine (Majno et al., 1969), phorbol
esters (Mullin and O'Brien, 1986), neutrophil-derived cathepsin G (Rochat et
a!., 1988), insulin (McRoberts et a!., 1990), and tumour necrosis factor-a
(McRoberts and Riley, 1994). All of these agents are associated with either an
increase in cell monolayer permeability, and/or with marked cytoskeletal
rearrangement.
Likewise, an increase in tight junctional permeability in intestinal epithelial
cells has also been observed in the presence of toxins released from
microorganisms. Toxin A of Chlostridium difficile nearly abolished the TER
of 184 monolayers within 6-8 hours, and flux and morphological studies
showed that this was due to an enhancement of tight junctional permeability
without damage to the integrity of the individual cells (Hecht et al., 1988).
When Caco-2 cells were infected with either Salmonella choleraesuis or
Salmonella typhimurium, there was a decrease in TER followed by loss of
monolayer integrity, in particular, elongation and denuding of brush border
microvilli (Finlay and Falkow, 1990). The toxin of Vibrio cholera has also
been found to increase tight junctional permeability in intestinal cells (Fasano
et a!., 1991).
Finally, exposure of epithelial cells to endogenous e.g. hydrogen peroxide
(Shasby et al., 1988), or exogenous e.g. NO2 (Gordon et a!., 1986), oxidants, has
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been associated with an increase in tight junctional permeability and
alteration in tight junctional structure.
Also in Caco-2 cells, the free radical gas nitric oxide (NO), reversibly increased
tight junctional permeability by damaging the F-actin in the apical area of the
enterocytes, where cell-to-cell contact occurs in the perijunctional ring of actin
filaments (Salzman et a!., 1995). This in contrast with the purported protective
effect of NO at preserving normal intestinal permeability by suppressing the
release of other mediators (notably histamine and platelet-activating factor)
from mast cells (Payne and Kubes, 1993; and Kanwar et al., 1994). Perhaps the
beneficial role of NO reflects its effects on mast cells or other nonenterocytic
cells in or adjacent to the gastrointestinal mucosa, absent in cultures of Caco-2
cells.
Salzman et a!. (1995), also found that NO reduced AlP levels in the Caco-2
cells. However, ultrastructural studies showed that dilatation of the tight
junctions by NO was not due to cell death, which may have ultimately
resulted from decreased cellular AlP stores. Instead, it appears that it may be a
direct effect of ATP on the cytoskeleton which is responsible for the increase





6.1	 Hypothesis and Original Aims of the Thesis
In the late 50's and early 60's, much investigation concentrated on the
biochemical effects of NSAIDs in an attempt to explain better their therapeutic
action. It was shown that numerous NSAIDs uncoupled mitochondrial
oxidative phosphorylation. Initially this was proposed as the mechanism of
action but later it was thought to possibly be involved in the damage caused
by these drugs. It then became widely accepted that the therapeutic and side-
effects of NSAIDs were caused by inhibition of prostaglandin synthesis.
However, the numerous reports demonstrating a lack correlation between
prostaglandin inhibition and damage, indicate that this could not be the sole
mechanism involved in the damage. Moreover, prostaglandin-independent
mechanisms of damage have been suggested including topical irritation,
increased intestinal permeability, neutrophil involvement, and Helicobacter
pylon invasion.
The purpose of this thesis was to accommodate many of the more reliable
experimental findings in a new hypothesis for NSAID damage, paying
particular attention to the mitochondrial effects as a possible initiator of the
intestinal damage. Indeed, mitochondrial dysfunction is a feature of many
other disease states (see table 6.1).
The hypothesis investigated for this thesis proposes that, on absorption, the
NSAIDs uncouple mitochondrial oxidative phosphorylation. This
uncoupling depletes the enterocytes of ATP, which has two effects. Firstly,
calcium efflux from mitochondria will trigger a cascade of secondary




Diseases associated with abnormal mitochondrial function
Disease	 Reference
Reye's syndrome	 Trost and Lemasters (1996)
Parkinson's	 Blandini et a!. (1998)
Alzheimer's	 Sims (1996)
Huntigdon's	 Schapira (1997)
Batten	 Tanner and Dice (1996)
Diabetes	 Gerbitz et a!. (1996)
Cardiomyopathy	 Mann-Garcia et a!. (1995)
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Shohet, 1981), and the activation of proteolytic enzymes (Tuena de Comes-
Puyou et al., 1980). Secondly, All? synthesis is decreased which results in a
disruption of epithelial intercellular junctions whose integrity is controlled by
ATP-dependent processes linked to the cytoskeleton (Madara et al., 1987a).
This latter effect would lead to an increase in mucosal permeability and the
exposure of the mucosa to luminal aggressive factors which, in the small
intestine include bile acids, pancreas secretions, ingested food, bacteria and
their degradation products, and in the stomach, acid, Helicobacter pylon and
pepsin. The reduced prostaglandin synthesis, caused by the NSAID inhibition
of cyclooxygenase, would prevent repair of the damage, prolonging mucosal
exposure to luminal contents. Such exposure will elicit an inflammatory
reaction, involving neutrophil chemotaxis and activation, causing
indiscriminate damage within the intestinal mucosa followed by blood and
protein loss (Bjarnason et a!., 1994).
Thus, a multistage framework for the pathogenesis of NSAID-induced GI
damage can be envisaged. The initial biochemical stage leading on to the final
macroscopic stage, with the transition being the increased in intestinal
permeability. However, the idea that the pathogenesis of NSAID-induced GI
damage involves several processes is not new. Ivey and Roth (1985) and Szabo
(1987) both alluded to there being a series of events leading to the eventual
macroscopic damage, with reduced mucosal ATP and prostaglandin levels
involved in the early stage of the pathogenesis. Curiously, the same authors
did not test their hypotheses at the mitochondrial level.
To test parts of this hypothesis, the effects of NSAIDs on several aspects of
mitochondrial function (namely oxidative phosphorylation, electron
transport, and ATP generation), was tested. In addition, the effects of these
drugs on intestinal permeability was investigated, using intestinal cell lines.
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6.2	 Summary of the Different Investigations
6.2.1 Uncoupling of Oxidative Phosphorylation
By adding small quantities of isolated rat liver mitochondria to a reaction
chamber attached to a Clarke-type oxygen electrode, it was possible to monitor
mitochondrial oxygen utilization in the presence of different substrates and
drugs. All the NSAIDs and acidic pro-NSAIDs tested, including the active
component of nabumetone 6MNA, produced a bell-shape curve when oxygen
uptake was expressed a percent of control and plotted against drug
concentration. Such a curve is characteristic of "inhibitory uncoup1ers
(Moreland, 1994). That is, the NSAIDs first uncouple oxidative
phosphorylation seen as a stimulation in oxygen uptake, but then at higher
concentrations they act like electron transport inhibitors. Both DNP and FCCP
also behave like this.
In order for a compound to act as an uncoupler it needs to possess a
dissociable group (usually an acid side-chain with a pKa around 4 to 6), and be
lipid soluble (Weinbach and Garbus, 1969). All the conventional NSAIDs
tested fulfilled these criteria: possession of an aromatic ring in their structure,
a lipophilicity conferring group, and a free acidic group, a carboxylic group or
an enolic group in the case of piroxicam (Salguiero-Pagadigorria et al., 1996a).
The two exceptions were nabumetone (nonacidic) and paracetamol (pKa 9).
These latter two compounds did not uncouple oxidative phosphorylation
and, interestingly, neither of these compounds are associated with
gastrointestinal damage in man. Mahmud et a!. (1996), has demonstrated an
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inverse relationship between NSAID pKa and concentration required for
maximum stimulation of respiration.
To further look at the importance of the carboxylic acid side chain in
uncoupling, the NSAID flurbiprofen was studied and compared to NO-
flurbiprofen, where the side chain had been nitrosylated. As expected,
flurbiprofen uncoupled but NO-flurbiprofen did not.
Misoprostol failed to prevent indomethacin-induced uncoupling, indicating
that prostaglandins are not involved in the "topical" stage of NSAID-damage.
Addition of glucose and citrate also did not affect the uncoupling induced by
indomethacin, suggesting that the protective effects of glucose and citrate seen
in vivo is not a direct protection at the mitochondrial level but an effect
related to whole cell metabolism.
The present experiments, therefore, demonstrated that the NSAIDs known to
cause CI lesions, also uncoupled mitochondrial oxidative phosphorylation.
Although relatively high concentrations of the NSAIDs were required for
uncoupling action in vitro (0-3.75mM), it is conceivable that such
concentrations could be reached within enterocytes during drug absorption, at
the therapeutic doses used to treat patients with rheumatoid arthritis (Insel,
1996). Indeed, therapeutic doses of aspirin have been shown to alter
mitochondrial structure and function in vivo in humans (Lauterburg et al.,
1995). However, due to the high concentrations required, it is unlikely that
the uncoupling is related to the antiinflammatory or analgesic properties of
the NSAIDs (McDougall et a!., 1983). It is suggested, therefore, that the
uncoupling action of NSAIDs may initiate the associated CI side-effects via a
"topical effect".
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However, such topical damage seen early on in the pathogenesis of NSAID
enteropathy cannot be the sole mechanism since drugs given intravenously,
bypassing the local effect, also cause gastric damage (Grossman et a!., 1961; and
Bugat et a!., 1976). Nor too would systemic mediated prostaglandin inhibition
alone account for all the deleterious effects of NSAIDs seen at this stage, as
suggested previously (see section 1.6.1, chapter 1). Therefore, as already
suggested, it seems feasible that the mitochondrial disturbances occur
alongside the inhibition of prostaglandin production to produce the lesions.
6.2.2 Inhibition of Respiration
The use of the oxygen electrode, an artificial electron acceptor system and EPR,
enabled inhibition of mitochondrial respiration by the drugs indomethacin,
aspirin, naproxen and paracetamol, to be localised and characterised. Oxygen
uptake studies revealed that all the drugs, including paracetamol, inhibited
complex I- and Il-mediated mitochondrial respiration in a concentration-
dependent manner. The inhibition occurred at higher concentrations than
those required to uncouple, a feature seen with most inhibitory uncouplers.
But as with the uncoupling, indomethacin was again the most potent at
inhibiting mitochondrial respiration.
Using the ferricyanide reductase system, the NSAIDs appeared to
preferentially inhibit in the vicinity of complex I. Investigation by EPR
demonstrated changes with the NSAIDs in some of the individual
components of the respiratory complexes, but no one complex in particular
appeared to be targeted. Overall, these inhibition studies indicated that
decrease in mitochondrial respiration by the NSAIDs was not localised to one
complex or component.
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6.2.3 Depletion of ATP Production
Spectroscopic assay of isolated mitochondria incubated with different
concentrations of NSAIDs and paracetamol, found that the NSAIDs decreased
ATP production concentration-dependently. A depletion in ATP generation
following NSAID-induced uncoupling could be responsible for the "local" cell
damage seen when NSAIDs are absorbed in the acidic environment of the
stomach (Domschke and Domschke, 1984; and Szabo, 1987). The fact that
paracetamol did not lower Al? formation suggested two things. Firstly, that
the uncoupling action of the drugs is more important in decreasing AlP
production than their inhibitory effects. Secondly, that perhaps a longer
incubation time than 1 minute was required to cause an adequate depletion.
The latter being exemplified by the failure of FCCP, antimycin A or cyanide to
give a marked decrease in ATP production.
6.2.4 Affect on Intercellular Tight Junctions
One of the possible consequences of a depletion in ATP production, is an
opening of intercellular tight junctions. In cell culture, this is generally
assessed as a reduction in the TER of cell monolayers. Therefore, using the
intestinal cell lines Caco-2 and T84, an attempt was made to measure their
TER and effects of NSAIDs on this using the Ussing chamber. The results
from this suggested that cell viability was being challenged and so any further
experiments with drugs would give of inaccurate results. Thus, the Millicell
electrode was employed, which gave more reproducible results. Here, T84
monolayers were incubated with the NSAIDs indomethacin, aspirin and
naproxen, also the prostaglandin misoprostol, and their TER measured. The
fact that misoprostol did not reduce TER significantly, would indicate that,
like uncoupling, tight junction function is not under prostaglandin control.
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In vivo, the loosening of tight junctions would result in the increase in
intestinal permeability which in the present in vitro experiments was
observed as increase in the paracellular transport of 51 CrEDTA across T84
monolayers in the presence of naproxen. Thus, overall, there is a strong
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REVIEW
The Biochemical Basis of Non-Steroidal Anti-Inflammatory
Drug-Induced Damage to the Gastrointestinal Tract: A Review
and a Hypothesis !
Non-stercidal anti-inflanunatory drugs (NSAIDs) are
amongst the most successful group of drugs ever marketed,
which demonstrates their overall efficacy. They arc not, how..
ever, without side effects (1). The gastrointestinal tract bears
the brunt of NSAID-related toxicity (2-5). The gastro-
duodenal side effects have attracted most attention because
of the frequency, severity, and ease of documentation of the
damage. Point prevalence studies suggest that 10-30% of
patients on NSAIDs have gastroduodenal ulcers (6-10), but
the clinical implications of these findings have been played
down by suggestions that definitions of ulcer in these studies
included a substantial number of large erosions (called endo-
scopic ulcers; purported to account for up to 50% of 'ulcers'
in these studies) of little clinical consequence as opposed to
clinically significant ulcers (pre-excising diathesis; implying
NSAID-assodated rather than NSAID-induced ulcers),
which have increased potential to perforate or bleed because
of NSAIDs (11). There are, on the other hand, ample exper-
imental data demonstrating NSAID-induced ulcers in all of
the intestinal tract of animals and some erosions may be tran-
sitory lesions in the development of ulcers in man and hence
markers of unacceptable mucosal damage (12).
Became of the ease of documenting the more serious coin-
plicationsofNSAlD-induccd (or associated) gastroduodcnal
ulcers—perforation, kaemorrhage, or sudden death—there
is a tendency to place special reliance on epidemiologic studies
that use these features as end-points for 'clinically relevant'
side effects of NSAIDs. Even here, however, there is no firm
agreement, and estimates vary from NSAIDs being respon-
sible for 30,000 hospital admissions in the UK with an attend-
ant death rate of 10% (13-19) to that of 200-600 premature
deaths annually. The fallacy is, however, to let surgeons, epi-
demiologists, or morticians set the reference for 'clinically
relevant outcomes' for conditions that are predominantly
managed by physicians. Most gastroenterologic events in
patients on NSAIDs are managed by rheumatologists, and
when the problems are referred to gastroente'rologists, it is
mostly became of NSAID-induced dyspepsia and exclusion
of malignancy because of iron deficiency rather than because
of life-threatening complications. Indeed, all of the gastro-
intestinal tract may be adversely affected by NSAID inges-
tion in man.
The role of NSAIDs in the small intestine is clear because
there are no confounding variables affecting interpretation of
ulcer size and depth, ulcer diathesis, or the possible par-
ticipation of Helicobacser pylon, such as maybe the case in
the stomach or duodenum (20-26). Sixty per cent of patients
on long-term NSAIDs develop small-intestinal inflammation
(20,27-31), with bleeding, protein loss, and, occasionally,
strictures (23-25, 32-34). l'hese may lead to management
problems (iron deficiency, hypoalbuminaemia) rather than
life-threatening events, which places the patients under the
care of physicians rather than surgeons, moiticians, or epi-
dentiologists.
NSAIDs may also affect the colon, although by com-
parison this is relatively rare and mostly documented in
isolated case reports. NSAID-induced colitis is described
following mefenamic acid and may also occur with other
NSAIDs (35-40). There is also evidence that NSAIDs are
associated with severe fistulous diveiticulith, appendicitis,
and relapse of inflammatory bowel disease (41-48).
The mechanism of NSAID damage to the gastrointestinal
tract is incompletely understood. Most studies to date have
concentrated on altered prostaglandin and leukotnene
metabolism or vascular changes as initiating factors (49,50),
and there is considerable information on the importance of
bile, refeeding, ucutrophils, and bacteria in the development
oLsmall-intestinal lesions in experimental animals (51-61).
It is now important to summarize and interrelate the more
reliable experimental observations in a comprehensive
pathogenic framework. The purpose of this review is to
provide some evidence for a two-stage pathogenic frame-
work for NSAID-induced damage, which postulates an
initial biochemical event at the site of absorption followed
by a tissue reaction governed by the luminal aggressive
factors, which vary in the stomach, duodenum, and small
intestine. In particular, the early biochemical effects of
NSAIDs, other than their effects on cyclo-oxygenase. will
be reviewed in detail, as there is now, despite some claims
to the contrary (62), serious doubt that inhibition of cyclo-
oxygenase with reduced mucosal prostaglandins by itself can
account for the initiation of the intestinal damage (63-66).
The hypothesis
Fig. 1. outlines the pathogenic framework for NSA[D-
induced damage to the small intestine. It is suggested that
stage one represents specific biochemical alterations initiated
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Fig. 1. Outline of the pathogenic framework for ooia-st.croidal an fl.tnsy thug (NSAID)-induced damage tu the small intestine
and stomata, which differ only st Stage 2. Consult text for details. HJ(P = hexose m000pbospbate shunt; AlP - adenosine trip4iosdaate.
phorytation of mitocbondria (or inhibition of the electron
transport chain), which Is most pronounced during drug
absorption. The immediate consequence is a reduction in
adenosine triphosphate (ATP) production and leakage of
(2+ out of the mitochocadria. This leads to i) an increase
in cytosc'ic Ca with subsequent Cafl' poisoning (67), ii)
damage to mitochondria and an increase in the generation
of reactive oxygen speties, iii) a disturbance in Na'/K"
ratios and cellular osmotse balance (68), iv) a loss of control
over intracellular junctions, resulting in increased intestinal
permeability (69-75), and v) decreased AT? and increased
adenosine diphospliate and m000pbosphate (ADP-AMP)
levels act synergistically to divert glucose 6-phosphate from
the hexose monophosphate (HMP) shunt, with loss of reduc-
ing equivalents to combat the damage (76).
Increased intestinal permeability is posulated to be the
central mechanism of the transition of the effect of NSAIDs
from a cellular biochemical (ultrastructural) change to stage
two, a tissue reaction (macroscopic). NSAID inhibition of
cyclo-oxygenasc effectively prevents production of repara-
tive prostaglandins, thus prolonging the permeability
changes rather than initiating the damage. The increased
intestinal permeability inevitably enables the balance
between the interplay of luminal aggressive factors and
anucosal defence to be tilted to the advantage of the former,
leading to non-specific tissue inflammation. This response
may act synergistically with the biochemical damage to
further maintain increased intestinal permeability. The first-
stage events do not differ among NSAEDS and occur, it
is postulated, at any site of absorption whether stomach,
duodenum, or the small intestine, which is in turn deter-
mined by the drug formulation, aim, solubility and plC of
the drugs, luminal pH, and so forth. The second-stage tissue
response is, however, sate-specific. Thus disruption su the
gastric mucosal barrier, as proposed by Davenport (77),
enables back-diffusion of acid, pepsin, and bile, the main
luminal aggressive factots here apart from Hdicobacter
pylon, whereas disruption of the small-bowel barrier exposes
the mucosa to digestive enzymes, bile, bacteria, and their
degradation pwducIa
We make a clear distinction between the two stages, which
is certainly an oversimplification. However, the framework
is useful from the investigational point of view and has
practical implications for the development of strategies
designed to limit and prevent NSAID-induced gastro-
intestinal damage.
Here follows a detailed account of the biochemical actions
of NSAIDs, with emphasis on the small-intestinal lesions,
which may be relevant to their adverse action on the whole
gastrointestinal tract.
Phase I: the biochemical changes due to NS,4ID
Enterocyte biochemistry. Enterocyte metabolic pathways
and their regulation differ from many other cells. Table I
shows some enzyme levels in enterocytes which, although
only crude indices of metabolic fluxes (78), reflect a high
degree of functional differentiation. The intestinal epa-



























lIMP - hcinse monophosphate pathway.
The amouni (percentage) of enzyme per wet weight us rat mteathue relative to the tissue with the biglicat cosceatration, which
shown as 100(62,87,185).
haemopoietic cells of the bone marrow. The high metabolic
needs of the enterocytes (79-81) is met by their dual access to
high-energy substrates (82) from the lumen and circulation.
Luniinal glucose (postprandially in concentrations in 10-fold
excess of blood) is actively absorbed by Na co-transport
(80,83) and phosphorylated by bexokinase to glucose-6-
phosphate. The precise fate of glucose-6-phosphate is uncer-
tain. At least 70% is transported and released as intact
glucose into the circulation by the action of glucose-6-phos-
phatase (78) and specific transporters at the basolateraj
border (84-86), and about 30% is funnelled into glycolysis
and the HMP shunt pathway, depending on the relative
activities of pbosphofructokinase (PFK) and glucoae-6-phos-
pliate dehydrogenase, respectively. The glycolytic capacity
of the enterocyte is, however, limited, as the enterocytes
have very low levels of phosphofructokinase 2(87), the main
regulator of glycolytic rates (Fig. 2), and most of the glucose-
6-phosphate is metabolized via the HMP pathway, in keeping
with the very high activities of gluccae-6-phosphate dehydro-
genase and phosphogluconate dehydrogenase (Table 1).
The lIMP shunt has two important roles. First, it converts
hexoses to pentoses (mostly ribose) used for nucleic acid
synthesis in the rapidly proliferating epitbelium. Indeed
(Table I), thyniidine phosphosylase and aspartate carbamyl
transferase activities are also high in comparison with other
tissues, reflecting the rapid cell turnover. Second, the lIMP
pathway provides extramitochondrial reducing equivalents
in the form of reduced nicotinamine adenine dinucleotide
(NADPH), used in the formation of reduced glutathione
(the intestine has high glutathione reductase activity) (88),
which is a key compound in limiting the damage of reactive
oxygen species (89,90).
During fasting enterocytes have a major alternative energy
supply from glutamine, derived largely from the breakdown
of muscle (91). The enterocytes are able to utilize glutamine,
unlike many other tissues, because of the high activities of
glutamate dehydrogenase, amine oxidase, and transglu-
tamanase (92). Other sources of energy are also readiLy
available, as the enterocyte may use -hydroxybutyric acid
and fatty acids as respiratory fuel (91). The main pathways
of ATP production are inteniegulated, and the dominant
pathway is determined by substrate availability (93).
Effect on jnitochondria. Most of the work on NSAID-
induced toxicity of the small intestine comes from studies in
rats, using various doses of indomethacin. There are three
important time points of study: i) within 1 h, when there are
no detectable light-microscopic changes; ii) at 4-6 h, when
iRamini.tnry cell infiltration becomes pronounced; and in)
at 20h, when macroscopic damage is evident as diffuse,
aphthous-like ulceration, predominantly in the middle of the
small intestine (94-96).
The earliest evidence of damage following NSAJDS in
experimental animals us seen by election microscopy as
lug, vacuolization, ballooning, and disruption of enterocyte
mitochondria (97). This ocs within 1 h of indomethacin
administration and is most pronounced in the middle of the
small intestine. The picture is seen after uncoupling of oxi-
dative phosphosylation or inhibition of electron transport
along the respiratoty chain (98). NSAID-induoed uncoupling
of oxidative piboaphorylation (by virtue of their low pK and
lipid solubility) has been demonstrated in vitroin gastric tissue
with reduced AlP production (96, 99-102). The only other
organelle found to be affected at this time was the endoplasmic
reticulum (97). At6 h, and still before macroscopic damage is
evident, there are significant changes in the specific activities
of marker enzymes of the mitochondria (including citrate syn-
thase,sucanate dehydrogenase,cytochromecoxidase) which
are in keeping with the Clectron microscopy studies (96).
Uncouplingofoxidative phosphorylation will increase oxygen
consumption and ATPase activities (103,104). Decreased
ATP and accumulation of ADP and AMP result in maximal
stimulation of glycolysas. In other cells pyruvate would be
converted into acetylcoenzyme A (CoA), but because of the
low activities of pyruvate dehydrogenase in enterocytes most
of the pyruvate so formed us shuttled into lactate (105). The
other effect of maximal stimulation of glycolysss by the above
mechanism is to reduce the amount of glucose-6-phosphate
available for the hexose monophosphate pathway (76)
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Fig. 2. Fate of giumse in enterocytes. Moat of the glunose.6-phosphatc I destined I,r the bexosc nionophosphate (HMP) shunt oc
transported by specthc camera (GLUT 2) at the basolateral border,. A minor portion enters glycolyais because enterocytes lack
pliopliofructokinase (PFK) 2. What does enter glycolysis us converted to lactate rather than to acetyl coenzyme A (C0A). because pyruvate
dehydrogensac activities .rc tow in the intestinal epithehum.
resulting in I) lowered glutathione reductase activity, which is
particularly detrimental as NSAIDs inhibit gastric peroxidase
(106); both hydroxyl and superoxide radicals are formed as a
consequence, with immediate macromolccular damage; ii)
decreased pentose production for nucleic acid synthesis; and
iii) inhibition of NADPH-dependent fatty acid synthesis for
maintenance of the brush border.
Lack of Al? because of uncoupling of oxidative phos-
phorylation or inhibition of the respiratory chain leads to
secondary damage by leakage of hydrogen ion into and(2+ effiux out of initochondria (107). The biochemical
consequences of increased cytosolic Ca2 concentrations
include activation of Ca 2 -sensitive enzymes, proteases,
endonucleases, and phospholipases (107-110). In addition.
generation of reactive oxygen species from membrane
phospholipids can occur by activation of phospholipase A2
(ill), and depolarization of microtubules will affect the
cytoskeleton (112).
Effect on endoplasnuc reuculum. NSAIDs cause electron
microscopy changes to intestinal endoplasmic reticulum
within 1 h of administration, but specific marker enzymes
are only abnormal at 24h, when macroscopic damage is
evident (96,113). NSAIDs inhibit desaturase activities. De-
saturascs are lightly bound to the endoplasmic reticulum as
intrinsic proteins (114-117), requiring oxygen, an electron
donor (NADH or NADPH), and cytochrome c reductase.
Desaturases are responsible for the synthesis of polyun-
saturated fatty acids, which are a component of membrane
phospholipids. Inhibition of desaturases causes alterations
in the relative proportions of polyunsaturated to saturated
fatty adds, resulting in altered membrane fluidity and perme-
ability (118).
Effect on brush border. No structural damage to the brush
border membrane is visible by electron microscopy within
an hour of indomethacin administration in rats (113), but
significant damage is seen by light microscopy at 4-6 h
(94,95) as shortened and blunted villi with polymor-
phonuclear infiltration of the mucosa. Biochemical marker
enzyme studies show significantly lower levels of activity at
6 and 24 h (97) as compared with controls. The biochemical
mechanisms of die effect of NSAIDS on the brush border
are uncertain, but it is conceivable that the consequence of
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reactive oxygen species damage is secondary to Ca2 effluX
from mitochondria (119).
NSAIDs increase basolateral membrane Na/K AIPSSC
activities involved in the active transport of nutrients (1)).
Their heightened activity may simply indicate increased
metabolic activity and energy requirement of the cell. Ho
ever, prostaglandin E activates adenylate cyclase, causing
increased levels of cAMP, whidi inhibits Na/K+ATPISe
(121). Alternatively, NSAID inhibition of prostaglandin
generation followed by lowered cAMP and hence increased
Na/K4ATPase activities could also explain these findings.
NSAIDs may damage the bnish border directly by their
action to act as detergents (122,123), and they may alter the
properties of the mucus layer (124), but neither is likely to be
important in the initiation of damage, as the histopatholOgiC
findings after detergent damage and mucus-altering agents
differ markedly from the damage caused by NSAIDs
Effect on prostaglandin metabolism. In this framework
NSAID-induced inhibition does not initiate the intestinal
damage. This is clearly a contentious issue, as it has been
claimed that intestinal lesions can be produced by including
antibodies toward prostaglandins (62). Other data, however,
suggest that there is no convincing temporal relationship
between inhibition of cycto-oxygenase and the macro-
scopic damage (65). There appears to be a lack of relation-
ship between the seventy of injury and the reduced mucosal
prostaglandins, and a 95% inhibition of prostaglandin syn-
thesis can be achieved without apparent damage (63,64).
There are at least two forms of cyclo-oxygenase. Cyclo-
oxygenase 113 constitutively expressed in most tissues, where
it plays a regulatory role in tissue physiology, whereas cydo-
oxygenase 2 is inducible (not normally present in the intes-
tine) and found mainly at inflammatory sites, playing a
part of the inflammatory cascade. NSAIDs have different
affinities for the two cyclo-oxygenases, but there is no con-
vincing evidence that NSAIDs with a predominant effect on
cyclo-oxygenase 1 (such as piroxicam) differ in their intes-
tinal toxicity from those that are more cyclo-oxygenase-2-
specific (such as dictofenac, naproxen). Consideration of the
normal physiologic role of prostaglandins (125), namely
regulation of blood flow, stimulation of mucus production
and facilitation of cell division (126-131), suggests that they
are predominantly involved in the regulation of a tissue
response. This is difficult to reconcile with their purported
role in the initiation of damage. Prostaglandin synthesis
is governed by substrate availabihty and cyclo-oxygenase
activity. NSAID5 (and bile acids) may perturb membranes,
providing cyclo-oxygenase with its substrate;but this is most
likely an indirect action in response to the severe cellular
metabolic damage. The cellular action of prostaglandins,
however, may be beneficial to the damaged cell. Prosta-
gtandrns aggregate with cytosolic-free calcium and may
thereby limit cellular damage. Prostaglandins may induce or
enhance the radical scavenger system by the induction of
superoxide dismutase (132).
Finally, the idea that NSAID-induccd injury involves inhi-
bition of cyclo-oxygenase with diversion of aractildonic acid
into lipo-oxygenase with production of pro-inflammatory
mediators is unlikely, as the two enzymes have different
subcellular locations (cytosol and endoplassnic reticulum,
respectively) (133). Direct measurement in P'ISAID-exacer-
bated experimental colitis also failed to demonstrate any
significant shunting of arachidonate into the lipo-oxygenase
pathway after NSAIDs (134).
There is considerable interest in the possible patho-
Physiologic role of other inflammatory mediators (throm-
boxane, platelet-activating factor) and cytokines (inter-
kukins, tumour necrosis factor and so forth) because of their
ulcerogenic potential, pro-inflammatory action, and vascular
effect (135-138). These compounds are, by and large,
Physiologic mediators of inflammation, and although they
may play an important sole in the pathogenesis of NSAID-
induced damage, the evidence is that this oceurs as a part of
the normal mflmmatoiy cascade. To implicate the lack of
prostaglandins in the late biochemical events of NSAID-
induced damage is in keeping with otherwise poorly under-
stood observations that pre-treatment with prostaglandins
will protect against macroscopic damage from various
assaults but not necessarily against microscopic or ultra-
structural damage (139-143).
Summary ofstagel. In summary, it is thus proposed that
NSAJDs have an initial detrimental biochemical action by
uncoupling mitochondrial oxidative phosphorylation and/or
inhibition of the electron transport of the respiratory chain.
The consequence of uncoupling is lowering of cellular ATP/
ADP, which alters intestinal permeability and releases cal-
cium into the cytosol, which in turn causes secondary bio-
chemical damage. NSAID inhibition of cyclo-oxygenase is
clearly not the initiator of damage in this framework; rather,
it plays a permissive role in the pathogenesis by delaying
repair.
Direct support for this hypothesis is presently scant. How-
ever, all active NSAIDs have the common physicochemical
properties required of an uncoupler—namely, the com-
bination of lipid solubility and a low pLIt has also been
shown that when glucose and citrate are co-administered
with indomethacin in appropriate concentrations, damage is
greatly diminished in the stomach and small intestine (144-
146). One possibility is that ATP levels are increased by
glycolysis, but it may also be that the simultaneous delivery
of glucose and citrate with indomethacin to the enterocyte
will counteract some of the secondary metabolic actions of
indomethacin. Hence citrate inhibition 0 glycolysis (effect
on PFK) could enable the simultaneously administered glu-
cose to be available for the HMP shunt pathway for pro-
duction of reactive oxygen species scavengers.
-
Tra,isstzonal stage
Role of increased uizestuial penneabduy. The biochemical
actions of NSAIDs on the enterocytes causes various kinds of
294	 Review
damage, one of which manifests itself as increased intestinal
permeability. The importance of increased intestinal per-
meabibty (as measured with molecular weight probes of 300-
600 Da) in the pathogenesis of various diseases is en-
aiip.tjal and reets mainly on the assumption that it
synoaymotts with increased macrornolecular permeation.
This is dearly not the case, but there is a significant cor-
relation between increased intestinal permeability and IgA
immune complexes in IgA associated isepbropathies, and in
the rat there is good correlation between increased intestinal
permeability to "Cr-labelled ethylenediaminetetraaoetic
acid and ovalbuinin and n-formyl-methionyl-kucyl-phenyl-
alanie (FMLP; a bacterial neutrophil chemoactic peptide)
permeation (147-149). In the context of NSAID-Induced
enteropathy it is suggestcd that increased intestinal per-
meability converts the biochemical damage to a tissue reac-
tion by enabling mucosal exposure of luminal contents that
are chemotactic for neutrophils. That this may be the case
in man is suggested by the finding that low-grade enterop-
athies are found after NSAID administration, in chronic
renal failure, in treatment with drug therapy for solid
tumours, and in human immunodeficiency virus and hypo-
gammaglobulinaemicenteropathy, all of which are preceded
by increased intestinal permeability (150-152).
Increased intestinal permeability to NSAIDs occurs within
12 b of ingestion in man. Quantitatively, it relates in a
crude way to drug potency to inhibit cyclo-oxygenase and is
partially prevented by large doses of synthetic (rioprostol
or misoproscol) prostaglandins (20,21,146,153-163). With
repeated doses of a NSAID, misoprostol looses its protective
effect, suggesting that the bilialy component of NSAID
damage (not covered by this combination) is sufficient to
cause damage (158.164). If true, this poses a particular
problem for the future development of prophylactic meas-
ures. Interestingly, NSAID pro-drugs (nabumetone, sulin-
dac, and fenbufen), which are only converted into this active
component in the liver after absorption, do not increase
intestinal permeability after a week's treatment in man
(157,162). The active component of nabumetone in par-
ticular does not appear to be excreted in bile.
Phase II: Non-spec4ftc tissue reaction
Lumina! aggressors leading to inflamsnatoiy changes. Fig.
1 outlines the luminal aggressive factors and how these differ
in the stomach and small intestine. It is suggested that the
differences in the aggressive factors explain the different
tissue responses and hence the macroscopic lesions, de-
pending on site. Here we will concentrate on the small-
intestinal aggressive factors and their role in the damage.
There is no doubt about the importance of bile and refeed-
ing of animals after NSAID administration in the patho-
genesis of the small-intestinal inflammation caused by
NSAIDs (52, 54,55,60, 165). The problem has been to
explain how they are interconnected and how they may
explain the predominant middle and distal small-intestinal
location of the damage. The importance of bile is suggested
by the finding that bile duct ligation greatly reduces the
prevalence of the lesions (54). The luminal concentration of
bile acids increases distally as food is absorbed, which may
perturb damaged enterocyte membranes and thus act syn-
ergistically with the biochemical damage to increase intes-
tinal permeability. Alternatively, most NSAIDI are
conjugated and secreted to a significant extent (20-60% of
an intravenously administered dose) in bile, which could in
practice lead to the selective delivery of large concentrations
of NSAIDs to the distal small intestine, where bacterial
deconjugation is significant, releasing free and active NSAID
(52,165).
RefeedIng animals after the NSAID dose dearly enhances
the macroscopic damage. This has usually been taken as
evidence of an environmental agent or bacteria playing a
pathogenic role in the damage (60). Alternatively, it may
simply be that ingested food causes bile secretion with the
above consequences.
The role of bacteria has been inferred by the almost
universal findings that very few macroscopic lesions are
found in the germ-free animal and that pre-treatment with
antimicrobials reduces the damage (51-53, 56-58). Cnn-
ously, treatment with the same antimicrobials does not facili-
tate healing in animals (166). But how do the bacteria bring
about macroscopic damage?
Knowledge of neutrophil function and pathophysiology
may be the key for the understanding of various available
experimental results and the sequence of events. Neutrophils
only migrate as aco-ordinated response to specific neutrophil
chemoatiractants (167-171). The mechanisms of neutrophil
migration are complex and not fully understood but include
adherence to endothelium, which involves expression of
endothelial and/or neutrophil receptors (in response to vari-
ous inflammatory mediators: leukotrienes, tumour necrosis
factor, and so forth), aggregation, budding, directed loco-
motion, and so forth) (172-174). Most importantly, there
is an absolute requirement for a neutrophil chemotactic
gradient, as without it the oeuftophil has no guided loco-
motion (169,173, 174), a problem faced by proponents of
a vascular/neutrophil-based initiation of NSAID-induced
intestinal damage (50, 126, 175, 176). Neutrophil contact
with a chemoattractant triggers a metabolic event known as
a respiratory burst, which initially involves activation of
neutrophil membrane-bound nicotinamide adenine di-
nucleotide phosphate oxidase with production of superoxide
anions (Or) (177-180). Many important reactive oxygen
intermediates are produced from the superoxide anion by
various catalysts, including hydrogen peroxide, hypo-
chiorous acid, and hydroxyl radical-hkc compounds. all of
which are highly reactive and exert antimicrobial effects.
This is followed by internalization of the chemoattractant
with subsequent lysosomal enzyme release into the immedi-
ate surroundings, provided the concentration of chemoat-
Iractant is sufficient (167-171). The neutrophils have dealt
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with the lumediate problem and have destroyed the
chemoattractant, but at the same time there is inevitable
tissue damage in the vicinity of the neutrophils.
Neutropitils appear to be the main effector celia in the
macroscopic tissue damage in NSAID-induccd enteropathy.
In man, metronidazole reduced inflammation in .11 13
patients as treated (181), and circumstantial data suggest
that the putative microbe is invasive (182). Hence there was
a significant correlation between inflammation and blood
loss in patients with NSAID enteropathy, which is what
would be expected if the chemoattractant was within the
mucesa, as opposed to minimal damage if it was luminai
(182). Similar studies in Ciolm's disease and ukcrative colitis
suggested a luminal and mucosal location of the neutrophil
chemoattractants, respectively (182). Additionally, when
treatment of the inflammation is successful in NSAID enter-
opathy, with metronidazote (181) or sulphasalazine (183),
there is concomitant reduction in intestinal blood loss but
no signifeant change in intestinal permeability. This suggests
that these agents are acting in the late stages of the patho-
genesis of the enteropathy. Similarly, macroscopic damage
is limited in rats when neutrophil recruitment is prevented
by induction of neutropenia (with antibodies or metho-
trezate) or after administration of antibodies to adhesion
molecules that interfere with anchoring of neutrophil to
endothelium (175,176). What is controversial is the precise
inechaniun by which the neutrophils make their way to
the mucoaa. There are several possibilities. In the above
framework neutrophil recruitment is due to luminally
derived anaerobic microbes or their products, which are
directly or indirectly, via macrophage and T.cell activation,
chemotactic for neutrophils. Alternatively, others postulate
that NSAIDs damage capillary endothelium directly (as a
piimary event) with subsequent expression of neutrophil
adherence molecules and hence the inflammation (50,126,
175,176) but face the problem of the lack of guided nets-
trophil movement (167-171, 174, 184). Furthermore, it is
questionable whether neutrophils recruited in this manner
are activated, which is after all a prerequisite for damage.
Sorting out the precise sequence of events will require careful
co-ordinated sequential studies, which include ultrastruc-
tural morphologic assessments along with basic biocheniicaj
and immunologic techniques.
Conclusion
A multistage pathogenic framework for NSAID-induced
enteropathy is presented, encompassing early specilic bio-
chemical alterations followed by a non-specific tissue reac-
tion in response to increased intestinal penneability. The
framework puts into perspective some of the experimental
findings from several workers which are otherwise difficult
to understand and invites further experimentation to conflzm
or refute the hypothesis. The practical aspects relate to
future development and targeting of treatment or prevention
of NSAID-related damage to the intestine and the possibility
that the second stage may have relevance as a common final
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Objective. There Is a lack of correlation between
cydoozygenase (COX) Inhibition and nonsteroldal anti-
Inflammatory drug (NSAID)-Induced gastroIntestInal
(GO d.ge it has been suggested that mucosal dam-
age may be initiated by a "topical" action of NSAIDs
Involving mltocbondriaJ. Injury. We evaluated the effect
of a range of NSAIDs and related compounds on alto-
chondrial function and assessed the differences between
them In relation to their physicochemical properties.
Methods. Stimulation of respiration, as an Indi-
cator of mitochoodrial uncoupling, was measured In
isolated coupled rat liver mitoehondrial preparations,
using an oxygen electrode.
Romhe. Conventional NSAJDs and addle prudnigs
all had stimulatory effects on mitochondrial respiration
at micromolar concentratIons (0.02-2.7 pM); higher
concentrations were inhibitory. The uncoupling potency
was inversely correlated with drug pKa (r = -0.87, P <
0.001; a = 12). Drugs known to have good GI tolerabil-
ity, Including modified flurbiprofen (dimero-
flurbiprofen and nitrobutyl-flurbiprofen), nabuinetone
(a non-acidic prodrug), and non-acidic highly selective
COX-2 inhibitors, did not cause uncoupling.
Conclusion. The ability to uncouple mitochon-
dnal oxidative phosphorylation is a common character-
istic of antiinflammatory agents with an ionizable
group. Modification or absence of an ionizable moiety
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reduces the effect o initochondria and could lea
Improved NSAID CI safety.
Nonsteroida.l antiinflammatory drugs (NSA
are widely used, with more than 26 million and
million annual prescriptions in the UK and USA, ret
tively. The main concern about NSAID treatment i
risk of gastrointestinal ((it) damage. Non-Ulcer e
scopic gastroduodenal lesions are seen in some 30-
of patients receiving regular NSAID treatment,
peptic ulceration in 1O-30% (1,2). In addition, long-
NSALD treatment causes small intestinal inflamas
(NSAID enteropathy) (associated with blood and
tein loss) in -65% of patients (3).
The mechanism of this NSAII) toxicity it
known, but, similar to the mechanism of the d
antiinflammatory therapeutic effects (4), is widet
lieved to be related to inhibition of cyclooxygt
(COX) activity. However, there is substantial evic
that COX Inhibition is not the only pertinent event,
95% Inhibition of COX activity has been ach
without apparent morphologic mucosal change (5
mice with a disabled prostaglandin synthase I
(resulting in the virtual absence of endogenous l
glandin) do not spontaneously develop 61 lesions.
doxically, these mice have been shown to be equa
less sensitive to the damaging effects of indometi
compared with controls (6). An alternative hypotht
that NSAID-induced (ii damage is initiated by a'
cal" effect in which mitochondrial energy metaboli
disrupted (7), but alteration in prostanoid product
probably an important cofactor in the developmc
ulcers. NSAID ingestion results in increased achy
specific mitochondrial enzymes in rats and in ir
mitochondrial changes seen by electron micrce
compatible with uncoupling of oxidative phosph'
tion, before macroscopic damage becomes evider
Reduced levels of gastric mucosal ATP have
documented following NSAID administration, an
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coupling of oxidative phosphorylation has been demon-
strated with some NSAIDs (9-12).
Because of renewed interest in the suggestion
that the toxic effect of NSAIDs may be initiated by an
uncoupling of mitochondrial oxidative phosphorylation
and subsequent disruption of cellular energy metabo-
lism, we have evaluated the potency of a range of
NSAIDs to stimulate coupled respiration in mitochon-
dna and related this property to the physicochemical
nature of the drugs. We tested the hypothesis that the
acidic property of NSAIDs (pKa) influences their un-
coupling potency and that modification of the carboxyl
group may reduce their toxicity and also examined the
effects of highly selective COX-2 inhibitors, which are
reported to have an excellent (ii tolerability profile (13).
MATERIALS AND METHODS
Preparatlo. ci mftocbo.drls. Coupled rat liver mito-
chondria were obtained from 8-week-old Spraguc-Dawicy rats,
as described by Schneider and Hogebooni (14). The animals
were killed by ceivical dislocation and the liver rapidly dis-
sected and placed in ice-cold homogenizing solution (75 mM
sucrose, fl5 mM mannitol, 10 mM MOPS, 1 mM EDTA, 5
mghnl bovine serum albumin (BSAI, pH 7.4). The liver was cat
finely with iiu into approximately! x 1 x 1-cm pieces and
washed twice with homogenizing solution to remom excess
blood. The resultant mixture was suspended in 50 ml of the
same solution and homogenized in a Pottcr-Elvjehm homog-
enizer by6 rokes cia rotating Teflon pestle. The homoge-
nate was then centrifuged at 50(W for 10 minutes to remove
excess blood, nudei, and cell debris. The supernatant was
centrifuged at 11,00( for another 10 minutes, after which the
mitochondrial pellet was carefully removed and resuspended
in 40 ml of homogenizing solution. The last centrifugation step
was repeated and the mitochondrial pellet resuspended in 1-2
ml of homogenizing buffer. The isolation procedure takes
some 45 minutes, with the homogenate kept at between 0°C
and -4°C. The mitochondrial protein concentration was de-
tennined using a BCA protein assay kit (Pierce, Rockford, EL),
with BSA as the standard protein.
Measurement of oxygen consumption. Oxygen con-
sumption, P:O ratio, and resptratory control ratios were inca-
sured by the method of Chance and Williams (15), using a
aarke-type oxygen electrode (Rank Brothers, Cambridge,
UK). The electrode was fitted into a thennostated Plexiglas
chamber containing I ml of oxygen electrode buffer (150 mM
'sucrose, 10 mM KCI, 10 mM HEPES, 5 mM MgCl, 1 mM
KH2PO4, pH 7.4). Small amounts (20-SO gAl) of mitochondrial
preparation, 2 pl succinate (20mM), and 0.1-10 gal of drug (to
a final concentration of 0.01-10 pM) were introduced through
a small hole in the chamber lid. The experiments were carried
out at 30°C with continuous magnetic stirring. Baseline oxygen
consumption (in the absence of drug) was monitored for
approximately 2 minutes at the start of each experiment. Three
to eight experiments were performed with each drug concen-
tration. The P:O ratio with sucelnate as substrate was 1.6. The
respiratory control values ranged from 2 to 5.
Reagents. All substrates, the uncoupler carboxyl cya-
nide p-(tnfluoromethoxy)phenylhydrazonc (FCCP), and drugs
(salicylic acid, acetylsalicytic acid, (lurbuprofen, ibuprolen, di-
dofenac naproxen, indomethacin, ketoprofen, sulmdac, phe-
nylbutazone, piroxicam, fenbufen, etodotac, and acetammo-
phen) were obtained from Sigma (Dorset, UK). Nitrocalicylic
acid was obtained from Fluka (Buchs, Switzerland). Azapro-
pazone was supplied by Wyeth Pharmaceutical (Maidenhead,
UK), and the prodrugs nabumetonc and 6-mcthoxy-2-
naphthytacctic acid (6-MNA) were supplied by SmithKline
Beechain Pharmaceuticals (Wclwyn Garden City, Herifoid-
shire, UK). Nitrobutyl-flurbiprofen was supplied by Nicox SA
(Par, France) and dimero-flwbiprofen byAlchemia (Monza,
Italy). NSAIDs were dissolved in 100% DMSO. The final
concentration of DMSO in the chamber never exceeded 5%.
FCCP was dissolved in 100% ethanoL Control experiments
were performed using solvents oniy. The sto drug solubon
concentrations ranged from 0.1 mM to 2 mM.
RESULTS
R.elatiooslilp of drug pKa to stimulation of ems-
pled respiration by conventional NSAIDs. All of the
acidic NSAIDs investigated (nitrosalicylic acid, salicylic
acid, acetylsalicylic acid, didofenac, naproxen, ibupro-
fen, indomethacin, ketoprofen, piroxicam, phenylbuta-
zone, and azapropazone) stimulated coupled respiration
in isolated nutochondria. Figure 1 shows representative
findings with indomethacin and ketoprofen. l'here was
an initial increase in the respiratory rate, which reached
a maximum with drug concentrations of 0.02-17 pM per
mg of mitochondrial protein, followed by progressive
inhibition of respiration with higher drug concentra-
tions. Acetaminophen, the non-NSAID analgesic con-
trol, inhibited mitochondrial respiration only at concen-
trations higher than those required with the NSAIDs.
The vehide DMSO had no significant effect on mnito-
chondrial function at the volumes tested.
The pKa of the conventional NSAIDs and their
potency to uncouple mitochondrial respiration (defined
as drug concentration required for maximum stimula-
tion of respiration) are shown in Table 1. The maximum
degree of respiration stimulation was similar among the
NSAIDs tested, but the concentration needed for max-
imum stimulation varied with different NSALDs and was
related to drug pKa. Figure 2 shows that there was a
highly significant inverse correlation between the
NSAID concentration required for maximum stimula-
tion and drug pKa (Spearman's correlation coefficient
[rJ = -0.87, P < 0.001; n = 12).
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Flgare 1. Effects idciunethachi (A) and ketoprofen (B) on coupled
mitothoadrial rpwiri in.. The reaction mixture (at 3O pH 7.4)
L50mMivanse, lOinMKa, 10mM HEPES 5mM M52,
1 mM KHO,. 20 mM (as rcapisatoq asbetrate), drug
concentrations indicated, and rat ver miiocbondrial protein (1.3-
42 mghnl). The total voleme was 1.Owl. Values sbowa are the mean ±
SEM o16	 The rate ot esygea utilim1io in the aagke-
type onygen chamber i 	 & percentage relative to baseline
0
Uncoupling of mitochondrial oxidative phos-
phorylation by acidic pro-NSAIDs. The findings with
acidic pro-NSAIDs (etodolac, fenbufen, and sulindac),
were almost identical to the results seen with conven-
tional NSAIDs. Their pKa, concentration required for
NSAJD piCa
FIgure 2. Relationship between the pKao( nousteroidal antileflam-
inatoty dnip (NSAID) and their potency to uncouple oxidative
phosphorylatia.. There was a highly significant inverse correlation
between piCa and coneentration (cone) required let inaxunum edmu-
lation (r -0.87, P <0.001; a - 12).
maximum stimulation, and the maximum degrees al
respiratory stimulation are shown in Table 2. In contra*
as shown in Figure 3, the non-acidic pro-NSAID nabu-
metone (which does not possess a carboxyl or an ioniz-
able group) did not affect mitochondrial respiration
Table L Relationship between pKa and uncoupling 01 mitochondrial oxidative phospbotylation, for
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Table 2. Relationship between pK.a and uncoupling of mitochon-




Percentage required for maximum
	
maximum	 uncoupling
Drug	 pICa uncoupling	 (aMhng protein)
Elodolac	 465	 180	 0.5 ± 0.47
Fenbufen	 5.7	 170	 046 ± 021
Sulindac	 47	 190	 026±0.18
Nabumetonc	 -	 I00	 -
(MNA	 5.0	 180	 046±0.27
4itrobut4-flurbiprokn -
	 100	 -
Dimero-fluitaprofen	 -	 100	 -
SCSSI2S	
-	 100	 -
DuP-697	 -	 100	 -
cOX-2 - cydooxygenaac-2. Sec Table 11cr other definitions.
whereas its carboxylated active metabolite 6-MNA did
stimulate respiration at concentrations comparable with
those observed for conventional NSAIDs.
Abolition of mitochondrial uncoupling by modi-
fication of the carboxylic moiety. The role of the car-
boxyl group possessed by most NSAIDs (except azapro-
pazoac, phenylbutazxme, and the oxicams) in uncoupling
was explored further usng the flurbiprofen derivatives
250
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I	 2	 3	 4	 5
Naburutons concetliatun (uMling proatit)
dimero-flurbiprofen (2 Ilurbiprofen molecules linked by
acid anhydride bond) and nitrobutyl-flurbiprofen (car-
boxyl group esterified with butyl nitric oxide. The
chemical structure of these molecules is shown in Figure
4. As seen in Tables I and 2, flurbiprofen was a potent
uncoupler, but both dimero-flurbiprofen and nitrobutyl-
flurbiprofen failed to stimulate mitochondrial respi-
ration.
Lack of effect of COX-2 Inhibitors on mitochon-
dnal uncoupling. Two highly selective non-acidic
COX-2 inhibitors, SC58125 and DuP-697, had no effects
on mitochondrial respiration at concentrations compa-
rable with those used for the conventional NSAIDs
(Table 2).
DISCUSSION
In this study, commonly prescribed NSAIDs (as-
pirin, flurbiprofen, didofenac, indomethacin, naproxen,
ibuprofen, piroxicam, and ketoprofen), non-aspirin sa-
licylates, azapropazone, phcnylbutazone, and acidic pro-
NSAID, (etodolac, fenbufen, and sulindac), at micro-
molar concentrations, were found to stimulate coupled
respiration in isolated rat liver mitochondrIa. Acetamin-
ophen did not stimulate mitochondrial respiration.
These results and previous data from studies with aspirin
(11) and andomethacin (10) indicate a common action of
NSAIDs to uncouple mitochondrial oxidative phosphor-
6-MNA concciVrata,n (uMhng piotell)
Figure 3. Effects of nabumetone (A) and 6-methoxy.2-naphthylacetic
acid (6-MNA) (B) on coupled mulochondrial respiration. The reaction
mixture and measurement conditions were smular to those described
in Figure 1. Values shown are the mean SEM of 4 experiments.





ylation. All of these drugs are associated with significant
01 damage in humans and animals. We expanded on
previous studies by assessing a variety of NSAIDs at a
range of doses, and we found that their potency to
stimulate coupled respiration is signIficantly related to
their pKa. At neutral pH, NSAIDs with low pKa had to
be present in higher concentrations in order to uncouple
oxidative phosphorylation, presumably because under
these circumstances a greater proportion of the drug
exists in an ionized state and is thus unable to partition
effectively across the inner initochondrial membrane to
translocate protons, compared with a drug whose pKa is
close to neutral.
The pathogenesis of NSAID-induced 01 injury is
probably initiated by a "topical" biochemical damaging
action of these drugs (7). it is suggested that a conse-
quential increase in mucosal permeability is transformed
into a tissue reaction by mucosal exposure to luminal
aggressive factors (7) The ion-trapping hypothesis (16),
which postulates that accumulation of NSAII) in gastric
epithelial cells is dependent largely on interaction of the
NSAID pKa and gastric luminal pH (locally), provides a
possile explanation for drug absorption (along with
mokcular size, lipid solubility, dilution, and transit
times), but not the mechanism of damage. The common
action of acidic NSAIDs on mitochondrial metabolism,
suggested previously by Whitehouse (17) and McDou-
gall et a! (18), provides a logical explanation of the
mechanism of the "topical" phase of damage. Further-
more, butyl-nitric oxide modification of flurbiprofen
(19) and other NSAID esterifications that render the
drugs non-acidic, and hence ineffective uncouplers
(20,21) result in less gastric damage than is seen with the
parent compound, when administered on a short-term
basis (19,20). In the case of nitrobutyl-flurbiprofen, the
nitric oxide released locally during drug absorption may
also have a significant role (19).
The relative importance of the "topical" phase in
the initiation of the damage, as opposed to systemically
mediated inhibition of COX activities, is unknown. The
contribution of the former is indirectly supported by
enhanced gastric tolerability with changes in drug for-
mulation, such as enteric coating, use of a slow-release
preparation, or rectal administration, in short-term en-
doscopy studies (22). Further support comes from the
abrogation of aspirin (pKa 3.5)-induced gastric damage
by elimination of acid secretion (23); as a result, aspirin
is fully ionized, and hence unavailable for partition
across the gastric mucosa. The acidic pro-NSAIDs
etodolac, fenbufen, and sulindac all uncouple mitochon-
dual oxidative phosphorylation and cause significant
endoscopic gastroduodenal damage when given on a
long-term basis (24,25). However, the non-acidic pro-
NSAID nabumetone, which does not uncouple oxidative
phosphorylation, causes less 01 damage in endoscopic
studies (26), and some dinical data suggest a reduced
frequency of long-term toxic effects such as peptic
ulcers, perforations, and bleeds (27). Since its acidic
active metaholite 6-MNA is not excreted in bile, the 01
tract is not exposed to uncoupling concentrations of the
drug, and this may account for its improved tolerability.
The patbogenesis of NSAID-induced 01 disease
is clearly a multistep mechanism. It has been suggested
that the tqpical effect of NSAIDs is important in the
initiation of this damage and may be due to uncoupling
of oxidative phosphorylation. Here we have shown that
many commonly used acidic NSAIDs uncouple oxidative
phosphorylation, which coincides with their known dam-
aging effect on the 01 mucosa, and at neutral pH their
potency to uncouple is inversely related to the pKa of
the drug. in the case of flurbiprofen, the uncoupling
property was shown to be abolished by nitrobutyl ester-
ification of the parent compound. Furthermore, non-
acidic nabuinctonc and highly selective COX-2 inhibi-
tors, all Of which have favorable GI proffles, failed to
uncouple oxidative phosphorylation. These results sug-
gest that rendering NSAIDs. incapable of acting as
proton translocators may enhance their (3! tolerability.
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Intestinal tolerability of nitroxybutyl-flurbiprofen
in rats
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Btackgrouad—Nitrlc oxide derivatives of
noa-,teroidal snti-lnflammntory drugs
(NSAID) are thought to be much less
ulcerogenic than their parent corn-
Aim—To compare the effect snd potency
of flurbiprofan and nitroxybutyl-flur-
biprofen to uncouple snitochondrial on-
dative phoephorylation (an early patho-
genic event In NSAID enteropathy),
Increase Intestinal permeability (tran-
sitional stage), and cause macroscopic
small Intestinal '"ge.
M.tisod.a—ln vitro uncoupling potency
was assessed using Isolated coupled rat
lIver mltochoadri* and In vivo by electron
microscopy of r*t small Intestinal mucosa
(two hours after the drug.). A dose-
response study with fiurbiprofen (single
doses of 5, 10, 20, and 40 mg/kg) and
equlinolar doses of nitroxybutyl-fiurbi-
profan was performed; assessing their
effect on Intestinal perinesbifity (at 18-20
hours), with EDTA, and the number
of pointed (Ci mm) and longitudInal (>5
mm) small intestinal ulcers at 24 hours.
Rwdg..—Fhublprofen, but not nitrozy-
butyl-fliaabipw&is, stimulated coupled
respiration In vitro. Both drug., however,
uncoupled In vivo; In the case of nitrozy-
butyl-flurbiprofen possibly because hy-
drolysis of Its ester bond released free
flurbiprofen. Intestinal permeability was
uniformly and equally Increased with both
drugs compared with controls. The
number of small intestinal ulcers, pointed
and iengi, was significantly re-
duced with nitroxybutyl-flurbiprofen
apart from the number of longitudinal
ukcrs with the highest dose.
Conchisiona—Theae studies show that
nitroxybutyl-fiurbiprofen Is associated
with significantly less macroscopic dam-
age In the small Intestine th*n flurbi-
profen but was associated with mite-
chondrial damage in vitro and caused
similar Increases In permeability of the
small intestine, suggesting that Its bene-
ficial effect Is on the later pathogenic
stages of the damage.
(Gut 1997; 40: 608-613)
Keywords: ustcsnnal tolerability, mrroxybutyl-
fiurbiprofen
The main concern with the use of non-
steroidal anti-inflammatory drugs (NSAIDs) is
the frequency and seventy of their gastro-
intestinal side effects,' which affect both the
-
stomach and small intestine.2 ' The devdop-
ment of safer NSAIDs depends on insights into
the mechanism by which these drugs cause
gastrointestinal toxicity. We and others have
suggested that there may be two stages to the
damage, • topical (biochemical) and a systemic
phase (tissue reaction)' linked by increased
intestinal permeability. The topical phase may
be due to NSAID induced uncoupling of mito-
chondrisi oxidauve phosphorytation (Soma-
sundsrsm at a4 manuscript submitted),'7
rather than by Inhibition of cydooxygenase5
and leads to increased intestinal permeability.9
Subsequently the tissue reaction is the result
of mucosal exposure of luinmal aggressive
factors; neutrophil recruitment and changes in
the microcirculation being important lbr the
development of inflammation and ulcers.' An
alternative suggestion is that NSAIDs damage
the intestinal vascular epithelium directly
during drug absorption, with expresuon of
adhesion molecules and activation of neutro-
p,t0-13 which cause damage by lysosomal
release, generation of reactive oxygen species,"
and by impairing microcirculatory blood flow.
There are data to support both the main
hypotheses of damage. Based on the this an
attempt has been made to limit the gastro-
intestinal toxicity of NSAIDs by attaching a
nitric oxide moiety to conventional NSAIDa in
the hope that the nitric oxide released during
drug absorption would counteract some of the
above detrimental vascular effects. Initial
reports of nitric oxide NSAIDs in animals have
been encouraging, showing minimal damage
compared with the parent NSAfD)7
The attachment of the nitric oxide geoup to
NSAIDa is achieved by linkage of a nitrozy-
butyric group." This connection modifies
the NSAII) carboxylic group, which is essential
for effective inhibition of cyclooxygenase." It
is therefore possible that some of the beneficial
effect of nitric oxide-NSAIDs (NO-NSAIDs)
might be due to rendering them non-acidic and
hence ineffective as proton translocators
(Somasundaram at al, manuscript sub-
mitted). 19 Here we report aspects of the topical
phase of damage (in vitro and in vivo effects on
mitochondria) and changes in intestinal per-
meability in relation to the macroscopic




Male pathogen free Spraguc-Dawley rats
(Charles River), 6-8 weeks old and weighing
200-250 g, were used throughout these studies.
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A dose response study was done by ad-
nunistranon (without sedation) of flurbiprofen
(5, 10, 20, and 40 mg/kg), NO-flurbiprofen
(7 .5, 15, 30, and 60 mg/kg; which are roughly
equimolar to the doses of flurbiprofen,
respectively), or vehicle by gastric gavage to six
(fasting) rats in each group followed by 1 ml
water. However, this comparison may be biased
against NO-flurbiprofen as previous studies have
shown that flurbipeofen and NO-flurbiprofen
have comparable efficacy on a weight to weight
basis.'5 The highest dose of flurbiprofen was
selected to be a roughly equivalent dose (extra-
polated from maximum recommended doses in
humans) of 20 mg/kg indosnethacin in rats,
which is the dose of indomethacin most
commonly used to induce intestinal damage.
The drugs were initially dissolved in 10%
dimethyf suiphoxide and then diluted so that
the final concentration of dimethyl .ulphoxide
was less than 5%. The dissolved drugs were
shielded from exposure to light and used
within one hour. Control ,nimals received 1 ml
vehicle and 1 ml water. After the gavage
animals remained fasting for a further two
hours after which they had free access to
standard rat food and water They were again
fasted the next night and placed in metabolic
cages for the intestinal permeability test after
which they were anaesthetised (with Hypnovel-
Hypnorm) and underwent laparotomy with
removal of the whole of the small intestine.
Animals were then killed by terminal
anaesthesia and cervical dislocation.
puarry AND sman.rrv oi' F RBIPROFEPJ AND
NO-PLURBIPROFEN
The purity of the solutions of flurbiprofen and
NO-flurbiprofen was checked using reversed
phase high pressure liquid chromatography
(HPLC) with ultraviolet detection (276 nm).
A Spectrasystem HPLC system was used
(I'hermo Separation Products, Stone, Cheshire,
UK) with a gradient pump (P4000), auto-
sampler (AS3000), and ultraviolet detector
(UV2000). Separation was by reversed gradient
elution, using a gradient of acetic acid (0 1 mM,
pH 427) and acetotinrile (0-20 minutes 40%
acetonitrile changing from 20-25 minutes to
60% acetonitrile which is maintained until 35
minutes). A C18 column was used (RP-l8
LiChrosorl, 5 mm, 250X46 mm, Phenomenex,
Macclesfield, Cheshire, UK) at room temper-
ature. Samples were dissolved in methanol and
25 l was injected on to the column. The
retention times were: flurbiprofen 235 minutes,
indomethacin (internal standard) 264 minutes,
and NO-flurbiprofen 39 minutes.
The stability of the two NSAIDs within the
intestine was assessed by incubating (shielded
from light) flurbiprofen and NO-flurbiprofen
for one hour at 37 C with intestinal mucosal
scrapings from male Sprague-Dawley rats that
had been fasted overnight.
MITOCHONDRIAL FUNCTION
In vitro uncoupling experiments were done on
isolated coupled liver mitochondria 2 The liver
was cut into 1 cm' pieces and homogenised in
a 74 mM sucrose, 225 mM mannitol, 1 mM
EDTA, 5 mg/mI BSA solution in 10 mM
MOPS-NaOH buffer, pH 74, by six strokes of
a tight fitting teflon pestle. The homogenate
was centrifuged at 500 gfor 10 minutes and the
resulting supernatant recentrifuged at 12000 g
for 10 minutes. The pellet was resuspended in
the isolation medium and centrifuged for 10
minutes at 12000 g, to give the resulting
mitochondrial enriched pellet used for these
experiments. All procedures were carried out at
4°C. Protein concentration was determined
using aBCA protein assay kit (Pierce, illinois,
USA).
Oxygen consumption, P,O values, and
respiratory control ratios were measured with
a Clarke type oxygen electrode (Rank Brothers,
Cambridge, UK).2' The reaction mixture con-
sisted of 150 mM sucrose, 10 mM potassium
chloride, 5 mM magnesium chloride, and 1
mM potassium phosphate in 10 mM HEPES-
NaOH buffes, pH 74. Mitochondrial protein
(1-5 mg/mI final concentration), substrates,
and drugs were introduced into the chamber
(1 .0 ml capacity) through a small hole in the
lid by syringe. Reactions were carried out at
30°C under magnetic stirring. PlO ratios and
respiratory control (using carbonyl cnide-
(trifluoromethoxy) phenylhydrazone (FCCP)
as uncoupler) were measured on each of the
mitochondrial preparations at the start and end
of each series of experiments. PlO ratios with
succinate u substrate were 40 (SEM 16).
Respiratory control values ranged from 2 to 5.
The effects of drug addition on coupled
mitochondrial respiration over a concentration
range of 001-50 p.mollmg mitochondrial
protein was monitored by oxygen uptake for
two minutes after drug addition. Results are
expressed as a mean (SEM) percentage of
control (absence of drug) of the duplicates of
4-10 experiments performed on different
days.
All substrates, FCCP, and flurbiprofen were
obtained from Sigma (Sigma Chemical
Company Ltd, Dorset, UK) and NO-
Ilurbiprofen was provided by Dr P Del Soldato
(Nicox, Dublin, Ireland).
For the in vitro studies flurbiprofen and NO-
flurbiprofen were solubiised in dimethyl
sulphoxide before dilution and the pH adjusted
to 74. Control experiments used the solvent
alone. The final concentrations of dimethyl
sulphoxide never exceeded 2%.
The in vivo effects of flurbiprofen and NO-
flurbiprofen on mirochondria were assessed by
electron microscopy. Groups of four rats each
received flurbiprofen (10 mg/kg), NO-
flurbiprofen (15 mg/kg), or vehicle after an
overnight fast, by gastric gavage. Two hours
later an abdominal incision was made under
anaesthesia, the stomach opened, and a
catheter placed in the second part of the duo-
denum. The whole of the small intestine was
then flushed, avoiding distension, with a 30%
gluteraldehyde solution in 0l M sodium phos-
phate phosphonc acid buffer, pH 73-74. One
cm length of jejunum (30 cm distal to the
ligament of Trietz) was then routinely
processed for electron microscopy and placed
in gluteraldehyde for three days. After fixation,
samples were washed in 1% osmium tetroxide
in 01 M sodium phosphate buffer (pH
7'3-7'4) followed by a phosphate buffer wash.
Dehydration was achieved by increasing con-
centranons of acetone (25%, 50°!., 70%, 90%,
100%) and infiltration in araldire and acetone
mixture (50:50) overnight. Samples were
washed (two hours) in neat resin, embedded in
araldite, and cut ultrathin with an uliratome MrTOCHONDRLU.. PUNC77ON
(Richart Uhracut-E). The samples were then Dimethyl suiphoxide aJonc at the coacen-
examined with a Joel 1200 cm electron trations and volumes used in the experiments,
microscope in transmission mode. All samples had no effect on purified mnochondrial oxygen
had been coded and morphology was assessed consumption. Figure 1 shows that flurbiprofen
by one pathologist unaware of the treatments, stimulates respiration in coupled mitochondria
over a concentration range of 0-05 to 4 pnioW
mg protein. At concentrations of flurbiprofen
above 5 ja.moUmg protein respiration is greatly
inhibited. NO-flurbiprofen by comparison had
no significant effect on mitochondnal res-
piration over the concentrations tested.
Figure 2 shows representative electron
microscopy from animals two hours after
receiving vehicle only and the NSAIDs. All
four control rats were normal, with mito-
chondria of uniform size and dearly visible
cristae. However, there were identical and
equally prominent mnochondrial changes in all
the rats receiving flurbiprofen and NO-flufoi-
profen. The changes ranged from subtle
elongation of mitochondria and swelling to
condensation of the matrix due to loss of clarity
of the cnstae. In some cases there was mito-
chondrial vacuolisation with disnaption of the
cristae. The range of abnormalities is
compatible and highly suggestive of mild to
severe uncoupling of oxidative phosphory-
lation or inhibition of electron transport,23 the
only other common cause for such changes
being exposure to very hyperosmolar solutes.
The endoplasmic reticulum was slightly
vacuolated and distended in both groups of
animals receiving NSA1Ds. The brush border
and other subcellular organelles were un-
affected by the drugs.
STATISTICAL ANALYSES
The SYSTAT statistic package was used It
calculations. Results are expressed as mcii
(SEM). Statistical differences between groi
were assessed by the non-parametric Mas
Whitney U test.
flSflNAL PERMEABIUFY
Gastric intubation (without anaesthesia) was
carried out after an overnight fast 18-20 hours
after receiving the NSAIDs or vehicle.
51-Chromium labelled ethylenediaminetetra-
acetate (CrEDTA; Amersham International,
Aniersham, UK 0-5 ml; 10 mCi) was admin-
istered (containing approximately 50 nmol
31CrEI)TA), followed by 1 ml water. The
animals were placed in individual metabolic
cages for five hours for collection of urine.
Laparotomy was then performed under anaes-
thesia and the bladder emptied by puncture.
The urine obtained was mixed with that
excreted during the five hour test period. Urine
was counted along with standards ins Wallac
1284 gamma counter for five minutes,
which allowed minimal detectable activity of
<0-001% of the administered dose.
MACROSCOPIC DAMAGE
The intestinal mucosa was exposed by a cut
through the mesenteric side and laid out on a
piece of cork for assessment of macroscopic
damage 24 hours after giving the drugs. The
assessments were carried out by one person
who was unaware of the treatments. An ulcer
count was made distinguishing between
pointed (<5 mm) and longitudinal (>5 mm)
ulcers. PURITY AND STABIUTY OF PLIJRBIPROFEN AND
NO-PLURBIPROPEN
Flurbiprofen and NO-flurbiprofen had dis-
tinctly different retention times. Single peaks
were obtained with the neat drugs dissolved
in dimethyl sulphoxide. However, after in-
cubation with intestinal homogenate for 60
minutes the amount of NO-flurbiprofen was
reduced by 50% with a corresponding increase
in flurbiprofen, suggesting that the ester












Figure 3 shows that intestinal permeability to
MCrEDTA was significantly increased after
each dose of flurbiprofen and NO-flurbiprofen.
There was no significant (p>0' I difference
between excretion values between groups
receiving 5, 10, 20, and 40 mg/kg flurbiprofen
or equimolar doses of NO-flurbiprofen
1	 2	 3	 4	 5
pmOI/mg protein
Figure! Effect offlwh,pn,fen (0 and NO-fl urb,prsfen(S on coupled rat inser mssochondrsal respimzson in vuro.
The rate of oxygen use is expressed as a percentage relative
to the baseline resp,ranon Each data penis represents the
mean SEM offour to eight experiments
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Furthermore, there was no significant differ-
ence (p>O 1) in the urinary excretion of
"CrEDTA between groups of rats receiving
different doses of the drugs.
MACROSCOPIC DAMAGE
Figure 4 shows that the number of pointed
ulcers (<5 mm) and longitudinal ulcers (>5
mm) were significantly fewer after NO-flurbi-
profen than after each equnnolar dose of flurbi-
profen except for the highest dose, with which
there was no significant difference between the
number of longitudinal ulcers between the two
drugs.
D
The mulustep pathogenic framework for
NSA1D induced gastrointestinal toxicity pro-
poses that there are distinct and sequential
phases of damage. The first is due to the
"topical" action of NSAIDs to uncouple oxi-
dative phosphorylation, which leads to in-
creased intestinal permeability (Somasundaram
m a4 manuscript submitted). This may then
transform the biochemical phase of damage to an
inflammatory reaction, by allowing mucosal
exposure of luminal substances, and the develop-
ment of ulcers mediated either by altered micro-
circulatory blood flow or by nutrophils.'°"
Here we assessed three important patho-
physiological aspects of NSAID induced
damage to the sinai! intestine at different time
points after single doses of Qurbiprofen and
NO-flurbiprofen. Firstly, we showed that
chemical modification of flurbiprofen to NO-
flurbiprofen rendered it ineffective as a mito-
chondrial uncoupler in vitro. Secondly, in vivo
the two drugs were equally associated with
mitochondrial damage at the electron mi-
croscopy level. Thirdly, there was no signifi-
cant difference between the increased intestinal
permeability after the two drugs. Collectively
this suggests that the nitric oxide moiety of
NO-flurbiprofen does not have a role in
altering the early pathogenic events in NSAJD
enteropathy. A possible reason for the apparent
discrepancy between the in vitro and in vivo
naitochondrial results is that the ester bond of
NO-flurbiprofen may be cleaved by intestinal
esterases24 (present also in abundance in
pancreatic secretions) to yield the parent
NSAID, which is then able to exert its bio-
chemical effect during drug absorption.
By contrast with the sunilarities in the early
pathophysiological changes seen with flurbi-
profen and NO-flurbiprofen, the latter is asso-
ciated with a significantly improved tolerability
of the small intestine as shown in the reduction
in number of ulcers, as has been found in the
stomach"" These findings conform to the
idea that NO-flurbiprofen releases nitric oxide
and thereby causes vasodilatation, increases
microcirculatory mucosal blood flow, and
prevents neutrophil recruitment," all of
which are important components in the later
stages of NSAID induced gastrointestinal
damage.' 6 II 25 Previous gastrointestinal toler-
ability studies with NO-flurbiprofen and
0	 5/7.5	 10/15	 20130	 40/80
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nitrofenac (nitroxybutyl-diclofenac) have
shown minimal gastric damage compared with
the parent compound when given at doses
comparable with those used in the present
study.'55' Furthermore NO-flurbiprofen given
orally to Wister rats (15 mg/kg twice a day) for
a week was not associated with any small
intestinal pathology whereas all five rats given
equimolar doses of flurbiprofen had damage to
the small intestine) 5 Similarly, subcutaneous
nitrofenac (30 mg/kg twice a day for 35 days,
and 15 mg/kg twice a day for two weeks) did







Wister rats or rabbits, respectively." ' Our
results, although not directly comparable
because of the different strain of animals used
and mode of drug administration, extend these
findings and show that at equimolar doses NO-
flurbiprofen is associated with significantly less
small intestinal ulceration than flurbiprofen.
Reduced ulceration along with the findings
chat it does not seem to affect the early patho-
genic events (namely, uncoupling of mito-
chondrial oxidauve phosphorylation leading to
the permeability changes) in the damage
supports the contention that nitric oxide-
NSAID may counteract some of the later
vascular effects of NSAIDs. Indirectly this
provides some evidence for the importance of
the microcirculanon in the formation of ulcers
as opposed to inflammation which may be
predominantly driven by the permeability
changes (Somasundarain a a4 manuscript
submitted).' a
Although not directly studied here, it seems
possible that the esterification of flurbiprofen
which occurs when butyric nitric oxide is
attached provides additional protection for the
stomach mucosa as this renders the drugs
incapable of acting as proton translocators;
circumventing the topical phase of damage
(Soniasundaram a at, manuscript submitted).
Eaterification of other NSAIDs, without intro-
duction of the nitric oxide soup, provides
compounds with less gastric ulcerogenic action
while maintaining in vivo anti-inflammatory
activity.27 a Because most NSAIDs are
relatively ineffective as cyclooxygenase inhibi-
tors without the carboxyl group,' it was
suggested that in vivo anti-inflammatory
activity of esterifled NSAIDs was due to
generation of the parent compound by in-
testinal or plasma esterases,4 27 However, as
NO-flurbiprofen is a comparably potent in-
hibitor of cyclooxygenase to flurbiprofen in
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inhibition or estenfication of the NSAID
would seem to explain our results. On the
contrary there is a differential effect of NO-
fiurbiprofen and fiurbiprofen on the later
pathophysiological stages of the damage, as
opposed to the early stages, implying an
additional beneficial effect of nitric oxide as
detailed above. The importance of the nitric
oxide group is also evident from other studies,
in particular by the finding of Elliott a a1 who
showed that mtrofenac accelerated healing of
experimental gastric ulcers in the rat.'°
In conclusion, orally administered fiurbi-
profen and NO-flurbiprofen in the rat are
equally associated with changes in mito-
chondrial morphology, that are indicative of
uncoupling of oxidatsve phosphorylarion, and
increased intestinal permeability. Howevei, the
development of ulcers is significantly decreased
with NO-fiurbiprofen, which is consistent with
the suggestion that alterations in the micro-
circulation may be the driving force in con-
verting the biochemical damage of NSAIDs
into ulcers.
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Mitochondrial damage: a possible mechanism of
the "topical" phase of NSAID induced injury to
the rat intestine
S Somasundaram, S Rafi, J Hayllar, G Sigthorsson, M Jacob, A B Price, A Macpherson,
T Mahinod, D Scott, J M Wriggjesworth, I Bjarnason
pyretic agents. The main concern with this
group of drugs is the frequency and severity of
_________	 their gastrointestinal side effects.''
The pathogenesis of intestinal damage is
incompletely understood. It is generally ac-
cepted that the early pathogenic events include a
"topical" phase in addition to the inhibmon of
cyclooxygenase, followed by a multistage patho-
genic event in which intestinal pcnneabilmty,
himinal contents, neutrophils, and the microcir-
culation all play a role in the development of
inflammation and ulcers.'' The importance of
inhibition of cydooxygenase in the damage
induced by NSAIDs has been clearly
documented.' Nevertheless, it is it is possible to
inhibit cyclooxygenase selectively without in-
ducing intestinal damage." Furthermore, dis-
ruption of the prostaglandin synthase-1 gene
coding for cyclooxygenase-1 in mice, with
resulting mucosal prostaglandin concentrations
of less than 1% of that of controls, is not associ-
ated with gastrointestinal pathology." In the
stomach changes in drug formulation (enteric
coating, rectal administration, etc.)" and abol-
ishing gastric acid secretion (abrogates aspirin
(piCa 3.5) induced damage" presumably by
limiting the gastric absorption of the drug)
greatly increase toLerability of NSAIDs in the
short term. This suggests that the "topical"
action of NSAIDs may be an important
co-fctor in the initiation of the damage.' The
"ion trapping" hypothesis which postulates that
accumulation of NSAIDs in intesunal epithelial
cells depends largely on the interaction of the
acidity of the NSAID (p1(a) and himinaj pH
provides a basis for (along with molecular size,
lipid solubility, contact time, etc.) the "topical"
action of NSAIDs but not the mechanism.' "
One suggestion is that uncoupling of oxidauve
phosphorylanon may be the biochemical mech-
anism underlying the "topical" toxicity of
NSAIDs." "Uncoupling of oxidauve phospho-
rylanon has been documented in vitro with
some NSAIDs' "" and in vivo in the case of
be aspirin."
an Important component of the "topical" The aim of this study was to examine theDepartment OIK.in ,
	
phase of damage induction, 	 possible mechanism of the "topical" phase of
College,	 (Gait 1997,41: 344-353)	 NSAID induced gastrointestinal damage in the
Road, Kensington,	 rat by using electron microscopy and subcellu-
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Material and Methods
Abstract
Background—The "topical" effect of non-
steroidal anti-inflimiiiatory drugs
(NSAID5) seems to be an important cause
of NSAID induced gastrointestinal dam-
ag
Aim—To eamsitle the possible mechniii.m
of the "topical" phase of damage in the
small Intestine.
Methods—Electron microscopy and sub-
cellular organelle marker enzyme studies
were done In rat small Intestine after oral
administration of Indomethacin (doses
varied between S and 30 mnjkg). The effect
of conventional and non-acidic NSAIDs
on rat liver niltochondrial respiration was
measured In vitro in a Clarke-type oxygen
electrode.
Results—The subcellular organelle
marker enzymes showed mitochondrial
and brush border Involvement within an
hour of Indomethacin administration.
Electron microscopy showed dose dc-
pendant mitochondrial changes following
ladosnethacin administration consistent
with uncoupling of oxidative phosphoryla-
don (or Inhibition of electron transport)
which were Indistinguishable from those
seen with the uncoupler dlnitrophenol.
Parenteral indomethacin caused similar
changes, but not In rats with ligated bile
ducts. A range of NSAJDs, but not pars-
cetamol or non-acidic NSAIDs which have
a favourable gastrointestinal tolerability
profile, uncoupled oxidative phosphoryla-
lion in vitro at micromolar concentrations
and inhibited respiration at higher con-
centrations. In vivo studies with nabume-
tone and aspirin further suggested that
uncoupling or inhibition of electron tans-
port underlies the "topical" phase
NSAID induced damage.
Conclusion—Collectively, these stud
suggest that NSAID induced changes
nutochondrial energy production may
Non-steroidal anti-inflammatory drugs
(NSAIDs) are the most prescribed drugs
w ridwide which attests to their efficac y as
analgesics, and anti inflammatory and ann-
A'41%SALS
Male pathogen-free Sprague Daw ey rats
(Charles River), 6 8 weeks old weighing 200
250 g were used through ut these studies l
Inpocal dan,ag. of NSA 11)5 and uncoapllng
documentation and confirmation of the ulcer
location and frequency, histology, subcellular
organelle marker enzyme studies and electron
microscopy, animals were fasted overnight
before receiving NSAEDs or solvent by gastric
gavage via a soft rubber tube (without seda-
tion) at 0800 or L 200 hours. The 0800 hours
group of animals remained fasted and were
ansesthetised (with Hypnovel-L-lypnorm) 1-6
hours later, underwent laparoromy and were
killed by cervical dislocation after the proce-
dure. In the case of the animals receiving the
drugs at noon, these were re-fed (two hours
later) and operated on the next day 20 hours
later (with a preceding overnight fast).
For the in vivo studies indomethacm (5, 10,
20 or 30 mg/kg) was dissolved ins bicarbonate
buffer (pH 7.4) pnor to gastric gavage. The
range of indomethacin doses used was similar
to that used in moss other comparable studies
when assessing the acute gastrointestinal toxic-
ity of NSAIDs. These doses are somewhat
higher than that required to demonstrate anti-
inflammatory activity in carrageenen paw
oedema (2.5 mg/kg). Aspirin (100 mg/kg) and
nabumetone (600 mg/kg) were initially dis-
solved in 10% dimethylsulphoxide (DMSO)
and diluted to I ml just prior to administration
(final conosniration of DMSO <5%) and was
followed by 1 ml water. The doses of aspirin
and nabumetone are roughly equivalent to
about eight and 21 times the mTimum
amount given to a 70 kg person with rheuma-
toid arthritis, respectively (assuming 3-4 g/day
for aspirin and 2 g/day nabumetone). The
equivalent dose of indomethacin, calculated in
the same way, is 2.5-fuld (5 mg/kg dose) to
14-fold (30 mg/kg dose) higher. Dinitrophenol
(0.4 ml of a 6 mM solution) was dissolved in
10% DMSO and administered at a final
concentration of less than 2% DMSO. The
same amount of solvent was used in control
experiments.
SUBCEUU1..AR ORGANELLE MARKER ENZYME
STUDIES
Groups of eight to 24 rats received indometh-
san (30 mg/kg) or solvent by gavage and
underwent laparotomy one, six, or 20 hours
later. Samples from the duodenum (third part),
jejunum (30 cm distal from the ligament of
Treitz) and ileum (10 cm proximal to the cae-
cum) were minced finely in a Polytron homog-
eniser (Kmemanca GmbH, Lucern, Switzer-
land) for 15 seconds at speed setting I and
disrupted by 15 strokes of a loose fitting (type
A) pestle in a Dounce homogeniser in (10%
w/v) ice cold 0.25 M sucrose containing
disodium EDTA (1 mmol/l, pH 7.4) and etha-
nol (22 mmol/l). Homogenates were stored at
-70°C until assay of enzyme activities.
Organelle specific marker enzymes studies
were carried out as described previously" 10.
alkaline phosphatase (EC 3.1.31), brush bor-
der; lactate dehydrogenase (EC 1.1.1.27),
cytosol; DNA, nucleus; succinate dehydroge-
nase (EC 1.3.99.1), inner mitochondnal mem-
brane; citrate synthase (EC 4.1.3.7), mito-
chondrial matrix (tricarboxylic acid cycle);
cytochrome c oxidase 1 9 3 I), mitochondrial
matrix (electron transport chain), b-N-acetyl-
D-glucosaminidase (EC 3.2.1.30), lysosomes;
u-glucosidase (EC 3.2.1.20), endoplasmic re-
ticulum.
Mitochondrial enzymes were assayed after
freeze thawing three times to disrupt the mao-
chondrial membranes.
Protein content was analysed according to
Lowry a al," and DNA content according to
Carter at a!
MORPHOLOGY AND ELECTRON MICROSCOPY
A straightforward small intestinal ulcer count
was made, following exposure of the mucosa by
a longitudinal cut along the mesenteric border,
20 hours after administration of the drugs.
For microscopy an abdominal incision was
made under anaesthesia, the stomach was
opened and a catheter placed in the firit pars of
the duodenum. The whole of the small
intestine was then flushed, avoiding dissension,
with a 3.0% gluteraldehyde in 0.1 M sodium
phosphate buffer pH 7.3-7.4. One centimetre
lengths of duodenum (third part), jepunum
(30 cm distal to the ligament of Trietz) and
ileum (10cm proximal to the caecum) were
then processed: (1) to paraffin wax blocks and
3-4 pm sections were cut and stained with
haematoxyhn and eosin (six animals each stud-
led as controls and at one, six, or 20 hours after
administration of indomethacin 20 mg/kg); or
(ii) for electron microscopy and placed in glu-
teraldehydc for three days (four animals as
controls and at one, two, or five hours after
indomethacin 20 mg/kg was given). A further
four animalo in each group were studied by
election microscopy (jejunum only) one hour
after instillation in the small intestine of 0.4 ml
of a 6 mM solution of dinitrophenol, a potent
uncoupler of oxidative phosphorylanon, and
two hours after administration of 5 and 10 mg/
kg indomethacin by gastric gavage to assess a
possible dose response relation.
After fixation, samples for electron micros-
copy were embedded in araldite and ultrathin
sections were cut using an Ultratom.e-Richart
Ukracut-E. The samples were then examined
with a Joel 1200 cm electron microscope in
transmission mode. All experiments were
carried out without knowledge of treatment.
IN VITRO Mrr0CH0NDR1AI. STUDIES
Animals were fasted overnight. Rat liver unto-
chondria were isolated and used for these stud-
ies as it is exceedingly difficult to obtain high
yield, purified coupled mitochondria from
intestinal tissue." However, it is generally
accepted that there are no major differences
between mitochondria isolated from different
organs with regard to responses to uncoupling
agents or inlubitors of the respiratory chain."
After cervical dislocation livers were rapidly
removed and placed in ice cold 0 9% sahne.
The liver was then cut into approximately
1 cm' pieces and homogenised in 50 ml of a
74 mM sucrose, 225 mannitol, 1 mM EDTA,
5 mg/mI bovine serum albumin solution in 10
mM MOPS-NaOH buffer, pH 7.4, by six
strokes of a tight fitting Teflon pestle The
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cyanide p-(trifluoromethox) phenyihydrazonc
(FCCP) prior to the addition of the drugs
Rotenone and FCCI' were dissolved in etha-
nol whereas the rest were solubilised in 10%
DMSO prior to dilution and pH adjusted to
7.4. The solvent was used by itself in the con-
crol experiments. The chemical structures o
the drugs used in these experiments are shown
in fig 1. The conventional NSAIDs studied
were mdomethacin (pICa 4.5), naproxen (pKa
4.2), aspirin (pICa 3.5), flurbiprofen (pKa 4.2),
and piroxlcain (pICa 6.3); paracetamol wal
studied as a non-NSAID analgesic control.
Three non-acidic NSAIDs were also studied:
nabwnetone (and its active acidic metabolite
6-methoxy-2-naphthylacenc acid (6-MNA
pKs 4.5)) and two chemical modifications oi
fluzbiprofrn, namely NO-flurbiprofen (fIg 1), a
nitroxybutylester derivative of flurbiprofen
and a flurbiprofen diner where a molecule ol
flurbiprofen is linked to another flurbiproferi
molecule via an acid anhydrite bond. Each
drug was tested over a range of concentrations
and the data presented represent the mean ed
three to five experiments performed on differ-
ent days.
Mitochondrial protein was measured b
using Pierce's BCA protein assay kit, using





minutes and the resulting supernatant re-
centrifuged at 12 000 g for 10 minutes. The
pellet was resuspended in the sucrose soluuon
and centnfiiged for 10 minutes at 12 000 g to
give the resulting mitochondrial enriched pellet
used for these experiments. All procedures
were performed at 4°C.
Oxygen consumption was measured iiii a
Clarke-type oxygen electrode, as described
previously. 2' The reaction mixture consists of
150 mM sucrose, 10 mM potassium chloride,
5 mM magnesium chloride, and 1 mM potas-
sium dihydrogen orthophosphate in 10 mM
HEPES-NaOH buffer, pH 7 4. Substrates,
inhibitors and drugs were introduced into the
chamber (I ml capacity) by syringe and
reactions were earned out at 30 C under mag-
netic stirring
Electron transport experiments were done
with mitoch ndria after addition of 0 I mM
BaLE DuCr LIGATION EXPERiMENTS
Pharmacokinetica permits three possible
routes by which NSAIDs may come into
contact with the small intestinal mucosa.
Firstly, the 'topical" phase following ingestion
(during absorption), secondly, a systemic route
as the drug enters the vascular compartment
and is distributed throughout the body, and,
thirdly, following excretion in bile which may
re-expose the small intestine to the 'topical"
phase. In an attempt to discriminate between
the "topical" effects of indomethacin on intes-
tinal anitochondrial morphology and the sys-
temically mediated effect, one group of rats
underwent bile duct ligation while the other
underwent sham operation (all animals were
re-fed after the procedure). Twenty four hours
later, after an overnight fast, the animals
received indomethacin 20 mg/kg intraperito-
neally. The animals whose bile ducts had been
ligated also received chenodeoxycholic acid by
gavage (1 ml of a 10 Utnolar solution) the chief
constituent of bile acid in the rat. This is an
important control as bile plays a pathogenic
role in indomethacin induced damage in the
rat." Electron microscopy (jejunum only)
was done two hours later on groups of four
anunals.
ASPIISIN EXPERiMENTS
Of the NSAIDs studied in the rat, aspirin by
gavage (and intrapentoneally)' is the only con-
ventional NSA!!), apart from nabumetone,2
that does not cause small intestinal ulcers.
Aspirin and nabumetone (6-MNA) are also not
excreted in significant amounts in bile follow-
ing parenteral administration The lack of
small intestinal toxicity of aspirin is puzzling
One possibility is that the small intestine may
not expo ed to significant "topical" conccntra
Iopa..Ida.nugr o/ ,\ SAII) and .,nonp1ing	 317
Ki I Organdk ,uor*cr enryrnc aclivnies in rut Jqunum
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Spr.gue-Dawley rats (eight in 24 in each group) received indaunethacin (30 mg/kg) by pv. and were killed one, sax, re 20 hours
later
The results thom sigisthcasdy ("p'cO 01 • Wilcoaon's rank wan test) lower DNA level, at 20 ho,as possaly because oh reduction
in cull numbers in a result oh ulceration Alkaline phospliataae activities (bnasl, boider marker) we significantly reduced througisoax
which could represent dscadansaje by NSAIDs or inactivation due to eay5en reactive meubolees. "Thent ace significant mercanes
in the three un,todsrondiai worker enzyme activities at oae hour, ,lbese tranuesst in the cate o(cytocheome c oxidase.
lions because of rapid absorption from the gas-
troduodenal mucosa (and the lack of excretion
in bile).'4
To study this possibility, rats underwent
laporatomy under anaesthesia. One group
received 100 mg/kg (volume of 1 ml) aspirin
directly into the small intestine whereas the
other group received the same dose by gastric
gavage. Electron microscopy (jejunum only)
was done two hours later on groups of four
animals and an ulcer count at 20 hours (six
animate in each group).
Rasules
ZNDOMEiHACD4 AND SMALL DrrE5TmLAL LSSIONS
Macroscopic, predominantly mid-small intesti-
nal, damage occurred consistently 20 hours
after gastric gavage of 20 or 30 mg/kg in-
domethacin in male Sprague-Dawley rats, as
shown previously. tm There were 15-120
ulcers (median 49) in 26 of 30 treated animals.
Light microscopy showed no histological in-
flammatory changes at one hour. At six hours
there was a minor polymorphic inlilirate which
became intense around the focal erosions and
ulcers at 20 hours as described previously in
much greater detail by Anthony ir a!"
Indomethacin (5 mg/kg) caused small intes-
tinal ulcers in two of eight animals (numbers 3
and 12) whereas seven (median 22, range
2-56) of 10 animals receiving the 10 mg/kg
dose had ulcers.
SUBCEUIJLAR ORGANELLE ENZYME MARKER
After indomethacin (30 mg/kg) ingestion the
most noticeable changes in subcellular or-
ganelle marker enzyme activity were found vi
the jejunum (table 1). There was a significant
decrease in the activities of the brush border
marker (alkaline phosphatase) at one, six, and
20 hours. All three mitodiondrial marker
enzymes were increased at one hour, persisting
throughout in the case of succinate dehydroge-
nase and citrate synthase. Markers for other
subcellular structures did not alter significantly
until ulcers were evident, which presumably
represents the combination of the biochemical
Figure 2 Represenlanve ekczmn transm,s,wn m,crtigiaph, a/nsf small mresnne ()qunvin, 30 car distal to the ligament of
Tress) demonstrating A) normal enurocyre m.rochondna, (B vaaaohsarson of muochandr,a one hour after indonterhac,n
ad,rnntsnunorr, (C ttzcarduanon of ,n:xhondrsa one hour a/tsr the admu,,srranos, t the uncoupler thnlisophenol, and
0) normal enrervc3re mirochondna one hour after nabumerone adnnn,sznzrson Noes normal brush border appearances
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nica,s nmndau mitachoudrial rpon (uncouple
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	 (SE) of 3-S expermteius,pe,t,rmedon dsfferen: days
action of indomethacin and the presence and phology in the indomethacin (20 mgfkg
consequence of the damage associated with the treated rats. These changes were indistrnguish-
acute inflammatory cell infiltrate,
	 able from those found one hour after th
administration of the uncoupler dmitrophenot
ELECTRON MICROSCOPY which was associated with the range ol
Electron microscopy was carried Out in groups mitochondrial morphological changes as do
of four rats at one, two, or five hours after gay- scribed previously in other tissues. 2 ' Two houri
age of 20 mg/kg indomethacin (or vehicle on after administration of 5 mg/kg indornethacic
mucosa from the duodenum, jepunum and there was subtle and patchy swelling and don.
ileum. Alterations were found at each site in all gation of mitochondria in two rats which
the indomethacin treated animals, but were increased in severity with the 10 mg/kg in
most pronounced in the duodenum and domethacin dose where loss of crlstae alic
Jejunum. Figure 2 shows representative and the became evident, but with only occasional vacu-
most severe changes in mitochondrial rnor- olisation These findings are consistent with
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milder degree of uncoupling or inhibition of
electron transport" and are within the range of
pathology seen with dinitrophenoL
One hour after indomethacin (20 mg/kg)
administration, there were also minor degen-
erative changes (dilatation and some minor
vacuolisation) in endoplasmic reticulum, but
the brush border and other subcdliular or-
ganelles appeared normal. There was an
impression that the morphological changes
became more severe with time.
IN VITRO MITOCHONDRIAL STUDIES
Figure 3 shows that indomethacin, aspirin,
naproxen, and piroxicam uncoupled oxidanve
phosphorylation of isolated rat liver mitochon-
dna in rnicromolar concentrations whereas
paracetamol did not. However, both paraceta-
mol and NSAIDs at higher concentrations
inhibited respiration in coupled mitochondria.
The mechanism of this inhibition was
studied further. Figure 4 shows that indometh-
acm, naproxen, aspirin, and paracetamol in-
hibit both glutamatelmalate and succinate
(with rotenone) stimulated respiration in un-
coupled mitochondnia. Using sonicated mito-
chondria with potassium femcyanide as an
artificial electron acceptor in the presence of
appropriate inhibitors (rotenone, antimycin A
or cyanide)" to define the effects on individual
respiratory complexes, all the drugs inhibited
electron transfer in complex I and complexes
II plus III, in a concentration dependent man-
ner (data not shown).
349
" 0	 0.5	 1	 1.5	 2
250-	 ______B 1iirbiprofen
I -o-NO-Flunprofen 1
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STUDIES WFH NON-ACiDiC NSAIDs
The effects of nabumetone, a non-acidic
pro-NSAID, on in vitro and in vivo uncoupling
and its active acidic metabolite 6-MNA in
vitro, were studied.
A single 600 mg/kg dose of nabuznetone by
gastric gavage in eight rats did not cause mac-
roscopic or microscopic small intestinal dam-
age at 20 hours. Furthermore, electron micro-
scopy of the mid-small intestine (four rats)
following this dose at one and five hours
showed no alterations in initochondrial mor-
phology (fig 2). Nabumetone also had no effect
on mitochondnal respiration in isolated cou-
pled rat liver mitochondria up to a maximum
solubility (about 1.0 mM) in 10% DMSO fig
5). The active metabolite of 6-MNA, however,
increased respiration by 180 to 200% in the
concentration range of 0.3-0.7 mM.
Figure 5 shows that the chemically modified
versions of flurbiprofen (nitroxybutyl-
flurbiprofen and flurbiprofen dimer), which
render them non-acidic and in the case of the
former abolish gastnc toxicity and reduce small
intestinal damage significantly,' had no sigridi-
cant effects on mitochoridnial respiration.
Figinv & Rep,rsntade'e dcmm mznsmusion ,,,jc,ugnq,lu of nir s,isd .aen,nefia7owing
Innupevuonaz! mdomethacai (20 mg/kg) m (A) a nit sad, a hgrztmd bsi a,ct showing
nonnal ,meg,nal muocho,ia with thsast. cnsza and (B) a sham opmtmad ainma!
showu,g thwwpon of iinwchouthid a',uae, vacuohsadon and occaowid ásrupatm of hod,
the our and imur muothor4'ial awmb,wws. Endopiasmic rgncitktm a ,tho thiarod.
Ongu,almag,nficasiois. x 30000.
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BILE D(JC UGATION EXPERIMfllTS
Sham operated animals with intact bile ducts,
receiving indomethacin mtrapentoneally, had
abnormal jejunal mitochondria (representative
picture shown in fig 6) resembling that seen
after gavage (as above), whereas rats with
ligated bile ducts had normal mitochondrial
morphology. Collectively, this shows that the
systemically mediated effect of indomethacin,
at the doses given, is insufficient to affect small
intestinal mitochondrial morphology whereas
the bihary excreted component seems suffi-
cient to cause the "topical" effect.
ASPIRIN EXPERIMENTS
Aspirin uncoupled in vitro (fig 3). Animals
receiving aspinn by gastric gavage had normal
jejunal mitochondrial morphology on electron
microscopy whereas those receiving aspirin
directly into the small intestine had changes
identical to those following indkmethacin and
dinitrophenol suggestive of uncoupling of
oxidarive phosphorylation and/or inhibition of
electron transport. None of the animals recew-
ing aspirin by gavage had small intestinal ulcers
whereas those receiving it directly into the
small bowel had severe, extensive and conflu-
ent small intestinal ulceration distal to the
administration site of aspirin, suggesting that
the lack of apparent small intestinal toxicity of
orally administered aspirin may be due to lack
of the "topical" effect because of rapid
absorption."
Discussion
Here, we show directly by a subcellular marker
enzyme technique that intestinal mitochondria
and brush border are affected within one hour
of indomethacin administration. Electron mi-
croscopy shows dose dependent mitochondrial
changes that are indicative of uncoupling of
oxidanve phosphorylaoon or inhibition of elec-
tron transport. We expand on the previous in
vitro studies of NSAIDs on mitochondrial
energy production, show that uncoupling
relates to the acidic nature of NSAIDs and that
rendering NSA1D non-acidic and ineffective
as proton iranslocators coincides with their
improved gastrointestinal tolerability Along
with the bile duct ligation and aspirin studies,
this suggests that the mechanism of the
"topical" phase of NSAID damage may involve
uncoupling of oxidative phosphorylation
and/or inhibition of electron transport.
Although the pathogenic events of NSAID
induced gastrointestinal damage are controver-
sial, there is a consensus that there is an impor-
tant "topical" component of the damage both
in the stomach and small intestine' "" which is
independent of NSAII) action to inhibit
cyclooxygenase. 3 The precise nature of the
'topical" phase of damage is uncertain. Firstly,
one suggestion is that NSAJDs have a
detergent-like action which disrupts mucus
gel" and/or cell membrane integrity'" The
decreased activity of the brush border enzyme
alkaline phosphatase is consistent with this
suggestion, although no major structural
changes were seen on electron microscopy
Secondly, acidic NSAIDs may concentrate in
the mucosa ("ion trapping"),tm4' but how this
causes damage is uncertain. The subcellular
órganelle marker enzyme studies suggest that
mnochondria are affected following oral in-
domethacin. Mitochondrial enzyme activities
were all significantly increased, which is,
however, an unusual response to damage and
not readily explained. One possibility is that
substrate access to the membrane bound
enzymes is facilitated via increased mitochon-
dnal membrane permeability caused by the
effect of indomethacin on mitochondrial en-
ergy production Whatever the explanation, the
electron microscopy studies showed dose
dependent in vivo mitochondrial changes
following indomethacin administration which
are suggestive of uncoupling and/or inhibition
of electron transport. The in vitro studies show
that all the acidic NSAIDs uncoupled oxjdacive
phosphorylation at concentrations which are
likely to be achieved within intestinal epithelial
cells following ingestion of NSAJD , whereas
iopical dwnac of NSA ID, and uncouphg
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paracetamol, an analgesic without gastrointes-
unal toxicity, and the non-acidic NSAIDs
which have an improved gastrointestinal toler-
ability profile, did not. These findings expand
on earlier studies which demonstrated that
some NSAIDS uncoupled oxidative
phosphorylation," and indirect evidence that
suggested that uncoupling of oxidative phos-
phorylation or inhibition of electron transport
may play a role in their intestinal toxicity.""
Furthermore, our studies show that the uncou-
pling property of NSAIDs reside within their
carboxyhc or enolic acid groups (along with
their lipid solubiity characteristics).
The doses of indomethacin used to demon-
strate in vivo uncoupling in rat small intestine
were 2.5- to 14-fold higher than maximum
doses used in a 70 kg human. Administration
of these high doses, notwithstanding differ-
ences in species susceptibility, is a compromise
between the desire to use comparable pharma-
cological doses as in humans and those
required for consistent ulcer formation in the
rat. The doses of indomethacin used in this
study, although an order of magnitude greater
than that required to inhibit cyclo-
oxygenase," 4' are, however, within the range
conventionally used to investigate the patho-.
genesis of NSAID induced gastrointestinal
toxicity
The "topical" effect of NSAIDs is most pro-
nounced at the site of drug absorption follow-
ing ingestion. Absorbed NSMDs are largely
(over 99%) bound to albumin so that an
effective concentration for mitochondrial tin-
coupling may not be reached in other tissues.
Certainly, there was no evidence of uncoupling
of small intestinal mitochondria when in-
domethacin was administered parenterally to
rats with ligated bile ducts. However, the main
objection to the importance of the "topical"
phase of damage of NSAIDs comes from the
observations that: (i) parenterally administered
NSAIDs cause small intestinal damage" "; (ii)
oral aspirin does not cause small intestinal
damage (which also suggests that inhibition of
cyclooxygenase is not the only explanation for
the damage). In respect of (i) our studies show
that parenteral indomethacin uncouples lines-
tinal mitochondrial oxidacive phosphorylation
or inhibits electron transport via excretion in
bile. Indeed most NSAIDs, apart from the
active metabohte of nabumetone, 6-MNA, and
aspirin have a significant biliary excretion
component2" which exposes both the stom-
ach (reftux of duodenal contents) and the small
intestine to concentrations of the drug which
may be sufficiently high to uncouple, depend-
ing on the doses given. We could not
demonstrate small intestinal toxicity following
very large doses of nabumetone or an effect to
uncouple oxidauve phosphorylanon in vivo or
in vitro which accords with its purported
favourable gastrointestinal side effect profile in
humans.2 '°' However, the active metabotice of
nabumetone, 6-MNA, uncoupled mitochon-
dna in vitro, which in keeping with the results
of the other acidic NSAIDs. Although oral
6-MNA clearly causes gastric damage (small
bowel damage was not looked for), large
intravenous doses of 6 MNA cause no intesti-
nal damage, possibly because the intestine is
not exposed to intact 6-MNA" when adminis-
tered by this route. Lastly, the nitroxybutyl
modification of flurbiprofen or the flurbiprofen
dirtier renders the drug non-acidic and ineffec-
tive as a mechanical proton ti-anslocator.
Wallace at at' showed that the former modifi-
cation diminishes or abolishes the gastric
toxicity of the drug. It was suggested that the
basis for reduced toxicity was the release of
nitrogen oxide from the molecule, but the
present studies suggest that it might addition-
ally be due to the modification of the carboxyl
group, rendering the molecule inactive as an
uncoupler of oxidative phosphorylanon. In this
context it is interesting that esterification of
aspirin is associated with strikingly improved
short term gastric tolerability in the rat." Col-
lectively, these findings support an important
pathogenic role of the "topical" action of
NSAIDs in intestinal damage.
Aspirin is clearly toxic to the gastric mucosa,
but it has been particularly difficult to explain
why it does not cause small intestinal damage
regardless of the route of adnunistranon (orally
or parenterally). Here, we show that when
aspirin is instilled directly into the small intes-
tine it is associated with uncoupling of intesti-
nal mirochondrial oxidative phosphorylation
and/or inhibition of electron transport and
leads to severe small intestinal ulceration, but
not when given by gastric gavage. This suggests
that aspirin is so rapidly absorbed by the
gastroduodenal mucosa following ingestion'4
and that insuflicient concentrations are
achieved in the more distal small intestine
(along with its lack of excretion in bile) to affect
initochondria and hence it does not exert a
'topical" action at this site or cause damage.
Indeed the gastric 'barrier breaking" effect of
aspirin is only seesifollowing ingestion and not
after intravenous administration" of moder-
ate doses. Parenteral aspirin in large doses
does, however, cause stomach damage, possi-
bly because blood borne, highly acidic
NSAIDs, accumulate in gastric mucosal cells."
Hence, two of the main theoretical objections
to the importance of the "topical" action of
NSAIDs in the pathogenesis of gastromrnestinal
damage have been answered in these studies.
The dual action of NSAIDs to uncouple oxi-
dative phosphorylation—inhibit electron trans-
port ("topical" action) and inhibit cyclooxyge-
nase ("topical" and systemic action) provides a
logical explanation for the mechanism and high
prevalence of gastrointestinal toxicity of these
drugs. Hence, uncoupling/inhibition following
indomerhacin (the precise site of absorption is
in part determined by size, lipid solubility and
charge of the NSAID, drug formulation, gastric
pH, etc.) would result in diminished cellular
ATP production, cellular calcium toxicity,'
production of reactive oxygen species' " result-
ing in increased mucosal permeability.' "
Increased intestinal permeability allows lumi-
nal aggressive factors access to the mucosa
which results in an inflammatory reaction. The
concomitant inhibition of cyclooxygenase
(which occurs a picomolar concentrations of
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NSAIDs and hence evident irrespective of the
mode of administration of the drugs), with
decreased prostaglandins, may then alter local
blood flow and therefore be an important
cofactor in dnving the inflammation to
ulcers. "
The importance of elucidating the mccli-
anism of the "topical" damaging effect of
NSAIDs lies in the fact that it may be possible
to make them safer by chemical modification.
Although NSAJD damage to the gastrointesti-
nal tract is clearly a multistage pathogenic
process,° the results of this study suggests that
uncoupling of oxidative phosphorylation or
inhibition of electron transport by NSAIDs
may be an early pathogenic event which under-
lies the atopicaln phase of the biochemical
damage. This suggests an alternative strategy
for the development of "safer" NSAIDs,
namely modifications of the carboxylic group
common to most NSAIDs, to render the drugs
ineffective as proton translocators.
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